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Propositions 
 
 
1. Metabolome analysis in plasma of the host can detect an effect of a compound on 
the gut microbiome.  
(this thesis) 
2. Post-puberty Wistar rats at the age of 10 weeks show no or negligible sex-specific 
effects, neither in the microbial community (the microgenderome) nor in the feces 
metabolome.  
(this thesis) 
3. Test strategies for potential genome damage from CRISPR/Cas9 gene editing are 
needed to clarify potential risks with the final goal, to facilitate and accelerate 
innovative research in the field of plant science, biobased chemicals or gene 
therapies in Europe.  
4. Algorithms will provide artificial intelligence systems with computational 
narrative intelligence, which will transform them to human-like members of our 
society.  
5. The cruelest and most merciless master teacher of our mind and attitude (to life) is 
our body.  
6. Rhineland-Palatinate will lose their famous cultivation areas of Riesling grapes 
due to the climate change.  
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GENERAL INTRODUCTION 
The microbiome consists of trillions of microbial cells with a high inter- and intraspecies 
variability [1]. Nobelist and visionary Joshua Lederberg proposed the expression 
“microbiome, to signify the ecological community of commensal, symbiotic, and 
pathogenic microorganisms that literally share our body space and have been all but 
ignored as determinants of health and disease” [2]. Research reveals that the totality of the 
microbes inhabiting the intestine – the gut microbiome – has thousands of times more genes 
than the human genome and that the bacterial cells in the human host have been estimated 
being in the same order as the number of human cells [1,3]. The gut microbiome seems to 
have a central function in the eukaryote organism, not just as digestive system or for the 
synthesis of essential vitamins and amino acids, but also in the development of the immune 
system, the maintenance of the energy balance, bile acid and lipid metabolism, 
detoxification of potentially harmful chemicals, prevention of infections, angiogenesis and 
many others [4–12]. However, since many of these findings are based on associations, the 
mechanisms behind the interplay between microbes and host remain to be explored.  
Rapid developments and refinement of metagenomic techniques coupled with increasing 
computing capacities and bioinformatic tools have enabled a microbial journey of discovery 
up to a molecular level. While bacterial cells represent the vast majority , they are just one 
part of the microbiome: it is also composed of archaeal organisms, the mycobiome, the 
virome and other microbes such as protists and metazoans [13]. Studies of these parts of the 
gut microbiome, however, are still in their infancy. 
The gut microbiome has become a burgeoning field of research and is proven to play a role 
in scientific findings in toxicology, pharmacology, oncology, neurology and many others. 
As research has demonstrated, it plays an important role in health and disease of the host, 
and can be influenced by factors such as diet, the host condition, environmental chemical 
exposure and drugs [14–17]. The crosstalk between microbiome and host is often based on 
signal molecules or metabolites [18]. The microbiome-derived metabolites can affect the 
host, for example via nuclear receptor signaling, leading to changes in signaling pathways 
including for example energy metabolism and regulation of the immune system [19].  
Although the fundamental role of the microbiome in the well-being of the host is clear, 
science is now dealing with a bigger challenge, i.e. understanding the mechanisms by 
which these processes of the tight microbial-host interaction are driven. Integrative 
approaches that not only assess the composition of the gut microbiome but also its 
functionality must be implemented to unravel the complex dynamics of these interactions 
[11]. There are high intra- and interspecies variabilities regarding the composition of the 
microbiome, however, there are also indications that the functionality in terms of gene 
activity and metabolic output of the microbes have a lower variability [20–22] which 
supports assessing functional microbial changes with metabolomics approaches.  
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Inter- and intraspecies variability of the gut microbiome 
The composition of the gut microbiome has a high inter- and intraspecies variability in 
general which makes it difficult to define a healthy gut microbiome regarding the species 
inhabiting the gut [1,23]. Bacteria are the major part of microorganisms present in the gut 
microbiome: they outnumber eukaryotes and archaea by 2–3 orders of magnitude [1]. The 
gut microbiota of each individual is similar at the highest taxonomic level, the phylum: 
Bacteroidetes and Firmicutes are the most prominent, followed by Proteobacteria, 
Verrumicrobia, Actinobacteria, Fusobacteria and Cyanobacteria [24,25]. However, it shows 
differences at the genus and species levels because the composition of the gut microbiome 
is influenced by diet, genetics, lifestyle and exposure to xenobiotics. The human intestinal 
microbiome consists of 70 bacterial phyla that include 500 to 1,000 resident species, 7,000 
to 40,000 bacterial strains, representing 1800 genera [11,17,26]. 
In experimental studies, rodents are commonly used as animal models exploring the 
interaction between gastrointestinal microorganisms and the host, and to correlate changes 
of the gut microbiome with diseases. A comparison of the human and mouse intestinal 
microbiota showed considerable similarity at the genus level but large quantitative 
differences. Analyses of the rat intestinal microbiota revealed a bacterial diversity 
exceeding that of the human gut by a factor of two to three [27]. In a recent study, the core 
microbiota of the Sprague-Dawley rat digestive tract was assessed: at the phylum level, 21 
different taxonomic groups were identified: 80% belonging to the Firmicutes, and the 
remaining 20% consisted of Bacteroidetes, Proteobacteria, unclassified bacteria, 
Tenericutes, Actinobacteria, Cyanobacteria, Deferribacteres and Deinococcus-Thermus 
[28]. However, only Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria were 
found in all samples [28]. In general, rats, the golden standard model in toxicological 
studies, are proposed to be more representative of the human gut microbiota than mice, and 
the gut bacterial communities of humanized rats more closely reflect the gut microbiota of 
human donors [28,29]. However, while many species inhabiting the human gut are well 
described [30,31], the majority of rodent gut bacteria remain to be cultured and 
characterized [20]. 
 
Metabolic capacity of the gut microbiome 
The gut microbiome is known to have an immense metabolic capacity: on the one hand the 
bacterial cells are able to produce a wide variety of metabolites (e.g. short chain fatty acids, 
amino acids, vitamins and hormones), and on the other hand it can modify or further 
metabolize (foodborne) chemicals or pharmaceuticals. [32]. Interestingly, contrary to 
differences in the human and murine intestinal genera in mice almost 80% of the functional 
genes were identical to the human microbiome indicating a functional overlap [33]. Also in 
humans the variation in expression of bacterial metabolic enzymes is less diverse than the 
taxonomic profile [34]. 
The microbiome-derived metabolites can be essential for the host’s health, and enable the 
host to harvest otherwise inaccessible nutrients [35]. With rapidly developing technologies, 
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scientists are now able to unravel the microbiome-host interactions, including the 
identification of a number of small molecules, produced by the microbiome, which may 
play a role in this interaction and the host’s health [18,36]. Knowing which molecules are 
produced by the microbiome and how to detect these in the host are essential points for a 
better understanding of the mammalian-microbiome co-metabolism of endogenous 
metabolites.  
A prominent example of the metabolic interaction between the gut microbiome and the host 
are the components of the bile [37]. Bile acids are the major functional components of the 
bile and act as signaling molecules in the host. Via complex molecular mechanisms they 
can influence the gut-liver axis, the immune system and other body systems. Primary bile 
acids are synthesized in the liver from cholesterol and are conjugated with either taurine or 
glycine, and thereby gaining their amphiphilic character, before they are secreted into the 
bile and finally into the small intestine to emulsify lipids into micelles and assist in the 
nutrient absorption. The majority of bile acids is actively reabsorbed in the ileum. A minor 
amount escapes the reabsorption, reaches the colon and is partly excreted. When reaching 
the intestine primary bile acids are further metabolized by unique microbial enzymes to 
unconjugated, secondary and tertiary bile acids. The microorganisms possess enzymes to 
modify these bile acids, for example the bile salt hydrolase (BSH) that cleaves the peptide 
linkage between the amino acid and the primary bile acid. Furthermore, some microbes, 
mainly anaerobes, possess a 7α- dehydroxylation activity to convert primary into secondary 
bile acids [38]. Modified bile acids can enter the enterohepatic circulation, which means 
they are absorbed into the system, recycled and re-conjugated in the liver, and then re-
secreted into the bile and to the intestine.  
Bile acids have direct or indirect antimicrobial effects, i.e. bile acids can modulate the 
composition of the microbiota, which in turn has an effect on the liver and consequently on 
the bile acid pool [39]. Yet, a change of the gut microbial community, e.g. via xenobiotics, 
can also lead to change of the bile acid pool which may also have implications for the 
host’s health [40]. In general, bile acids are known to have tumor-promoting properties and 
are associated for example with gastrointestinal carcinogenesis and liver cancer [41,42].  
The gut microbiota – as the host’s second liver – can also directly and indirectly affect drug 
and xenobiotic metabolism of the host but can also be itself affected by these compounds as 
recently described by Maier et al. reporting an impact of non-antibiotic drugs on human gut 
commensals [43]. Microbes are able to transform molecules via direct reactions like 
reduction, hydrolysis, removal of succinate groups, dehydroxylation, de-/acetylation, 
cleavage of N-oxide bonds, proteolyse, or denitration [44]. This can lead to an activation or 
inactivation of the drug, or the formation toxic byproducts and metabolites possessing 
antimicrobial activity.  
It is essential to identify both the molecules produced by gut microbiota and their effects on 
the host, as well as understanding how xenobiotic compounds are biotransformed by 
resident microbiota. There is also a need to determine the effects of xenobiotic exposures 
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on gut microbiota function, composition, community organization, and resulting host-
microbiota interactions. Determining the functional endpoints rather than the composition 
can contribute to a better understanding of how microbial communities function, their 
metabolic capacities and complex interactions, also with the host. 
 
The role of the gut microbiome in toxicology and pharmacology 
The gut microbiome is increasingly recognized as a critical component in development, 
health and disease [45] as it has been shown to be associated with a number of diseases 
[46]. A shift in the microbial community, or dysbiosis, has been correlated for example to 
cancer, cardiovascular, immune and liver diseases, decreased mental abilities and 
behavioral effects [12,15,47–50]. Many of these correlations just hint a relationship since 
the mechanisms behind it are vaguely understood. However, these mechanisms or the mode 
of action may play an important role in the field of pharmacology and toxicology.  
Considering the metabolic capacity of the gut microbiome, it has for one the potential to 
metabolize or modify (foodborne) chemicals or pharmaceuticals, and for another it is able 
to affect the host metabolism by signaling molecules or metabolites.  
The consequence of the microbial metabolism for the host was demonstrated in a case in 
Japan where 18 patients died caused by interactions of sorivudine, an antiviral drug, with 
the metabolism of the cancer drug 5-fluorouracil [51]. Here, the metabolite of sorivudine 
produced by the gut microbiota inhibited an enzyme responsible for detoxification of the 
cancer drug. There are many other studies where the metabolic capacity of the microbiome 
was shown to affect human (drug) metabolism, for instance acetaminophen [52] or 
deleobuvir [53]. 
Further, metabolites exclusively produced by the gut microbiome can act as agonists or 
antagonists of nuclear receptors and hence can directly influence the host’s metabolism. For 
instance, secondary bile acids are recognized as important signaling molecules serving as 
ligands for numerous nuclear receptors [54–56]. Through binding to these receptors, similar 
to hormones, bile acids can regulate genes involved in lipid and glucose metabolism, and 
energy homeostasis of the host [57,58]. It is also conceivable that an altered bile acid pool 
due to changes of the gut microbiome may affect the absorption or excretion of metabolites 
or xenobiotics. Further, it may activate or inactivate nuclear receptors in the liver or 
intestine, which could lead to altered plasma concentrations or a detoxification or 
toxification of a compound of interest.  
The metabolic capacity of the gut microbiome may influence the absorption, distribution, 
metabolism and excretion (ADME) of a compound. However, although the microbiome can 
act as a first pass metabolism, it is not taken into account in the general concepts of 
toxicology and pharmacology. Indirect interactions have also been described, including 
microbial effects on the host gene expression in the liver, and activity of components of 
host xenobiotic metabolism, which finally can lead to an altered host (drug) metabolism 
[59,60]. 
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In summary, either a change of the gut microbiome through xenobiotics, its metabolic 
capacity of metabolites, or the first pass metabolism of xenobiotics can influence the host’s 
metabolism or the toxicity of a compound, which may have implications for the host’s 
health.  
However, since mechanistic studies are mostly performed in rodents, the results are 
difficult to extrapolate to humans and other species due to the interspecies differences in the 
composition of the microbiome. Furthermore, the microbiome is influenced by several 
factors such as a change in diet, the host condition, radiation, xenobiotics and genetics, 
which results in a high variability regarding the composition of the microbial community 
within species, but also between different species [14–16,61–63]. Hence, an essential first 
step is to identify host species-specific effects, e.g. to measure the endogenous metabolite 
profile, to identify key metabolites and to correlate them to bacterial species. 
New technologies such as the omics technologies enable a deep research of the complex 
interaction between microbiome and host, potentially having the power to elucidate its 
outstanding role in the developing organism. To understand its role in toxicology and 
pharmacology, it is essential to determine the microbiota’s function, composition, 
community organization, and resulting host-microbiota interactions. Omics technologies, 
especially metabolomics, can be suitable tools to identify microbiome-derived or -
associated metabolites and to reflect changes in the composition of the microbiota that 
could potentially lead to disease [18]. Analyzing the production of microbiota-derived 
metabolites is the first stage of a series of investigations that have the final goal of assessing 
the impact of the microbiome on the host.  
 
Metabolomics and the MetaMap®Tox database 
Small endogenous molecules within a biological sample – in its entirety called the 
metabolome – such as carbohydrates, amino acids, nucleic acids or fatty acids and their 
derivatives resulting from biochemical pathways, are defined as metabolites within the 
context of the omics technology metabolomics [64]. Compared to other omics technologies, 
metabolomics is from a statistical perspective more powerful in detecting robust effects 
[65] and the use of sensitive LC-MS and GC-MS techniques offers the possibility to detect 
a broad range of metabolites. Furthermore, metabolomics provides the opportunity of 
finding relevant biomarkers or patterns of change [66]. In the past years it has been shown 
that metabolomics can serve as a powerful tool in risk assessment, e.g. as a read-across tool, 
and in toxicological research [67,68]. Practical advantages of metabolomics include the use 
of, for example, urine or blood as a matrix. Thus, samples can be obtained by a less 
invasive method and in animal experiments it is not necessary to sacrifice the experimental 
animals, which also enables the rarely performed but valuable longitudinal study design. 
Since with metabolomics a broad range of metabolites can be quantitatively or semi-
quantitatively measured, metabolic fluxes can be analyzed [69]. The data obtained can be 
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further used in a systems biology approach, a rapidly growing field of research, integrating 
these high-throughput data in computational network models [70]. 
In toxicological research, metabolomics can be used for identifying relevant biomarkers or 
metabolite patterns of change which indicate an adverse effect or organ toxicity. Measuring 
the metabolite profile in plasma of rats, which are a widely used animal model in 
toxicology, and its sensitivity to well-known toxic model compounds is an essential first 
step in developing the use of the plasma metabolome to detect adverse health effects [71]. 
Initial investigations demonstrated that after substance treatment it was possible to identify 
different modes of action (MoAs) or adverse outcomes in rats [71]. It was noted that the 
chemicals or diseases that produce a specific form of toxicity, generally through a shared 
mode of action, produced a subset of common specific metabolite changes. Such a common 
set of consistently regulated metabolites can be used to establish metabolic patterns specific 
for certain toxicities [72,73]. Using this approach in toxicology as a screening tool, various 
metabolite patterns for different toxicological targets and MoAs (liver, kidney, thyroid, 
testes, blood, nervous system and endocrine system) were established in the MetaMap®Tox 
[74], a metabolomics database for the identification and prediction of toxicological MoAs 
of new test substances. The MetaMap®Tox database has been built based upon 28-day 
studies in rats, adapted to the OECD 407 guideline, with blood sampling and metabolic 
profiling of more than 200 metabolites after 7, 14 and 28 days of test substance treatment. It 
contains the metabolite profiles as well as the toxicity data of approximately 800 chemicals, 
agrochemicals and drugs.  
In the last years, research has demonstrated the impact of the gut microbiome on the host, 
especially on the state of the host health. It was shown that gut microbiome-derived 
metabolites can be found in mammalian blood and arise exclusively in the presence of gut 
microflora, suggesting a major interplay between bacterial and mammalian metabolism 
[18]. It became clear that metabolites produced or modified by the gut microbiota can be 
absorbed across the intestinal cell wall and can be further modified by the liver, ending up 
circulating in the blood stream of the host (see Figure 1). Some bacterial species and their 
related metabolites including their main function have been already described [75,76]. 
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Figure 1 Influence of the gut microbiome on plasma metabolite patterns. Microbes in the lumen of the intestine 
produce metabolites which are absorbed into the blood. They can be further metabolized by the liver and analyzed 
in the plasma with metabolomics. 
 
The crosstalk between host and microbes in the form of molecules can be measured with 
metabolomics which can serve here as a tool for assessing the functional status of the 
microbiome beyond taxonomics [18,45]. Especially metabolites formed by the microbiota 
available for uptake by the host are important to analyze since they have the potential to 
affect the host organism systemically. 
 
 
Figure 2 During a 28-day study 225 metabolites are analyzed on three time points in plasma of rats treated with 
test substances. The specific plasma metabolite pattern can identify and predict toxicological mode of actions of 
new substances. Metabolites in the blood are composed of gut microbial metabolites, endogenous metabolites of 
the rat, and co-metabolites of the microbial-mammalian crosstalk. 
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Since the metabolite profile in plasma combines both the microbiome-derived or -
associated metabolites as well as the endogenous metabolites, the scope of the project was 
to find out which metabolites were derived specifically from the gut microbiome and what 
kind of impact they have on the metabolite profile (see Figure 2). Using the metabolomics 
approach and the existing knowledge and data availability of the MetaMap®Tox database, 
microbiome-related metabolites in rat plasma should be identified after treatment with 
substances which are known to induce a shift of the microbial community.  
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Aim and outline of the thesis 
The intestinal microbiota plays an important role in many host physiological aspects, also 
contributing to the blood metabolome that is otherwise produced by tissues of the host 
organism. Thus, when assessing the toxicological profile of a substance, its effect on the 
microbiome cannot be ignored. To enable studies on mammalian-microbiome co-
metabolism, understanding of effects of the microbiome’s functionality on the endogenous 
plasma metabolome is required. The aim of this project was to obtain detailed insight in the 
mammalian-microbiome co-metabolism of endogenous metabolites and the extent to which 
the microbiome influences the plasma metabolome observed with the help of the 
MetaMap®Tox database and metabolic profiling.  
 
Background information and an outline of this thesis are provided in Chapter 1, the present 
chapter. Also, the aims of the thesis are defined here. 
Analyzing the production of microbiota-derived metabolites absorbed by the host was the 
first stage of the investigations, which was achieved via assessing the influence of new 
compounds with antibiotic activity on the host plasma metabolome as described in Chapter 
2. Changes of the metabolome in plasma samples of male Wistar rats were analyzed after 
administration of antibiotics known to induce an artificial shift of the intestinal microbiota. 
This study was a first metabolic approach to establish a specific metabolome pattern for 
selected classes of antibiotics in the MetaMap®Tox database, and to identify plasma 
metabolites related to changes of the gut microbiome’s functionality due to antibiotic 
treatment. 
After successful identification of first plasma metabolites derived from the gut microbiome, 
further studies with six antibiotics of five different classes as well as vehicle controls were 
conducted. Besides plasma, also gut tissue and gut content samples were taken for further 
investigations. 
Chapter 3 presents a study where metabolite profiling of different matrices of the gut of 
rats was performed, after antibiotic treatment in order to evaluate metabolite changes 
observed at different dose levels and in different sexes, and to identify the best tissue matrix 
for further investigations. The aim of this study was to assess if the same metabolites 
previously detected in plasma could be found in the different gut matrices, to investigate if 
a treatment-related effect can be observed in the analyzed matrices tissues, and if different 
activity spectra of antibiotics are reflected in the metabolite profiles. Furthermore, it was 
evaluated if metabolite changes can be observed at different dose levels and if they were 
sex-dependent. Lastly, the evaluations should reveal the best sample matrix for the 
assessment of effects of new compounds affecting the gut microbiome. 
In Chapters 2 and 3, metabolite profiling was performed in different matrices. In the study 
described in Chapter 4, metabolite profiling in both plasma and feces of rats after 
lincosamides treatment was performed in order to establish specific metabolite patterns in 
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the MetaMap®Tox database and to identify further key metabolites indicating gut microbial 
changes. Additionally, a community analysis was performed to characterize changes in the 
gut microbiome following treatment, vehicle treatment and general differences between the 
male and female animals. These evaluations help gaining a more comprehensive 
understanding of the effects and dynamics of microbiome alterations. 
In the previous studies, various key metabolites derived from the microbiome or indicating 
changes of the microbiome could be identified in plasma. Since the primary bile acids could 
be identified as key metabolites, an additional method for a bile acid screening was set up 
to further elucidate changes in the bile acid metabolism. This study is described in Chapter 
5. The evaluation of changes in the plasma and feces bile acid pool could help to gain a 
more comprehensive understanding of how microbial changes may influence the bile acid 
metabolism which, regarding the important role of these signaling molecules, can have far 
reaching consequences for the host.  
Chapter 6 discusses the results of the previous chapters. Further, it provides future 
perspectives, discusses the limitations of the rodent model used in the studies as well as 
alternatives to animal studies. The final chapter, Chapter 7, provides a concluding 
summary of the results delivered in this thesis. 
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ABSTRACT 
The intestinal microbiota contributes to the metabolism of its host. Adequate identification 
of the microbiota’s impact on the host plasma metabolites is lacking. As antibiotics have a 
profound effect on the microbial composition and hence on the mammalian-microbiota co-
metabolism, we studied effects of antibiotics on the “functionality of the microbiome” - 
defined as the production of metabolites absorbed by the host.  
This metabolomics study presents insights into the mammalian-microbiome co-metabolism 
of endogenous metabolites. To identify plasma metabolites related to microbiome changes 
due to antibiotic treatment, we have applied broad-spectrum antibiotics belonging to the 
class of aminoglycosides (neomycin, gentamicin), fluoroquinolones (moxifloxacin, 
levofloxacin) and tetracyclines (doxycycline, tetracycline). These were administered orally 
for 28 days to male rats including blood sampling for metabolic profiling after 7, 14 and 28 
days. Fluoroquinolones and tetracyclines can be absorbed from the gut, whereas 
aminoglycosides are poorly absorbed. Hippuric acid, indole-3-acetic acid and glycerol were 
identified as key metabolites affected by antibiotic treatment, beside changes mainly 
concerning amino acids and carbohydrates. Inter alia, effects on indole-3-propionic acid 
were found to be unique for aminoglycosides, and on 3-indoxylsulfate for tetracyclines. For 
each class of antibiotics specific metabolome patterns could be established in the 
MetaMap®Tox data base, which contains metabolome data for more than 550 reference 
compounds. The results suggest that plasma based metabolic profiling (metabolomics) 
could be a suitable tool to investigate the effect of antibiotics on the functionality of the 
microbiome and to obtain insight into the mammalian-microbiome co-metabolism. 
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ABBREVIATIONS 
CKD  chronic kidney disease 
HA  hippuric acid 
IAA  indole-3-acetic acid 
IPA  indole-3-propionic acid 
IS  3-indoxylsulfate 
GC  gas chromatography 
LC  liquid chromatography 
MOA  mode of action 
MS  mass spectrometry 
SPE  solid phase extraction 
 
 
INTRODUCTION 
The intestinal microbiota is known to produce a variety of metabolites (e.g. short chain 
fatty acids, amino acids, vitamins and hormones) which are essential for the host’s health. 
However, it has also been shown to be associated with a number of diseases (Cho and 
Blaser 2012; Zhang et al. 2015). A shift in the microbial community, or dysbiosis, has been 
correlated with diseases such as cancer, cardiovascular, immune and liver diseases, 
decreased mental abilities and behavioral effects (Guarner and Malagelada 2003; Kirpich et 
al. 2015; Lecomte et al. 2015; Toh and Allen-Vercoe 2015; Velasquez-Manoff 2015; Zhang 
et al. 2015). Evidence suggests a strong interaction between the gut microbiome, the gut 
and the host’s wellbeing. We are now starting to unravel the microbiome-host interactions, 
including a number of small molecules, produced by the microbiome, which may play a 
role in this interaction (Martin et al. 2009; Wikoff et al. 2009). Knowing which molecules 
are produced by the microbiome, their role in the host’s well-being and how to detect these 
in the host are essential points for a better understanding of the mammalian-microbiome co-
metabolism of endogenous metabolites. 
The human microbiome consists of 100 trillion cells of microbes with a high inter- and 
intraspecies variability (Huse et al. 2008; Arumugam et al. 2011; Ottman et al. 2012). 
Several factors such as a change in diet, the host condition, radiation, and toxicological 
insult (e.g. antibiotics) can influence the microbiome (David et al. 2014; Modi et al. 2014; 
Zhang et al. 2015). A concept to assess risks associated with microbiome changes is the 
investigation of the microbiome’s functionality (defined as the production of metabolites 
absorbed by the host). Therefore, it is essential to determine the microbiota’scomposition, 
organization and the host-microbiome interactions. Omics technologies, especially 
metabolomics, could be suitable tools to identify microbiome derived metabolites and to 
reflect changes in the composition of the microbiota that could potentially lead to disease 
(Wikoff et al. 2009). 
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In the past years it has been shown that metabolomics can serve as a powerful tool in risk 
assessment and toxicological research (Beger et al. 2010). Within the context of 
metabolomics, metabolites are defined as small endogenous compounds such as 
carbohydrates, amino acids, nucleic acids or fatty acids and their derivatives resulting from 
biochemical pathways (Lindon et al. 2004). Practical advantages of metabolomics include 
the use of, for example, blood as a matrix. Samples can be obtained by a less invasive 
method and it is not necessary to sacrifice animals, also making time course analysis 
possible. The use of sensitive LC-MS and GC-MS techniques offers the possibility to detect 
a broad range of metabolites and thus is one increment to increase the chance of finding 
relevant biomarkers or patterns of change (Looser et al. 2005).  
 
The interpretation of biomarkers or patterns of change in plasma metabolites requires 
insight into to what extent (adverse) effects on the host and microbiota are reflected in the 
plasma metabolite profile. Measuring the metabolome (metabolite profile) in rat plasma and 
its sensitivity to well known toxic model compounds is an essential first step in developing 
the use of the plasma metabolome to detect adverse health effects (van Ravenzwaay et al. 
2007). Therefore, the aim of the present study was to identify the metabolome in blood 
samples of Wistar rats after administration of antibiotics known to modify the intestinal 
microbiota, which is likely to contribute essentially to the plasma metabolite profile of the 
mammalian host organism (Wikoff et al. 2009; Zheng et al. 2011; Nicholson et al. 2012; 
Marcobal et al. 2013; Heinken and Thiele 2015a; Marcobal et al. 2015). Some phyla/strains 
and their related main/most important metabolites including their main function have been 
described (Heinken and Thiele, 2015b; Nicholson et al., 2012, M Fischbach, personal 
communication). With the help of an artificial shift of the microbiota, e.g. with antibiotics, 
it is conceivable to specifically identify microbiota-related metabolites in the blood and to 
correlate these metabolites with their bacterial producers. 
 
In this study, a metabolic blood profiling after oral administration of broad-spectrum 
antibiotics of different classes (aminoglycosides, tetracyclines, and fluoroquinolones) in 
male Wistar rats was performed. Relative levels of endogenous metabolites in treated rats 
were compared to the levels of these metabolites in untreated controls. To distinguish 
between metabolite changes caused by systemic toxicity of the antibiotics and microbiota 
related changes, we applied aminoglycosides. When orally administered, this class of 
antibiotics is poorly absorbed from the gut (1 – 6%) (Renshaw et al.; Brown and Riviere 
1991; Dhillon 2006). Thus, a change in the plasma metabolite pattern can be associated 
with changes in the functionality of the gut microbiota and effects on plasma metabolites 
due to organ toxicity are negligible. To interpret the metabolome data obtained, the data 
base MetaMap®Tox with more than 550 reference compounds was used. This data base is 
used to identify and predict the systemic toxicity or toxicological modes of action (MOA) 
of new compounds by creating sets of common metabolite level changes (metabolite 
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pattern) (van Ravenzwaay et al. 2007; Strauss et al. 2009; van Ravenzwaay et al. 2010a; 
Van Ravenzwaay et al. 2012; Kamp et al. 2012b). 
 
 
Figure 1 Metabolic profiling in different gut matrices of antibiotic treated rats. To identify plasma metabolites 
related to microbiome changes due to antibiotic treatment, we have employed a metabolomics approach. Broad-
spectrum antibiotics (Vancoymcin, Streptomycin and Roxithromycin), with each a different activity spectrum, 
were administered orally to rats in a toxicity study. Feces, cecum content and gut tissue (jejunum, ileum, cecum, 
colon, rectum) were sampled for metabolic profiling on day 28 of the study. 
 
Analyzing the production of microbiota-derived metabolites absorbed by the host is the first 
stage of our investigations, which aims at assessing toxicological risks of new compounds 
with antibiotic activity.  
This study here is a first metabolic approach to 1) establish a specific metabolome pattern 
for selected classes of antibiotics in the data base MetaMap®Tox, and 2) identify plasma 
metabolites related to changes of the gut microbiome’s functionality due to antibiotic 
treatment. 
 
 
MATERIALS AND METHODS 
Five independent studies were performed according to the OECD 407 protocol. Animal 
handling, treatment, and clinical examinations have been described earlier (van 
Ravenzwaay et al. 2007; van Ravenzwaay et al. 2010b; Strauss et al. 2012; Van 
Ravenzwaay et al. 2012; Kamp et al. 2012b). 
 
Ethics statement 
The studies were approved by the BASF Animal Welfare Body, with the permission of the 
local authority, the Landesuntersuchungsamt Rheinland-Pfalz (reference number 23 177-
07). The laboratory is AAALAC (Association for Assessment and Accreditation of 
Laboratory Animal Care International) certified since 2007.  
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Animals and Maintenance Conditions 
Briefly, Wistar rats (CrI:WI(Han)) were supplied by Charles River, Germany, and were 
approx. 70 days old at the beginning of the studies. The animals were maintained in an air-
conditioned room at a temperature of 20 to 24°C, a relative humidity of 30 to 70%, and a 12 
hour light / 12 hour dark cycle. Ground Kliba mouse/rat maintenance diet was supplied by 
Provimi Kliba SA, Kaiseraugst, Switzerland. The diet and drinking water were available ad 
libitum (except before blood sampling) and regularly assayed for chemical contaminants 
and the presence of microorganisms. 
 
Treatment of animals with compounds 
Treatment groups of five animals per group were compared with a dietary control group (10 
male rats) irrespective of the administration route of the antibiotics (doxycycline and 
levofloxacin were applied in the same study, i.e. these antibiotics were compared against 
the same control animals). This was done in order to compare the groups with reference 
compounds of the MetaMap®Tox database based on uniform diet control groups. In former 
studies the metabolome of control groups with different administration routes had been 
compared: rats gavaged with 0.5% carboxymethyl cellulose (CMC; administration route of 
some antibiotics in the present study) had less than 5% significantly altered metabolites 
compared to diet controls (Welch t-test, p < 0.05). This is regarded as an incidental change, 
which does not interfere with antibiotic-related effects of the present treatment-groups. 
Dose-levels (according to literature data (U.S. Food and Drug Administration; Dietz 1989; 
van Koten-Vermeulen and van Leeuwen 1995; Dalhoff 2001; Kuroda et al. 2001; Center 
for Drug Evaluation and Research 2003; Tanaka et al. 2004; Schoonen et al. 2007; U.S. 
Food and Drug Administration 2008; Center for Drug Evaluation and Research 2013)), 
routes of administration and form of preparation of the antibiotics are summarized in Table 
1. 
 
Table 1 Compounds used, dose levels, routes of administration (oral administration by gavage or administration in 
feed), form of preparation, and class of antibiotics. 
Treatment Dose/day Route Form of preparation Class of 
antibiotics
Tetracycline Hydrochloride approx. 5,000 mg/kg body weight Diet - Tetracyclines
Doxycycline Monohydrate 250 mg/kg body weight gavage in water containing 
0.5% CMCa 
Tetracyclines
Moxifloxacin Hydrochloride 750 mg/kg body weight gavage in water containing 
0.5% CMCa 
Fluoroquinolones
Levofloxacin 200 mg/kg body weight gavage in water containing 
0.5% CMCa 
Fluoroquinolones
Neomycin Sulfate 250 mg/kg body weight gavage in water Aminoglycosides
Gentamicin Sulfate 100 mg/kg body weight gavage in water Aminoglycosides
a carboxymethyl cellulose: Tylose CB30000  
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Blood Sampling 
Between 7:30 and 10:30 h, blood samples were taken from the retro-orbital sinus in all rats 
under isoflurane anesthesia (1.0 ml K-EDTA blood on study days 7, 14 and 28) after a 
fasting period of 16 – 20 hours and one day after the last administration of the test 
substances. The blood samples were centrifuged (10 °C, 2000 x g, 10 minutes) and the 
EDTA plasma was separated. The EDTA plasma samples were covered with nitrogen and 
frozen at -80 °C until metabolite profiling was performed. 
 
Clinical Examinations 
All animals were checked daily for any clinically abnormal signs and mortalities. Food 
consumption was determined on study days 6, 13, 20 and 27. Body weight was determined 
before the start of the administration period in order to randomize the animals and on study 
days 0, 6, 13, 20 and 27. At the end of the treatment period, the animals were sacrificed by 
decapitation under Isoflurane anesthesia. Metabolome evaluation of the blood samples was 
performed for all control, and treated animals.  
 
Metabolite Profiling 
For mass spectrometry-based metabolite profiling analysis, K-EDTA plasma samples taken 
on study days 7, 14 and 28 were extracted by a proprietary method as described below. 
Three types of mass spectrometry analysis were applied to all samples: GC-MS (gas 
chromatography-mass spectrometry) and LC-MS/MS (liquid chromatography-MS/MS) 
were used for broad profiling (van Ravenzwaay et al. 2007). SPE-LC-MS/MS (Solid phase 
extraction-LC-MS/MS) was applied for the determination of catecholamine and steroid 
hormone levels. Proteins were removed from plasma samples by precipitation using 
acetonitrile. Subsequently polar and non-polar fractions were separated for both GC-MS 
and LC-MS/MS analysis by adding water and a mixture of ethanol and dichloromethane. 
For GC-MS analysis, the non-polar fraction was treated with methanol under acidic 
conditions to yield the fatty acid methyl esters derived from both free fatty acids and 
hydrolyzed complex lipids. The non-polar and polar fractions were further derivatized with 
O-methyl-hydroxylamine hydrochloride and pyridine to convert oxo-groups to O-methyl-
oximes and subsequently with a silylating agent before analysis (Roessner et al. 2000). For 
LC-MS analysis, both fractions were reconstituted in appropriate solvent mixtures. HPLC 
was performed by gradient elution using methanol/water/formic acid on reversed phase 
separation columns. Mass spectrometric detection technology was applied which allows 
target and high sensitivity MRM (Multiple Reaction Monitoring) profiling in parallel to a 
full screen analysis (WO2003073464). 
For GC-MS and LC-MS/MS profiling, data were normalized to the median of reference 
samples which were derived from a pool formed from aliquots of all samples to account for 
inter- and intra-instrumental variation. Steroid hormones, catecholamines and their 
metabolites were measured by online SPE-LC-MS/MS (Solid phase extraction-LC-
Chapter 2 
32 
MS/MS) (Yamada et al. 2002). The method resulted in 225 semi-quantitative analytes, 171 
of which are chemically identified and 54 are structurally unknown.  
 
Statistics 
The data were analyzed by univariate and multivariate statistical methods. The sex- and 
day-stratified heteroscedastic t-test ("Welch test") was applied to compare metabolite levels 
of dose groups with respective controls. Hereafter these ratios are referred to as ‘relative 
abundance in plasma’. The p-values, t-values, and ratios of corresponding group medians 
were collected as metabolic profiles and fed into the MetaMap®Toxdatabase. For a detailed 
description on the use of statistics in MetaMap®Tox see van Ravenzwaay et al. 
(Ravenzwaay et al. 2016). Whenever we write “significantly”, "statistically significantly” is 
meant. Briefly, the best balance for finding the maximum number of truly regulated 
metabolites while minimizing the number of false positive regulated metabolites is obtained 
at a p-value of 0.15. Therefore, for pattern recognition p-values between 0.1 – 0.2 are used 
in the data base. 
 
Establishment of Metabolite Pattern in Metamap®Tox 
Patterns of characteristically changed metabolites for a certain toxicological mode of action 
were developed from the metabolite profiles as described before (Kamp et al. 2012b). In 
this study, characteristic metabolite changes were identified based on two antibiotics of the 
same class (see Table 1) from the MetaMap®Tox data base to establish a metabolite profile. 
After identification of the significantly changed metabolites and a consistency check 
through an expert panel, the pattern is validated against the data base and should not 
identify compounds in the MetaMap®Tox with a different toxicological mode of action. 
 
 
RESULTS 
Clinical signs 
There were no mortalities observed in any of the animals, which received the different 
antibiotics, or signs of clinical toxicity, except for moxifloxacin (slight salivation) and 
tetracycline (piloerection). Table 2 presents the results on food consumption and effects on 
body weight upon different treatments. Food consumption was reduced in the animals 
receiving tetracycline. With the exception of gentamicin, there was a reduction in food 
consumption in all test groups on day 7, and occasionally also on day 14. Towards the end 
of the study (day 28), food consumption had returned to levels close to controls for these 
compounds. Observed changes in body weight were in the range of -10% of the controls, 
showing that the MTD (maximum tolerated dose) was not exceeded. 
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Table 2 Relative changes in body weight and food consumption of male Crl:Wi(Han) rats (N = 5 per group) dosed 
for 4 weeks compared to the corresponding controls. Data were collected on study days 6, 13 and 27, data in in 
yellow boxes are statistically significantly decreased (p < 0.05) compared to controls (N= 10 per group). 
Antibiotic Day Body 
Weight
Food 
Consumption
6 0.91 0.58
13 0.91 0.82
27 0.89 0.99
6 0.97 0.86
13 0.95 0.84
27 0.94 1.02
6 0.96 0.93
13 0.95 0.96
27 0.97 1.08
6 1.01 0.83
13 0.99 0.99
27 0.96 1.02
6 0.95 0.66
13 0.95 0.87
27 0.88 0.97
6 0.94 0.90
13 0.92 0.95
27 0.90 1.15
Levofloxacin
Tetracycline 
hydrochloride
Doxycycline 
monohydrate
Gentamicin 
sulfate
Neomycin 
sulfate
Moxifloxacin 
hydrochloride
 
 
Metabolomics 
The outcomes derived from the metabolome data analysis for the three different classes of 
antibiotics are presented in Figs. 2, 3 and 4. Each metabolite value of a treated group was 
evaluated against the value of the concurrent control and expressed as relative (fold-
change) value of the control. For each class of antibiotics specific metabolome patterns 
were established using a p-value of 0.2. 
Key metabolites affected by antibiotic treatment of all three classes were hippuric acid 
(HA), indole-3-acetic acid (IAA) and glycerol, in addition antibiotic class specific changes 
were identified in metabolites belonging to amino acids, lipids and carbohydrates.  
 
Aminoglycosides 
After treatment with aminoglycosides 17 plasma metabolites were significantly decreased 
and two were significantly increased (sphingomyelin (d18:2/16:0) and (d18:2:18:0)) 
compared to the control group (see Fig. 2). Changes were seen in amino acids and related, 
complex lipids, fatty acids and related, energy metabolism and related, hormones, signal 
substances and related as well as miscellaneous. At all three time points (day 7, 14, 28) and 
for both aminoglycosides tested, indole-3-propionic acid (IPA) and hippuric acid were 
remarkably decreased. The lowest relative abundances in plasma for IPA were 0.12 
(neomycin) and 0.06 (gentamicin), equivalent to a 12-fold and 16-fold decrease relative to 
control values. For both substances the relative abundance in plasma for hippuric acid were 
around 0.5 on day 7 and fall to 0.20 for neomycin and 0.17 for gentamicin on day 28. As 
for the patterns of tetracyclines and fluoroquinolones (see Figs. 3 and 4), the relative 
abundance in plasma for indole-3-acetic acid was also decreased for gentamicin and 
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neomycin. Low values compared to the control, 0.23 – 0.48, could also be found for 3-O-
methyldopamine after neomycin treatment.  
 
Metabolite Direction Metabolite class
7 d 14 d 28 d 7 d 14 d 28 d
Alanine ↓ 0.89 0.81 0.99 0.82 0.76 0.81
Proline ↓ 0.96 0.87 0.92 0.83 0.86 0.91
Tyrosine ↓ 0.96 0.87 0.86 0.81 0.78 0.89
Indole-3-acetic acid ↓ 0.55 1.23 0.66 0.59 0.65 0.86
Ketoleucine ↓ 0.94 0.78 0.98 1.04 0.65 0.81
Indole-3-propionic acid ↓ 0.24 0.12 0.30 0.06 0.07 0.42
Glycerol, lipid fraction ↓ 0.64 0.68 0.83 0.85 0.77 0.88
Glycerol, polar fraction ↓ 0.94 0.81 0.89 0.91 0.94 0.92
dihomo-gamma-Linolenic acid (C20:cis[8,11,14]3) ↓ 0.72 1.02 0.88 0.92 0.78 0.79
Sphingomyelin (d18:2,C16:0) ↑ 1.04 1.17 1.27 1.17 0.97 1.11
Sphingomyelin (d18:2,C18:0) ↑ 1.08 1.19 1.15 1.01 1.31 0.79
TAG (C16:0,C18:2) ↓ 0.77 0.92 0.91 0.87 0.86 0.83
TAG (C18:1,C18:2) ↓ 0.59 0.71 0.82 0.83 0.87 0.87
Lysophosphatidylcholine (C20:4) ↓ 1.03 0.91 0.92 0.82 0.89 0.90
TAG (C18:2,C18:3) ↓ 0.46 0.62 0.90 0.71 0.65 0.75
Lactate ↓ 0.75 0.83 0.69 1.02 0.71 0.85 Energy metabolism and related
Normetanephrine ↓ 0.69 0.66 0.88 0.88 0.65 0.62
3-O-Methyldopamine ↓ 0.48 0.23 0.31 0.75 0.70 0.73
Putrescine ↓ 0.87 0.86 0.86 1.00 0.81 0.89
Hippuric acid ↓ 0.45 0.27 0.20 0.54 0.12 0.17
Amino acids
Amino acids related
Complex lipids, fatty acids and related
Hormones, signal substances and related
Miscellaneous
Neomycin sulfate Gentamicin sulfate 
 
Figure 2 Heatmap of statistically significantly increased and decreased values of metabolite changes after 
treatment with aminoglycosides. Metabolite concentration changes in plasma of male Crl/Wi(Han) rats (N = 5 per 
group) dosed with neomycin sulfate (250 mg/kg bw/d) or gentamicin sulfate (100 mg/kg bw/d) for 28 days. Blood 
samples were taken on study days 7, 14 and 28 after overnight fasting: Figures in red boxes are statistically 
significantly increased and those in blue boxes statistically significantly decreased metabolite value changes 
compared to controls (N = 10 per group). Metabolites are mentioned which were statistically significantly altered 
in the same direction at least at two sampling dates (Welch t test; p < 0.2) per compound. 
 
Fluoroquinolones 
With 29 significant changes, the plasma metabolite pattern of fluoroquinolones showed the 
highest number of altered metabolite values compared to the patterns of aminoglycosides 
and tetracyclines, respectively. Fifteen significantly decreased and fourteen significantly 
increased metabolite changes were found compared to the control group (see Fig. 3). 
Changes were seen in amino acids and related, carbohydrates, complex lipids, fatty acids 
and related, hormones, signal substances and related, miscellaneous, nucleobases and 
related as well as vitamins, cofactors and related. Over all time points (day 7, 14, 28) 
hippuric acid was remarkably decreased for both fluoroquinolones tested. The relative 
abundance in plasma ranged from 0.10 to 0.30 (levofloxacin) and 0.17 to 0.43 
(moxifloxacin). Indole-3-acetic acid showed decreased relative abundance in plasma 
(around 0.5) over all time points except on day 28 for levofloxacin with 0.90. Low relative 
abundance in plasma could be found for metanephrine. On day 28 relative abundance in 
plasma twice as high as compared to the control group were found for complex lipids or 
fatty acids, like 4-hydroxysphinganine, nervonic acid, 3-O-methylsphingosine and 
sphingomyelin. The relative abundances in plasma of 3-methoxytyrosine and progesterone 
were up to 10 times higher than control but with a high variation between the three time 
points, especially day 28. High ratios were observed for coenzymes Q9 and Q10. 
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Altogether theses metabolites were more strongly affected after the treatment with 
moxifloxacin compared to levofloxacin. 
 
Metabolite Direction Metabolite class
7 d 14 d 28 d 7 d 14 d 28 d
Taurine ↑ 1.19 1.50 1.21 1.07 1.27 1.24
Glutamine ↓ 0.82 0.79 0.75 0.68 0.61 0.67
Valine ↓ 0.96 0.85 0.87 0.89 0.94 0.96
Glutamate ↓ 0.76 1.07 0.77 0.72 0.93 1.00
Isoleucine ↓ 1.05 0.89 0.80 0.93 0.91 1.07
5-Oxoproline ↓ 0.89 0.83 0.80 0.71 0.66 0.77
Indole-3-acetic acid ↓ 0.41 0.52 0.90 0.55 0.63 0.63
Ketoleucine ↓ 0.77 0.81 0.50 0.69 0.68 0.50
Glucose ↑ 1.27 1.11 1.04 1.37 1.21 0.94
Xylitol ↑ 1.68 1.04 1.42 1.95 1.62 0.94
4-Hydroxysphinganine (t18:0, Phytosphingosine), total ↑ 1.29 1.42 1.72 1.58 1.83 2.28
Nervonic acid (C24:cis[15]1) ↑ 0.94 1.17 1.21 1.27 1.66 2.23
Cholesterol, total ↑ 0.88 1.28 1.35 0.85 1.35 1.66
3-O-Methylsphingosine (d18:1) ↑ 0.79 1.13 1.85 1.20 1.68 2.49
Glycerol, polar fraction ↓ 0.92 0.97 0.67 0.71 0.80 0.88
Sphingomyelin (d18:2,C18:0) ↑ 1.01 1.32 1.27 1.47 1.51 2.61
TAG (C18:2,C18:3) ↓ 0.42 0.48 1.27 0.65 0.99 1.31
Phosphatidylcholine (C18:0,C18:1) ↑ 0.99 1.13 1.19 1.08 1.19 1.17
Metanephrine ↓ 0.67 0.84 0.53 0.38 0.37 0.58
3-Methoxytyrosine ↑ 1.10 1.05 1.39 1.57 1.80 2.58
Hippuric acid ↓ 0.30 0.10 0.12 0.21 0.17 0.43 Miscellaneous
Cytosine ↓ 0.80 0.83 0.94 0.73 0.70 0.75 Nucleobases and related
Coenzyme Q10 ↑ 1.41 1.31 1.73 1.42 3.04 2.28
alpha-Tocopherol ↑ 1.00 1.34 1.47 1.57 1.44 1.24
Pantothenic acid ↓ 0.85 0.77 0.67 0.52 0.69 0.73
Coenzyme Q9 ↑ 0.93 1.12 1.47 1.66 2.91 2.56
Levofloxacin Moxifloxacin hydrochloride
Amino acids
Amino acids related
Carbohydrates and related
Complex lipids, fatty acids and 
related
Hormones, signal substances and 
related
Vitamins, cofactors and related
 
Figure 3 Heatmap of statistically significantly increased and decreased values of metabolite changes after 
treatment with fluoroquinolones. Metabolite concentration changes relative to controls in plasma of male 
Crl/Wi(Han) rats (N = 5 per group) dosed with levofloxacin (200 mg/kg bw/d) or moxifloxacine hydrochloride 
(750 mg/kg bw/d) for 28 days. Blood samples were taken on study days 7, 14 and 28 after overnight fasting: 
figures in red boxes are statistically signifi- cantly increased and those in blue boxes statistically significantly 
decreased metabolite value changes compared to controls (N = 10 per group). Metabolites are mentioned which 
were statistically significantly altered in the same direction at least at two sampling dates (Welch t test; p < 0.2) 
per compound. 
 
Tetracyclines 
After treatment with tetracyclines 13 significantly decreased and 9 significantly increased 
metabolite changes were found compared to the control group (see Fig. 4). Changes were 
seen in amino acids and related, carbohydrates, complex lipids, fatty acids and related, 
hormones, signal substances and related, miscellaneous, nucleobases and related as well as 
vitamins, cofactors and related. At all three time points (day 7, 14, 28) and for both 
tetracyclines tested hippuric acid was remarkably decreased. The relative abundance in 
plasma was between 0.09-0.15 (doxycycline) and 0.16-0.35 (tetracycline). The decreased 
relative abundance in plasma of indole-3-acetic acid ranged from 0.47 to 0.86. For both 
substances the relative abundance in plasma for 3-indoxylsulfate was around 0.5 over all 
time points. Low relative abundance in plasma, 0.53 – 0.83, could be found for 
metanephrine for both substances. On day 28 4-hydroxysphinganine showed almost 
doubled values compared to control with a time-dependent increase. The value of 3-
methoxythyrosine was 1.6 on day 28 for both antibiotics. Cytosine relative abundance in 
plasma was slightly lower for tetracycline, while coenzyme Q9 values were higher for 
doxycycline. 
The significantly increased or decreased metabolites generally belonged to the same 
metabolite classes with the exception of the aminoglycoside’s pattern. Here, lactate as 
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metabolite of the energy metabolism was affected but not from the metabolite class of 
carbohydrates, nucleobases, vitamins or cofactors (see Table 3).  
 
Metabolite Direction Metabolite class
7 d 14 d 28 d 7 d 14 d 28 d
Glutamine ↓ 0.81 0.76 0.83 0.76 0.75 0.62
Serine ↑ 1.03 1.19 1.22 1.05 1.10 1.26
Glutamate ↑ 0.92 1.13 1.23 1.32 1.14 1.49
Citrulline ↓ 0.91 0.90 0.89 0.91 0.88 0.91
5-Oxoproline ↓ 0.79 0.84 0.88 0.80 0.81 0.72
Indole-3-acetic acid ↓ 0.47 0.52 0.64 0.67 0.74 0.86
Ketoleucine ↓ 0.58 0.75 0.59 0.75 0.61 0.53
3-Indoxylsulfate ↓ 0.68 0.45 0.25 0.33 0.47 0.51
Xylitol ↑ 1.51 1.05 1.97 1.04 1.16 1.86
scyllo-Inositol ↑ 1.21 1.58 1.48 1.24 1.28 1.67
Tricosanoic acid (C23:0) ↑ 1.04 1.26 1.46 1.10 1.36 1.31
4-Hydroxysphinganine (t18:0, Phytosphingosine), total ↑ 1.33 1.57 1.71 1.37 1.59 1.81
Palmitoleic acid (C16:cis[9]1) ↓ 0.82 0.59 1.03 0.71 0.70 0.83
Glycerol, polar fraction ↓ 0.71 0.78 0.80 0.74 0.75 0.75
Metanephrine ↓ 0.53 0.59 0.58 0.75 0.58 0.83
3-Methoxytyrosine ↑ 1.33 1.28 1.61 1.11 1.34 1.62
Spermidine ↓ 0.83 0.87 0.76 0.71 0.90 0.87
Hippuric acid ↓ 0.15 0.09 0.10 0.35 0.19 0.16
Cytosine ↓ 0.75 0.89 0.84 0.59 0.57 0.49
Uracil ↓ 0.87 0.81 1.00 0.77 0.79 0.80
Allantoin ↑ 1.16 1.10 0.98 1.12 1.07 1.12
Coenzyme Q9 ↑ 1.44 1.78 1.76 1.46 1.21 1.30 Vitamins, cofactors and related
Doxycycline monohydrate Tetracycline hydrochloride
Amino acids
Amino acids related
Carbohydrates and related
Complex lipids, fatty acids and related
Hormones, signal substances and related
Miscellaneous
Nucleobases and related
 
Figure 4 Heatmap of statistically significantly increased and decreased values of metabolite changes after 
treatment with tetracyclines. Metabolite concentration changes relative to controls in plasma of male Crl/Wi(Han) 
rats (N = 5 per group) dosed with doxycy- cline monohydrate (250 mg/kg bw/d) or tetracycline hydrochloride 
(50,000 ppm/d) for 28 days. Blood samples were taken on study days 
7, 14 and 28 after overnight fasting: figures in red boxes are statisti- cally significantly increased and those in blue 
boxes statistically sig- nificantly decreased metabolite value changes compared to controls (N = 10 per group). 
Metabolites are mentioned which were statisti- cally significantly altered in the same direction at least at two 
sampling dates (Welch t test; p < 0.2) per compound. 
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Table 3 Statistically significantly increased and decreased metabolites changes after treatment with 
antibiotics of three different classes. Metabolite concentration changes in plasma of male Crl:Wi(Han) 
rats (N = 5 per group) dosed with aminoglycosides, fluoroquinolones and tetracyclines for 28 days. ↑ = 
metabolite level is increased in at least two of the three sampling dates; ↓ = metabolite level is 
decreased in at least two of the three sampling dates; metabolite values were compared to controls (N = 
10 per group; Welch-t-test; p < 0.2). 
Metabolite class Metabolite Aminoglycosides Fluoroquinolones Tetracyclines
Alanine ↓
Glutamate ↓ ↑
Glutamine ↓ ↓
Isoleucine ↓
Proline ↓
Serine ↑
Taurine ↑
Tyrosine ↓
Valine ↓
3-Indoxylsulfate ↓
5-Oxoproline ↓ ↓
Citrulline ↓
Indole-3-acetic acid ↓ ↓ ↓
Indole-3-propionic acid ↓
Ketoleucine ↓ ↓ ↓
Glucose ↑
scyllo-Inositol ↑
Xylitol ↑ ↑
3-O-Methylsphingosine (d18:1) ↑
4-Hydroxysphinganine (t18:0, Phytosphingosine), total ↑ ↑
Cholesterol, total ↑
dihomo-gamma-Linolenic acid (C20:cis[8,11,14]3) ↓
Glycerol, polar fraction ↓ ↓ ↓
Lysophosphatidylcholine (C20:4) ↓
Nervonic acid (C24:cis[15]1) ↑
Palmitoleic acid (C16:cis[9]1) ↓
Phosphatidylcholine (C18:0,C18:1) ↑
Sphingomyelin (d18:2,C16:0) ↑
Sphingomyelin (d18:2,C18:0) ↑ ↑
TAG (C16:0,C18:2) ↓
TAG (C18:1,C18:2) ↓
TAG (C18:2,C18:3) ↓ ↓
Tricosanoic acid (C23:0) ↑
Energy metabolism and 
related
Lactate
↓
3-Methoxytyrosine ↑ ↑
3-O-Methyldopamine ↓
Metanephrine ↓ ↓
Normetanephrine ↓
Hippuric acid ↓ ↓ ↓
Putrescine ↓
Spermidine ↓
Allantoin ↑
Cytosine ↓ ↓
Uracil ↓
alpha-Tocopherol ↑
Coenzyme Q9 ↑ ↑
Coenzyme Q10 ↑
Pantothenic acid ↓
Amino acids
Amino acids related
Carbohydrates and 
related
Complex lipids, fatty 
acids and related
Hormones, signal 
substances and related
Miscellaneous
Nucleobases and related
Vitamins, cofactors and 
related
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DISCUSSION 
Metabolome pattern for each class of antibiotics 
In our studies we demonstrate that antibiotics have a profound influence on the plasma 
metabolites in rats following oral administration. Aminoglycosides have, in contrast to the 
other antibiotics, poor activity against obligate anaerobic and most gram-positive bacteria 
(except for most staphylococci), but are active against most gram-negative aerobic or 
facultative anaerobic bacilli (Brown and Riviere 1991; Dortantz and Devices 1999; 
Mingeot-Leclercq et al. 1999). The antimicrobial spectrum of the third-generation 
levofloxacin and fourth-generation moxifloxacin includes aerobic and facultative anaerobic 
Gram-positive and most Gram-negative organisms, with additional activity of moxifloxacin 
against most clinically significant obligates anaerobes (Scoper 2008). Tetracyclines have a 
bacteriostatic activity against almost all medically relevant aerobic and anaerobic bacterial 
genera, both Gram-positive and Gram-negative, mycoplasmas, rickettsiae, chlamydiae, and 
even some protozoa (Boothe 2015). Here we show that there are antibiotic class specific 
changes in the plasma metabolome of rats: for each class of antibiotics specific metabolome 
patterns could be established. This could enable an identification of new compounds or 
biologicals with an antibiotic activity and associate the metabolome change with a specific 
class of antibiotics. The second purpose of these investigations was to ascertain which of 
the metabolites obtained in the plasma from rats are associated with microbiome 
functionality. 
 
The pattern of aminoglycosides (neomycin and gentamicin) with 17 decreased metabolites, 
while two significantly increased, is considerably different than the other patterns obtained 
with fluoroquinolones (levofloxacin and moxifloxacin) and tetracyclines (tetracycline and 
doxycycline). The particular importance of the aminoglycosides for this research is the fact 
that they are very poorly absorbed from the gastrointestinal tract. Numerical values for 
absorption range from 1 – 3%, the highest mentioned for rats is 6% (Renshaw et al.; Brown 
and Riviere 1991; Bergogne-Bérézin and Bryskier 1999; Dhillon 2006). If we assume that 
6% can be absorbed, we would obtain a systemic dose level of 15 mg/kg body weight for 
neomycin and 6 mg/kg body weight for gentamicin. Compared to safe human therapeutic 
dose levels (gentamicin up to 7 mg/kg IV every 24 hours for 7 to 21 days (Drugs.com 
[Internet, 2016a]; European Medicines Agency 2016), neomycin orally up to 100 
mg/kg/day divided every 6 hours with a treatment period of 2 weeks (Drugs.com [Internet], 
2016b) we can virtually exclude that systemic toxicity would have contributed significantly 
to the metabolite changes detected with these two compounds.  
This conclusion is in line with several studies in rats; the neomycin-NOAEL of a two-year 
oral carcinogenicity study with rats being 25 mg/kg bw/day and the same value being 
reported in a multi-generation reproductive and teratogenicity study in rats (van Koten-
Vermeulen and van Leeuwen 1995). Oral dosing of gentamicin in rats for a period of 13 
weeks up to doses of 116 mg/kg bw/day showed no treatment-related effects in kidneys, 
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liver, heart and brain even at the highest dose level. The NOEL was 19 mg/kg bw/day 
(Roberts 1995). 
 
Therefore, the changes in the plasma profile detected should not be caused by systemic 
effects (i.e. organ toxicity) and consequently, plasma metabolome changes caused by these 
antibiotics are highly likely the result of their effect on microbiome functionality. Thus, 
these results are a key component for the evaluation of microbiome specific effects. 
Compared to the other two patterns, 13 out of the 19 altered metabolites are unique for the 
aminoglycoside pattern (see Table 3).  
 
With 26 significantly lower or higher values, the metabolite pattern of fluoroquinolones 
showed the highest number of altered metabolite values compared to the patterns of 
aminoglycosides and tetracyclines. Increased relative abundance in plasma for 4-
hydroxysphinganine, nervonic acid, 3-O-methylsphingosine, sphingomyelin, coenzymes 
Q9 and Q10 were more pronounced for moxifloxacin. Moxifloxacin is an antibiotic of the 
fourth generation with a broader activity spectrum and thus is more effective against Gram-
positive bacteria and anaerobes than levofloxacin (Scoper 2008). This could explain the 
potentiation of the effect reflected by the higher relative abundance values in plasma for 
moxifloxacin than levofloxacin.  
 
After treatment with tetracyclines 22 significantly altered values of metabolite changes 
were found (see Table 3). On day 28 after tetracycline treatment values of 4-
hydroxysphinganine were almost doubled compared to control and a time-dependent 
increase could be observed. Cytosine relative abundance in plasma were slightly lower for 
tetracycline, while coenzyme Q9 values were higher for doxycycline. 
In contrast to the aminoglycoside pattern, the number of increased and decreased 
metabolites are similar after treatment with tetracyclines or fluoroquinolones.  
 
Identification of microbiota-derived metabolites 
Since it can be assumed that aminoglycosides do not have a systemic effect in this study, 
changes of the metabolites were probably due to an altered microbiome (see Table 3). All 
metabolites, except two sphingomyelin isomers, were decreased. Besides hippuric acid and 
indole-3-acetic acid, the metabolite indole-3-propionic acid, which belongs to the 
tryptophan and indole metabolic pathway, was found to be a unique biomarker metabolite 
for the aminoglycoside pattern. IPA is a potent antioxidant and because of its 
neuroprotective property it is being studied for therapeutic use in Alzheimer's disease 
(Chyan et al. 1999; Paul E. Bendheim, Burkhard Poeggeler, Eyal Neria, Vivi Ziv 2002). 
Since IPA could not be found in the plasma of germ-free mice in contrast to conventional 
mice, Wikoff et al. colonized them with Clostridium sporogenes ATCC 15579 (Wikoff et 
al. 2009). IPA was observed five days after colonization which demonstrates that the 
continuous IPA production from one bacterial species in the gastrointestinal tract is 
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sufficient to introduce IPA into the bloodstream of the host (Wikoff et al. 2009). However, 
C. sporegenes is an obligate anaerobe and hence should not be affected strongly by 
aminoglycosides. It could be speculated that either this strain is affected over the long time 
of the treatment or there are other strains that are able to produce enough IPA at levels, 
which are subsequently detectable in the serum.  
 
Three metabolites, of which relative abundances in plasma were decreased in all patterns, 
could be identified as key metabolites in all three patterns: indole-3-acetic acid, hippuric 
acid and glycerol. Since they could be found in the aminoglycoside pattern, it is highly 
likely that these metabolites are derived from the microbiota. We suggest that if these 
metabolites were derived from the diet, the metabolite values would not be altered. 
Indole-3-acetic acid, a protein-bound uremic solute, is generated either from bacterial 
indole production or from dietary tryptophan degradation by both endogenous and bacterial 
cells, e.g. Clostridium sporogenes, Clostridium bartlettii and E coli (Ramezani et al. 2015). 
IAA contributes to the progression of CKD in rats (Satoh et al. 2003), and in serum of CKD 
patients IAA is a significant predictor of mortality and cardiovascular events, inducing 
proinflammatory enzyme COX-2 and oxidative stress via the nongenomic AhR pathway 
(Dou et al. 2014). In antibiotic-treated rats, the tryptophan metabolism appeared to be 
significantly altered because levels of indole-containing substances like 3-indoxylsulfate 
and IAA were decreased both in urine and feces whereas tryptophan and tryptamine levels 
were increased significantly in feces (Zheng et al. 2011).  
Also, a well-known urinary metabolite of host-microbial origin is hippuric acid and its 
concentrations can be modulated by diet, stress, disease, and the microbiome (Phipps et al. 
1998; Nicholson et al. 2012). The microbes produce benzoate by metabolizing aromatic 
compounds and polyphenols, and benzoate is then conjugated with glycine in the liver, 
kidney and intestine (Strahl and Barr 1971; Chiba et al. 1994; Poon and Pang 1995). 
Related bacteria are Clostridium difficile, F. prausnitzii, Bifidobacterium, 
Subdoligranulum, Lactobacillus (Strahl and Barr 1971; Chiba et al. 1994; Poon and Pang 
1995; Nicholson et al. 2012). HA is associated to a variety of health and disease states: it 
may be a biomarker of hypertension and obesity in humans, may cause an increase of anion 
gap acidosis and glucose intolerance, interferes with erythropoiesis and platelet 
cyclooxygenase activity (Remer and Manz 2003; Li et al. 2008; Kohli et al. 2011; 
Ramezani et al. 2015). Bacterial suppression by antibiotics reduces the excretion of 
hippuric acid in blood, urine and feces of rodents (Williams et al. 2002; Swann et al. 2011; 
Zheng et al. 2011). Also in germ-free animals the plasma and urinary concentrations of 
hippuric acid are reduced (Nicholls et al. 2003; Wikoff et al. 2009).  
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Table 4 Potential microbiome-derived metabolites: statistically significantly increased and decreased metabolites 
changes after treatment with nonabsorbable aminoglycosides. Metabolite concentration changes in plasma of male 
Crl:Wi(Han) rats (N = 5 per group) dosed with neomycin and gentamicin sulfate; ↑ = metabolite level is increased 
in at least two of the three sampling dates; ↓ = metabolite level is decreased in at least two of the three sampling 
dates; metabolite values were compared to controls (N = 10 per group; Welch-t-test; p < 
0.2).
Metabolite Direction Metabolite class
Alanine ↓
Proline ↓
Tyrosine ↓
Indole-3-acetic acid ↓
Ketoleucine ↓
Indole-3-propionic acid ↓
Glycerol ↓
dihomo-gamma-Linolenic acid (C20:cis[8,11,14]3) ↓
Sphingomyelin (d18:2,C16:0) ↑
Sphingomyelin (d18:2,C18:0) ↑
TAG (C16:0,C18:2) ↓
TAG (C18:1,C18:2) ↓
Lysophosphatidylcholine (C20:4) ↓
TAG (C18:2,C18:3) ↓
Lactate ↓ Energy metabolism and related
Normetanephrine ↓
3-O-Methyldopamine ↓
Putrescine ↓
Hippuric acid ↓
Miscellaneous
Amino acids
Amino acids related
Complex lipids, fatty acids and related
Hormones, signal substances and related
 
 
Through ingredients of the diet, e.g. triacylglycerols and phospholipids, and/or by in situ 
microbial production or release from desquamated epithelial cells, glycerol can be found in 
the gastrointestinal tract (De Weirdt et al. 2010). Components of the lipids, like 
triacylglycerols, phosphatidylcholine, lysophosphatidylcholine, glycerol, myo-inositol and 
fatty acids, can be measured in the blood (Mellert et al. 2011). Evidence that glycerol is 
produced by the gut microbiota is provided by an experiment of Frost et al.: they compared 
human to gelada microbiota and found out that grass stimulated the gelada microbiota to 
produce ethanol and glycerol while it stimulated the human microbiota to produce acetate 
and propionate (Frost et al. 2014). In a 28 day study in rats Mellert et al. found that plasma 
glycerol levels were decreased in male rats under dietary restriction when compared to 
controls as well as when overnight fasted animals were compared to non-fasted individuals 
(Mellert et al. 2011). In human feces, a high concentration of glycerol and a reduced 
amount of butyrate was found in the feces of Crohn’s disease patients in comparison with 
the control group and ulcerative colitis patients, but the origin and role of glycerol in the 
feces is unclear (Marchesi et al. 2007). Compared to rat feces glycerol seems to be unique 
to the human (Saric et al. 2008). Glycerol seems to play an important role in the 
microbiome and we suggest that both dietary restriction and especially a gut bacterial 
reduction due to antibiotic treatment may lead to the decrease of glycerol levels in the blood 
of the rats. 
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Influence of systemic toxicity on metabolite patterns 
For the tetracycline and fluoroquinolone antibiotics, which are absorbed from the 
gastrointestinal tract, a possible influence of systemic toxicity must be taken into account 
when evaluating their effects on the metabolome (see Table 4). Side effects of 
fluoroquinolones in rats and/or humans can involve the blood, heart, liver, kidney, central 
nervous system (CNS), thyroid and oculotoxicity, and adverse effects of tetracyclines were 
seen in the adrenals, liver, bones, kidney, testes, thyroid heart, inner ear, CNS and on the 
skin (phototoxicity) (Adir 1975; Vargas-Estrada et al. 2008; U.S. Food and Drug 
Administration 2013; Musther et al. 2014; U.S. Food and Drug Administration 2015). The 
dose levels selected for the tetracycline and fluoroquinolone antibiotics were below the 
maximum tolerated dose for rats, but in a dose-range in which systemic toxicity cannot be 
excluded. 
 
In this study, several metabolites that were not significantly altered after the treatment with 
aminoglycosides and could be either produced by the microbes, the mammalian cells or 
were degraded from diet, are discussed in the following.  
 
Table 5 Classes of antibiotics, mechanism of action, main side effects and bioavailability of neomycin, 
streptomycin, tetracycline, doxycycline, levofloxacin and moxifloxacin. 
Class of antibiotics Mechanism of action Side effects
(rats)
Side effects
(humans)
Bioavailability
(rats)
Aminoglycosides inhibition of protein synthesis
bacteriostatic
kidney, inner ear kidney, inner ear 6% (gentamicin)a
Tetracyclines inhibition of protein synthesis
bacteriostatic
adrenals, bones, CNS, 
kidney, liver, testes, 
thyroid
kidney, heart, liver, inner 
ear, CNS, phototoxicity
80-100%b
Fluoroquinolones preventing bacterial DNA from 
unwinding and duplicating
bacericidal
CNS, heart, kidney, 
liver, testes, thyroid
blood, CNS, heart, kidney, 
liver, phototoxicity, bones 
(arthropathy), oculotoxicity
80%c
 
a(Renshaw et al.; Brown and Riviere 1991; Bergogne-Bérézin and Bryskier 1999; Dhillon 2006)  
b(Adir 1975; Vargas-Estrada et al. 2008) 
c(von Keutz and Schlüter 1999; Musther et al. 2014; Ahmadi et al. 2016) 
 
After tetracycline treatment serum levels for 3-indoxylsulfate (IS), which is a metabolite in 
the tryptophan and indole metabolic pathway, were reduced by around 50 percent. 
Tryptophan either derives from protein degradation from food or can be synthesized by the 
gut microbiota (Clarke et al. 2014; Heinken and Thiele 2015b). The bacterial tryptophanase 
can degrade tryptophan to skatole and indole, respectively. From the intestine the latter is 
further absorbed into the blood and metabolized in the liver via phase II transformation to 
indoxylsulfate (Zheng et al. 2011; Heinken and Thiele 2015b). IS is an uremic toxin and 
directly linked to vascular disease and mortality and progression of chronic kidney disease 
(Zeng et al.; Barreto et al. 2009; Wu et al. 2011). 
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Our results are concordant with other studies where plasma extracts from germ-free mice 
were compared to samples from conventional mice: IS was identified only in the serum of 
animals harboring microbes (Wikoff et al. 2009). Also decreased relative abundance in 
plasma of IS was detected in rat feces and urine after antibiotic treatment due to gut 
bacterial reduction and subsequently a loss of bacterial enzymes like tryptophanase (Wu et 
al. 2011; Zheng et al. 2011). 
In the metabolite pattern of fluoroquinolones and tetracyclines metanephrine values were 
decreased and 3-methoxytyrosine and coenzyme Q10 and/or Q9 are upregulated. 
Coenzyme Q serves as an important redox active constituent in both mitochondria and lipid 
membranes (Kamp et al. 2012a). This suggests that the mitochondrial membranes may have 
been affected by tetracyclines and that an increased plasma level of oxidized coenzyme Q9 
could finally lead to hepatotoxicity (Kohli et al. 2011). 
In both classes, there were also altered values of glutamine and glutamate, which may play 
an important role in the microbiome. Both metabolites are produced by the microbes and 
can be used as energy sources to enterocytes, especially during illness and stress, and many 
studies in the last decades indicated that glutamine is an important metabolite for the small-
intestinal mucosal cells regulating many cellular mechanisms (Dai et al. 2013; Davila et al. 
2013; Frye et al. 2015; Heinken and Thiele 2015b). In plasma and tissue profiles in murine 
colitis models altered values of these metabolites were found, which were correlated with 
the developmental phases of this illness and severity (Holmes et al. 2011; Shiomi et al. 
2011). Glutamine can be produced by glutamate and ammonia and in a study of Thomas et 
al. pretreatment with glutamine prior to surgical gut manipulation in rodents prevents gut 
and lung injury due to oxidative and inflammatory processes and protects enterocyte 
mitochondria (Thomas et al. 2005). 
 
Besides hippuric acid, there was a decrease of the polyamines putrescine and spermidine 
after treatment with aminoglycosides or tetracylines, respectively. They are generated from 
precursor amino acids by the microbes and in low amounts by normal colonocytes (Davila 
et al. 2013; Ramezani et al. 2015). They are involved in various physiological processes 
both in bacterial and endogenous cells, like the biofilm formation, bacteriocin production 
and the microbial pathogenesis (Tabor and Tabor 1985; Shah and Swiatlo 2008; Igarashi 
and Kashiwagi 2010). However, none of them was altered after the treatment with 
fluoroquinolones. 
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Table 6 Statistically significantly increased and decreased metabolites after treatment with fluoroquinolones or 
tetracyclines, respectively. The metabolites changes could originate from systemic/organ toxicity and can be found 
in different mode of action (MOA) metabolome patterns in the data base MetaMap®Tox. 
 
 
Various significantly increased and decreased metabolites after the treatment with 
fluoroquinolones or tetracyclines can be also found in MOA metabolome patterns in Table 
5 in the data base MetaMap®Tox. The metabolites and the corresponding MOA patterns are 
listed in Table 6. The findings suggest that these metabolites could be caused by organ 
toxicity, especially due to liver, kidney and testes toxicity, which can be found in 
toxicological studies in the rat (see Table 4). Other MOA patterns, which include the 
altered metabolites, are related to organ toxicity of the thyroid, the CNS and disturbances of 
the steroid hormones.  
 
The plasma metabolite profile is dependent on the bactericidal/-static efficacy spectrum of 
the antibiotic, its bioavailability, and consequently its potential systemic effect. This leads 
to specific changes in the metabolite pattern and is hence an opportunity to identify and 
characterize substances that may have antibiotic properties. 
 
Taken together, plasma metabolite changes of hippuric acid, indole-3-acetic acid and 
glycerol following antibiotic treatment and microbiota changes are highly likely to reflect 
changes in microbiome-derived metabolites. This could be concluded because 
aminoglycosides are poorly absorbed from the gut and thus just have an effect on the 
microbes. Indole-3-propionic acid was found to be a unique biomarker plasma metabolite 
for the aminoglycosides and 3-indoxylsulfate for the tetracyclines. Besides other amino 
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acids and amino acid related metabolites, coenzyme Q, glutamine, glutamate, putrescine 
and spermidine were found to be mammalian-microbiome co-metabolites.  
The results suggest that plasma based metabolic profiling (metabolomics) could be a 
suitable tool to investigate the effect of compounds on the functionality of the microbiome 
and to obtain insight in the mammalian-microbiome co-metabolism of endogenous 
metabolites. The investigation of the production of metabolites absorbed by the host, or 
microbiome’s functionality, is also a concept to assess toxicological risks of new 
compounds or biologicals associated with microbiota changes. Therefore, it is essential to 
determine the composition of the intestinal microbiota, organization and the host-
microbiota interactions. The combination of metabolomics, metagenomics, e.g. 16S rRNA 
sequencing, and systems biology would be an interdisciplinary approach to identify adverse 
effects on the microbiota that could lead to disease. Targeted manipulation of the 
microbiota with antibiotics and subsequent community analyses could enable a correlation 
between metabolites and bacterial species. Considering toxicological studies in rats, 
however, it is important first to investigate the “base line variability” of their microbiota 
analyzing control groups with standardized diet, control groups with corn oil or 
carboxymethyl cellulose, that are normally used as formulation of test substances. It also 
includes a control group with restricted diet because the effect of dieteray restriction on the 
metabolite pattern has been proven and ingestion of less food is likely to cause a shift in the 
microbial community. These targeted experimental investigations are currently carried out. 
The specific plasma metabolite patterns are a first step to in the future identify substances in 
the data base MetaMap®Tox with a similar effect on the microbiome. 
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ABSTRACT 
The metabolic functionality of the gut microbiota contributes to the metabolism and well-
being of its host, although detailed insight in the microbiota’s metabolism is lacking. Omics 
technologies could facilitate unraveling metabolism by the gut microbiota. 
In this study, we performed metabolite profiling of different matrices of the gut, after 
antibiotic treatment of rats in order to evaluate metabolite changes observed at different 
dose levels and in different sexes, and to identify the best tissue matrix for further 
investigations regarding an assessment of metabolic effects of new compounds with 
antibiotic activity. Three different antibiotics (vancomycin, streptomycin and 
roxithromycin) were administered orally to rats for 28 days according to the OECD 407 
guideline with a subsequent metabolic profiling in feces, cecum content and gut tissue 
(jejunum, ileum, cecum, colon and rectum). The data were analyzed in the MetaMap®Tox 
database. 
Treatment-related effects could be observed in the metabolite profile of feces and cecum 
content, but not of the different gut tissues. The metabolite profile showed compound 
specific effects on the microbiome. In line with the activity spectra of the antibiotics tested, 
vancomycin showed the largest effects, followed by roxithromycin and then by 
streptomycin for which changes were modest. In general, for all antibiotics the largest 
changes were observed for the classes of lipids (increase up to 94-fold), bile acids (increase 
up to 33-fold), amino acids (increase up to 200-fold) and amino acid related (increase up to 
348-fold). The most relevant changes in metabolite values were similar in feces and cecum 
content and among sexes. The results of this targeted analysis indicate that the metabolic 
profiles of male and female animals in the gut microbiome are comparable. Concluding, 
taking other samples than feces does not add any extra information. Thus, as a non-invasive 
sampling method, feces provide a suitable matrix for studies on metabolism by the gut 
microbiota.  
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ABBREVIATIONS  
GC  gas chromatography 
HD  high dose 
IAA  indole-3-acetic acid 
ILA  indole-3-lactic acid 
LC  liquid chromatography 
LD  low dose 
MOA  mode of action 
MS  mass spectrometry 
OECD  Organization for Economic Cooperation and Development 
PCA  principal component analysis 
SPE  solid phase extraction 
TAG  triacylglycerol 
 
 
INTRODUCTION 
The intestinal microbiome plays an important role in health and disease of the host, and can 
be influenced by factors such as diet, the host condition, environmental chemical exposure 
and toxicological insult (e.g. antibiotics) (David et al., 2014; Modi et al., 2014; Rosenfeld, 
2017; Zhang et al., 2015). The microbiome consists of trillions of microbial cells with a 
high inter- and intraspecies variability which makes it difficult to define a healthy gut 
microbiome regarding the species inhabiting the gut (Nguyen et al., 2015; Sender et al., 
2016). However, the functional genes and the metabolic output of the microbes are likely to 
have a lower variability (Cho and Blaser, 2012; McCoy et al., 2017). Regarding this 
assumption, disease risks arising from gut microbial changes can be investigated by 
studying the microbiome’s functionality, defined here as the production of metabolites. 
These metabolites can have a profound effect on the host, for example via nuclear receptor 
signaling, leading to changes in various pathways including for example energy metabolism 
and regulation of the immune system (Rooks and Garrett, 2016).  
To investigate this complex relation of host and microbes, a better understanding of the 
crosstalk between host and gut microbes is essential. This can be done by measuring the 
molecules that enable this interaction, including especially metabolites formed by the 
microbiota available for uptake by the host. Metabolomics can serve as a powerful tool for 
assessing the functional status of the microbiome beyond taxonomics (Silbergeld, 2017; 
Wikoff et al., 2009). Other practical advantages of metabolomics include the possibility to 
use different matrices like urine, blood or feces, which also enables a longitudinal study 
design. Furthermore, with metabolomics a broad range of metabolites can be quantitatively 
measured and metabolic fluxes can be analyzed (Fernie et al., 2004). In the context of the 
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complex mammalian–microbial co-metabolism, data obtained can be further used in a 
systems biology approach integrating these high-throughput data in computational network 
models (Heinken and Thiele, 2015). 
 
In a previous study, we analyzed changes of the metabolome in plasma samples of male 
Wistar rats after administration of antibiotics known to induce an artificial shift of the 
intestinal microbiota (Behr et al., 2017). We measured small endogenous molecules such as 
carbohydrates, amino acids, nucleic acids or fatty acids and their derivatives resulting from 
biochemical pathways (Lindon et al., 2004). Using this approach, microbiome-related 
metabolites in the plasma could be identified and specific metabolite patterns could be 
established in the MetaMap®Tox database. This in vivo metabolomic database allows the 
prediction of systemic toxicity as well as the identification of substances with the same 
mode of action. 
In the previous study it was difficult to distinguish between plasma metabolites derived 
from microbes and of endogenous origin. Therefore, in the current study we performed a 
metabolic profiling in different matrices of the gut after oral administration of broad-
spectrum antibiotics of different classes (see Figure 1). Vancomycin, streptomycin and 
roxithromycin were administered for 28 days in two dose levels to Wistar rats, and a 
targeted analysis of the same metabolites that were analyzed previously in plasma for usage 
in the MetaMap®Tox database were measured in feces, cecum content, and in tissues of 
jejunum, ileum, cecum, rectum and colon. Relative levels of metabolites in samples of 
treated rats were compared to the levels of these metabolites in untreated controls.  
 
 
Fig. 1. Schematic presentation of the study design for metabolic profiling in different gut matrices of antibiotic 
treated rats. To identify metabolites related to microbiome changes due to antibiotic treatment, we have applied a 
metabolomics approach. Broad-spectrum antibiotics with each a different activity spectrum (vancomycin, 
streptomycin and roxithromycin) were administered orally to rats in a toxicity study. Feces, cecum content and gut 
tissue (jejunum, ileum, cecum, colon, rectum) were sampled for metabolic profiling on day 28 of the study. 
 
The aim of this study was 1) to assess if the same metabolites previously detected in plasma 
could be found in the different gut tissues, 2) to investigate if a treatment-related effect can 
be observed in the analyzed tissues, and if different activity spectra of antibiotics are 
reflected in the metabolite profiles, 3) to evaluate if metabolite changes are observed at 
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different dose levels and if they are sex-dependent, and 4) to identify the best sample matrix 
for the assessment of effects of new compounds affecting the gut microbiome. 
 
 
MATERIALS AND METHODS 
Five independent studies were performed according to Organization for Economic 
Cooperation and Development (OECD) 407 guideline. Animal handling, treatment, and 
clinical examinations have been described earlier (Kamp et al., 2012; Strauss et al., 2012; 
van Ravenzwaay et al., 2012, 2010, 2007). 
 
Ethics statement 
The studies were approved by the BASF Animal Welfare Body, with the permission of the 
local authority, the Landesuntersuchungsamt Rheinland-Pfalz (approval number 23 177-
07/G 13-3-016). The study was performed in an AAALAC-approved (Association for 
Assessment and Accreditation of Laboratory Animal Care International) laboratory in 
accordance with the German Animal Welfare Act and the effective European Council 
Directive. 
 
Animals and Maintenance Conditions 
Briefly, male and female Wistar rats (CrI:WI(Han)) were supplied by Charles River, 
Germany, and were approximately 70 ±1 days old at the beginning of the studies. The 
animals were maintained in an air-conditioned room at a temperature of 20 to 24°C, a 
relative humidity of 30 to 70%, and a 12 hour light / 12 hour dark cycle. Ground Kliba 
mouse/rat maintenance diet was supplied by Provimi Kliba SA, Kaiseraugst, Switzerland. 
Diet and drinking water were available ad libitum (except 16 - 20 hours before plasma 
sampling) and regularly assayed for chemical contaminants and the presence of 
microorganisms. 
 
Treatment of animals with compounds 
Treatment groups of five animals per group and sex were administered the test substance 
via gavage using an appropriate vehicle and metabolite changes were compared with a 
dietary control group (10 rats per sex). Dose levels of the antibiotics were selected in such a 
way that the low dose (LD) would show a low and reversible toxicological effect, while the 
high dose (HD) would show the toxicological mode of action. Dose-levels, routes of 
administration and form of preparation of the antibiotics are summarized in Table 1. 
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Table 1 Compounds used, dose levels, form of preparation, and class of antibiotics. All compounds were 
administered orally by gavage. 
Treatment Dose/day Form of preparation Class of antibiotics
Vancomycin 400 and 50 mg/kg body weight in ultra-pure water Glycopeptides
Streptomycin sulfate 450 and 100 mg/kg body weight in water containing 
0.5% CMCa 
Aminoglycosides
Roxithromycin 600 (400)b and 200 mg/kg body weight in water containing 
0.5% CMCa 
Macrolides
a carboxymethyl cellulose: Tylose CB30000   b reduced on study day 3 in female and day 5 in male animals  
 
Sampling of gut tissues, cecum content and feces for metabolic profiling 
Gut tissue samples (0.5 - 1 cm), feces and cecum content were carefully removed during 
necropsy on day 28 after a fasting period of 16 – 20 hours and one day after the last 
administration of the test substances. Besides feces and cecum content, the following gut 
tissues were taken for metabolite profiling: jejunum, ileum, rinsed cecum, colon and 
rectum. Cecum epithelium was rinsed with sterilized isotonic NaCI solution to remove the 
content. The samples were collected in pre-cooled (dry-ice) vials, immediately snap-frozen 
in liquid nitrogen and stored at -80 °C until metabolite profiling was performed. 
 
Clinical Examinations 
All animals were checked daily for any clinically abnormal signs and mortalities. Food 
consumption was determined on study days 6, 13 and 27. Body weight was determined 
before the start of the administration period in order to randomize the animals and on study 
days 6, 13 and 27. At the end of the treatment period, the animals were sacrificed by 
decapitation under isoflurane anesthesia. Metabolite profiling of the gut tissues, cecum 
content and feces samples was performed for all control and treated animals.  
 
Metabolite Profiling in gut tissues, cecum content and feces  
For mass spectrometry-based metabolite profiling, the gut tissue, feces and cecum content 
samples taken on study day 28 were extracted by a proprietary method as described below. 
Three types of mass spectrometry analysis were applied to all samples: GC-MS (gas 
chromatography-mass spectrometry) and LC-MS/MS (liquid chromatography-MS/MS) 
were used for broad profiling (van Ravenzwaay et al., 2007). Proteins were removed from 
60 µL plasma samples by precipitation using 200 µL acetonitrile. Subsequently, polar and 
non-polar fractions were separated for both GC-MS and LC-MS/MS analysis by adding 
water and a mixture of ethanol and dichloromethane (1:2, v:v). Feces and cecum content 
samples were freeze dried and ground prior to extraction. Feces, cecum content (5 mg) and 
tissue samples (10 mg) were extracted with a mixture of acetonitrile, water, ethanol and 
dichloromethane in a sample tube with a 3 mm stainless steel ball using a Bead Ruptor 
(Omni International Inc.). Phase separation was achieved by adding additional 
dichloromethane. For GC-MS analysis (CTC GC PAL, Agilent 6890 GC gas 
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chromatograph, 5973 MSD mass spectrometer), the non-polar fraction was treated with 
methanol under acidic conditions to yield the fatty acid methyl esters derived from both 
free fatty acids and hydrolyzed complex lipids. The non-polar and polar fractions were 
further derivatized with O-methyl-hydroxylamine hydrochloride and pyridine to convert 
oxo-groups to O-methyl-oximes and subsequently with a silylating agent before analysis 
(Roessner et al., 2000). For LC-MS analysis, both fractions were reconstituted in 
appropriate solvent mixtures. HPLC was performed by gradient elution on reversed phase 
separation columns. Mass spectrometric detection technology was applied which allows 
target and high sensitivity MRM (Multiple Reaction Monitoring) profiling in parallel to a 
full screen analysis as described in patent WO2003073464 (Walk and Dostler, 2003). For 
GC-MS the acquisition in scan mode m/z 15-600 for polar compounds and m/z 40-600 for 
lipid compounds was applied. For LC-MS a MRM and Q3 Scan of m/z 100-1000 was used. 
MRMs off all analytes were determined using solutions of the authentic standard.  
GC-MS conditions: CTC GC PAL, Agilent 6890 GC gas chromatograph, 5973 MSD mass 
spectrometer, gradient: 70 °C to 340 °C, carrier gas: helium, acquisition in scan mode m/z 
15-600 (polar compounds) / m/z 40-600 (lipid compounds) 
 
LC-MS conditions: Agilent 1100 HPLC System, AB Sciex API 4000 mass spectrometer, 
gradient elution for polar compounds with water / acetonitril / ammonium formate, gradient 
elution for lipid compounds with water / methanol / methyl tert-butyl ether / formic acid, 
MRM and Q3 Scan m/z 100-1000 
 
For GC-MS and LC-MS/MS profiling, data were normalized to the median of reference 
samples which were derived from a pool formed from aliquots of all samples to account for 
inter- and intra-instrumental variation. The method resulted in 202 semi-quantitative 
analytes using the single peak signal of the respective metabolite and a normalization 
strategy according to the patent WO2007012643A1 (Walk et al., 2006) resulting in ratio 
values which represent the metabolite change of treated versus control animals, of which 
175 are chemically identified and 27 are structurally unknown. 
 
Statistics 
The data were analyzed by univariate and multivariate statistical methods. The sex- and 
day-stratified heteroscedastic t-test ("Welch test") was applied to compare metabolite levels 
of dose groups with respective controls. The p-values, t-values, and ratios of corresponding 
group medians were collected as metabolic profiles and fed into the MetaMap®Tox 
database. Here, the profile strength of the metabolic profile is addressed. This parameter 
represents the rounded down average of absolute medians of t-values and does not only 
include the absolute number of significantly changed metabolites, but also the magnitude of 
the respective changes. For a detailed description on the use of statistics in MetaMap®Tox 
see van Ravenzwaay et al. (van Ravenzwaay et al., 2016).  
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PCA scores plots and loadings of metabolites for all tissues and matrices on day 28 were 
generated in the statistical software R version 3.3.1. Since loadings represent the 
covariances/correlations between the original variables and the unit-scaled components, the 
values of each metabolite were used to establish a list of 25 metabolites with the highest 
loading for each PC1, 2 and 3 in the feces. Heatmaps of these metabolites after treatment 
with the three antibiotics were generated and compared to the corresponding values in 
cecum content (see Supplementary Material). In the heatmap data points statistically 
different (p < 0.05) from control expressed as fold-change of control indicated within the 
heatmap square.  
Whenever we write “significantly”, "statistically significantly” is meant. 
 
 
RESULTS 
Clinical signs 
There were no mortalities in any of the treatment groups, except for one animal at the 
beginning of the study in the female low dose (LD) group of streptomycin. Animals which 
received the different antibiotics showed no signs of clinical toxicity, except for the high 
dose (HD) group of roxithromycin (slight salivation, piloerection, semiclosed eyelids, 
encrusted nose, general poor condition) and the corresponding LD group (slight salivation). 
Table 2 presents the food consumption and on body weight development for the different 
treatments.  
 
Table 2 Relative changes in body weight and food consumption of male and female Crl:Wi(Han) rats (N=5 per 
group) dosed for 28 days compared to the corre- sponding controls. Data were collected on study days 6, 13 and 
27, values in bold are statistically significantly decreased (Dunnett test (two-sided), p < 0.05) compared to controls 
(N=10 per group). 
m f m f
6 0.99 1.01 0.90 0.93
13 0.98 1.02 0.96 0.93
27 0.96 1.03 1.00 0.96
6 0.99 0.98 0.88 0.85
13 0.97 1.00 0.93 0.92
27 0.95 1.00 0.93 0.95
6 0.99 1.01 0.92 0.97
13 1.00 0.99 1.02 1.01
27 1.00 1.00 0.98 0.96
6 0.97 0.98 0.92 0.91
13 0.96 0.99 0.92 0.99
27 0.95 0.97 0.97 0.93
6 0.88 0.90 0.36 0.43
13 0.85 0.91 0.63 0.71
27 0.88 0.94 0.94 0.85
6 0.98 0.99 0.85 0.80
13 0.96 1.00 0.86 0.97
27 0.96 1.01 1.04 1.03
Roxithromycin
HD
LD
Vancomycin
HD
LD
Streptomycin
HD
LD
Antibiotic Dose group Day
Body weight Food consumption
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There was a reduction in food consumption in the animals receiving roxithromycin in the 
HD group on day 7 and 14 but not at day 28. Towards the end of the study (day 28), food 
consumption had returned to levels close to controls. Observed changes in body weight loss 
in this group were about 10% compared to the controls within the first days of treatment, 
showing that the treatment was above the MTD (maximum tolerated dose). For this reason, 
the dosage was reduced to 400 mg/kg bw/d from study day 3 in female animals study and 
from study day 5 in male animals. 
 
Metabolite Profiling 
Table 3 shows the percentage of changed metabolites of the metabolome analysis in feces 
and cecum content compared to control. The sampled gut matrices (jejunum, ileum, rinsed 
cecum, colon, rectum) did not show a change of the metabolome compared to the control 
(see PCAs in Supplementary Material). 
In general, vancomycin had the most profound effect in the metabolome of feces and cecum 
content with 47-60% significantly altered metabolites out of 202 measured metabolites 
followed by roxithromycin (14-28%) and streptomycin (8-20%). The number of 
significantly upregulated metabolites was higher than the number of downregulated 
metabolites, except for the feces samples from the female animals of the LD and HD group 
of roxithromycin and the HD group of streptomycin. No dose-dependency could be 
observed based on the number of metabolite changes.  
 
Table 3 Statistically significantly (p < 0.05) downregulated (blue) and upregulated (red) measured metabolites 
compared to control in feces and cecum content of male and female Wistar rats after antibiotic treatment with 
vancomycin, roxithromycin and streptomycin for 28 days. 
LD HD LD HD LD HD LD HD
Total metabolites 194 195 188 191 190 193 192 193
% down 10.8 5.6 14.4 11.5 15.3 13.5 16.1 15.5
% up 45.9 41.5 42.0 48.7 40.5 34.7 36.5 35.2
% total 56.7 47.2 56.4 60.2 55.8 48.2 52.6 50.8
LD HD LD HD LD HD LD HD
Total metabolites 198 198 191 192 195 195 190 193
% down 4.0 10.6 5.8 10.9 15.9 18.5 11.1 9.3
% up 26.8 24.7 20.9 27.6 17.9 14.4 26.3 24.4
% total 30.8 35.4 26.7 38.5 33.8 32.8 37.4 33.7
LD HD LD HD LD HD LD HD
Total metabolites 195 197 191 189 193 189 187 190
% down 4.1 1.5 6.3 3.2 5.2 14.8 4.3 8.9
% up 13.8 18.8 13.1 19.6 8.3 16.9 8.0 14.2
% total 17.9 20.3 19.4 22.8 13.5 31.7 12.3 23.2
Streptomycin sulfate, males Streptomycin sulfate, females 
Feces Cecum content Feces Cecum content 
Roxithromycin, males Roxithromycin, females 
Feces Cecum content Feces Cecum content 
Vancomycin, males Vancomycin, females
Feces Cecum content Feces Cecum content 
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The number of significant changes between the feces and cecum content of males and 
females were in the same range, except the female group of the roxithromycin treatment. 
Here, the number of significantly upregulated metabolites in the cecum content was about 
10% higher than in the feces, while the number of downregulated metabolites was on 
average about 7 % higher in feces than in cecum content. 
 
In the MetaMap®Tox database the profile strengths of the metabolic profiles were 
calculated (see Table 4). This parameter includes the magnitude of the changes. In the 
database, the profile strength ranges between 0.49 and 5.58, with an average over all 
treatments of 1.43. For one, it clearly reflects the impact of each antibiotic on the 
metabolome, with vancomycin having the most profound effect, followed by roxithromycin 
and streptomycin. For another, the values also show the similarity between males and 
females and between both matrices.  
 
Table 4 Profile strength of the metabolite profile in feces and cecum content of male and female Wistar rats after 
antibiotic treatment after treatment with vancomycin, roxithromycin and streptomycin. 
f, LD m, LD f, HD m, HD f, LD m, LD f, HD m, HD f, LD m, LD f, HD m, HD
Cecum content 5.08 5.26 4.35 5.16 2.13 2.13 2.17 2.37 1.48 1.63 1.81 1.85
Feces 4.87 5.48 3.86 4.19 2.17 2.19 2.13 2.31 1.46 1.69 2.22 1.99
Vancomycin Roxithromycin Streptomycin
 
 
Treatment-related effect on feces and cecum content 
To reveal treatment-related effects on the metabolites in the matrices analyzed, a principal 
component analysis (PCA) was performed. In feces and cecum content, a clear treatment-
related effect could be observed. However, there were no differences in the metabolites in 
gut tissue samples (i.e. jejunum, ileum, rinsed cecum, colon, rectum) between treatment and 
control. The corresponding PCAs of the gut tissues can be found in the supplementary 
material.  
Feces and cecum content from males and females showed a similar pattern: vancomycin 
and roxithromycin showed a clear separation from each other and from the control group. 
For the feces samples, the male group treated with streptomycin is separated from the 
control and also from the vancomycin and roxithromycin data points, while in the cecum 
samples separation from streptomycin from the control was less evident (see PCAs in 
Figure 2, Figure 3, and Figure 4). In female animals, the streptomycin data were not 
separated from the control group in both feces and cecum content. Vancomycin showed a 
separation between LD and HD over all groups for both matrices and gender. This could 
also be observed for streptomycin in the feces samples of male animals and in the principal 
component (PC) 3 for both matrices (see Figure 4).  
 
Top25 metabolites of feces compared to cecum content  
To identify the metabolites that drive the separation of the different antibiotic treatments 
from the control, the loadings of the first three principal components for each metabolite, 
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matrix and sex were extracted. A ranking of the 25 metabolites with the highest loadings in 
the feces against the corresponding loadings of metabolites of the cecum content was done 
and heatmaps with the analyzed metabolite values from day 28 of male and female animals 
were established (see supplementary material). For each treatment, the focus was set on the 
principal component which shows the clearest separation from the control in the PCA. 
Therefore, for vancomycin loadings of the PC1, for roxithromycin loadings of the PC2 and 
for streptomycin loadings of the PC3 were evaluated (see Figure 2, Figure 3, and Figure 4). 
 
Vancomycin 
Compared to roxithromycin and streptomycin, vancomycin had the most profound effect on 
the metabolites in feces and cecum content. The 25 metabolites with the highest loadings in 
feces of vancomycin treated animals were all upregulated for both males and females in HD 
and LD, with creatinine and trans-4-hydroxyproline being upregulated more than 100-fold 
(see Figure 2).  
In the male group, triacylglycerols (TAGs) and other lipids, the amino acids valine, proline, 
leucine, histidine, alanine, isoleucine, glycine and phenylalanine were highly upregulated, 
as well as other metabolites including creatine, 2-hydroxybutyrate and pantothenic acid. 
Cholic acid was increased in all samples except in cecum content of the HD vancomycin 
group. Furthermore, two TAGs, pantothenic acid and 4-hydroxysphinganine were found 
only in the top25 of feces but not in that of cecum content. In cecum content of the male 
group 3-hydroxybutyrate, lysine and lactate were significantly upregulated.  
The female group showed a similar pattern of changes with a significant upregulation of 
TAGs, valine, leucine, proline, phenylalanine, isoleucine, alanine, histidine and glycine as 
well as creatine, 2- and 3-hydroxybutyrate, pantothenic acid, three unknown metabolites 
and a cholesterylester. Similar to the male group, cholic acid was upregulated in the feces 
but downregulated in the cecum content of the HD group. Besides cholic acid, two 
unknown metabolites and a cholesterylester just showed up in the top25 of the feces. In 
cecum content, lactate, myo-inositol-2-phosphate and lysophosphatidylcholine (C18:1) 
were significantly upregulated instead. 
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MALE ANIMALS FEMALE ANIMALS 
        Feces                            Cecum Content           Feces                          Cecum content 
      
Treatment group  Control    Vancomycin    Streptomycin    Roxithromycin 
Dose level                    ○ Low dose   ● High dose 
Metabolite
LD HD LD HD
Creatinine 125.4 111.7 63.9 63.9
trans-4-Hydroxyproline 135.9 95.0 181.8 348.3
TAG (C18:2,C18:2) 46.2 41.3 40.0 37.7
Valine 87.0 99.3 37.5 69.7
TAG (C16:0,C18:1,C18:3) 39.5 31.4 55.9 59.6
TAG (C18:1,C18:2) 42.2 34.8 31.6 35.5
Proline 41.4 15.5 28.5 46.4
Leucine 57.3 72.2 12.5 25.2
TAG (C16:0,C18:2) 41.1 28.1 24.9 24.9
Creatine 27.4 24.4 24.8 31.8
TAG (C18:1,C18:2,C18:3) 34.0 30.3 32.5 40.2
Histidine 25.0 25.9 18.9 32.8
Alanine 38.0 12.2 20.9 28.7
Isoleucineb 30.7 29.5 7.5 7.0
TAG (C52:5 (H) or C50:2 (Na))a 22.8 23.0 NA NA
Glycine 22.3 8.0 22.1 36.9
Phenylalanine 18.4 22.0 7.0 14.4
2-Hydroxybutyrate 24.7 14.0 16.8 28.8
Pantothenic acida 20.2 22.5 11.1 15.9
4-Hydroxysphinganine (t18:0, 
Phytosphingosine)a
6.6 10.6 12.0 7.1
Cholic acida 20.9 2.9 6.6 0.9
TAG (C18:2,C18:3)a 10.1 8.7 4.8 5.0
Cholesterylester, total 8.0 9.7 4.7 8.7
Unknown 8.8 8.0 10.2 9.8
Lysophosphatidylcholine (C18:1) 6.7 7.7 6.3 4.5
Vancomycin
Feces Cecum content 
 
Metabolite
LD HD LD HD
trans-4-Hydroxyproline 96.4 114.8 241.1 257.2
Creatinine 98.7 113.4 71.8 103.0
TAG (C16:0,C18:1,C18:3) 71.8 50.6 68.7 58.9
TAG (C18:2,C18:2) 93.5 43.1 51.1 44.0
Valine 60.6 50.0 46.2 58.3
Leucine 42.9 40.7 20.7 27.8
TAG (C18:1,C18:2) 42.5 30.7 45.8 38.5
Proline 19.0 23.3 51.1 59.0
TAG (C18:1,C18:2,C18:3) 32.8 23.4 39.9 31.2
Unknown 38.6 15.8 20.2 18.7
TAG (C16:0,C18:2) 37.2 18.6 54.9 48.2
TAG (C18:2,C18:3) 24.8 8.2 10.0 8.6
Phenylalanine 18.0 15.1 10.7 12.6
Creatine 19.5 20.8 19.6 24.9
Isoleucine 16.6 12.6 8.0 11.1
Alanine 15.6 14.6 32.4 22.9
Histidine 12.2 17.4 19.5 21.6
Glycine 11.4 14.6 22.4 30.8
2-Hydroxybutyrate 11.5 16.0 13.9 17.9
Pantothenic acid 17.4 13.6 6.9 7.0
3-Hydroxybutyrate 1.1 13.6 4.4 143.8
Unknown 8.9 7.1 10.9 8.6
Unknowna 7.1 6.5 4.3 4.8
Cholesterylestera 3.3 3.0 3.8 2.9
Cholic acida 27.2 2.9 12.0 0.8
Vancomycin
Feces Cecum content 
 
Fig. 2. PCAs of tested antibiotics and heatmap of top25 metabolites of feces for vancomycin. Metabolite 
concentration changes in feces and cecum content of male (m) and female (f) Crl:Wi(Han) rats (N=5 per group) 
dosed with vancomycin (50 and 400 mg/kg bw/d) for 28 days. Statistically significant changes (Welch-t-test; p < 
0.05) are shown in bold, red boxes mean upregulation and blue boxes downregulation. The intensity of the color 
corresponds to the magnitude of the fold change. “NA” indicates that for this analyte, treatment and/or analysis 
groups there are no contrasts available. a just in top25 of feces; in cecum content, males: 3- hydroxybutyrate, 
lysine, lactate; in cecum content, females: lactate, myo-inositol-2-phosphate, lysophosphatidylcholine (C18:1). b 
measured with LC-MS/MS and LC- MS. 
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Roxithromycin 
Roxithromycin had a lower impact on the metabolome than vancomycin based on the 
number and fold change of altered metabolites. Highest upregulation in both matrices of 
males and females was observed for allantoin, taurine, taurocholic acid, creatinine, 
kynurenic acid and isoleucine (see Figure 3). Malate and the amino acids tryptophan, 
tyrosine, asparagine, threonine, methionine and arginine were increased in all groups as 
well. 
In the male group, indole-3-lactic acid (ILA), lysophosphatidylcholine, myristic acid, 
glucose-6-phosphate, two unknown metabolites and aspartate was increased in feces 
samples but were not among the top25 metabolites of cecum content. Here, significantly 
altered were glucose, ornithine, leucine, glutamine, serine, phenylalanine, 
phosphatidylcholine (C18:0, C20:4). 
Contrary to the males, in the female group indole-3-acetic acid (IAA) was downregulated in 
feces and cecum content but only significantly in the cecum content LD. ILA was slightly 
increased in the feces. Phosphate, kynurenic acid, ketoleucine, IAA, 
lysophophatidylcholine, phenylalanine and an unknown metabolite just showed up in the 
top25 of the feces. A higher impact in cecum content was observed for the metabolites 
serine, glutamine, ornithine, hexoses, aspartate, lysine. 
 
Streptomycin 
Treatment with streptomycin showed a separation from the control in a plot of PC 1 versus 
PC 3 (see Figure 4). In both matrices, the HD group showed a separation from the control 
and a slight separation of the LD group. The overall effect on the feces metabolome after 
streptomycin treatment was less pronounced in female compared to male animals. In the 
top25 metabolite patterns of the feces, the treatment with streptomycin showed clear 
differences in quantitative changes and significantly altered values. Similarities in both 
matrices of males and females were observed for kynurenic acid and cysteine which were 
significantly upregulated. An increase of the amino acids taurine, valine, isoleucine and 
leucine was observed in the HD, for leucine only in the feces.  
In the male group, pantothenic acid was significantly upregulated in cecum content and 
feces. Interestingly, the LD group showed a 3-5-fold higher upregulation compared to the 
HD group. Also increased, though not consistently over all dose groups, were biotin, 
succinate, uracil, ILA, threonine, glucosamine, malate, glycerol and glucose. 
Glycochenodeoxycholic acid was significantly decreased in the HD group of cecum content 
and ethanolamine plasmalogen was significantly decreased in the LD group for both 
matrices. Both bile acids, ILA, salicylic acid, glucosamine, an unknown metabolite, 
leucine, glycerol, ethanolamine and elaidic acid were found in the top25 of feces samples 
but were not present in the top25 of cecum content. In cecum content calcitriol, 
lysophosphatidylcholine (C17:0), threo-sphingosine (d18:1), 5-O-methylsphingosine 
(d18:1), four unknown metabolites, 3,3',5-triiodothyronine, and significantly altered 
spermidine were found (data not shown). 
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In the feces of the female group taurocholic and cholic acid were both significantly 
upregulated. In both matrices an upregulation of spermidine, TAG and glycerol-3-
phosphate was observed.  
Sphingomyelin, isoleucine, three bile acids, leucine, glucosamine just showed up 
significantly upregulated in the top25 of the feces. In cecum content the following 
metabolites were significantly altered in the top25: three TAGs ((C16:0,C18:2); 
(C18:1,C18:2,C18:3) (C18:2,C18:2), (C18:1,C18:2)), erythro-sphingosine, 
docosapentaenoic acid (C22:cis[7,10,13,16,19]5) and uric acid. 
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MALE ANIMALS FEMALE ANIMALS 
        Feces                              Cecum Content        Feces                            Cecum content 
        
Treatment group  Control    Vancomycin    Streptomycin    Roxithromycin 
Dose level                    ○ Low dose   ● High dose 
Metabolite
LD HD LD HD
Allantoin 28.2 39.2 19.6 22.1
Taurine 120.9 42.0 13.8 23.6
Taurocholic acid 14.9 14.2 3.1 4.3
Unknown 4.6 6.4 6.0 6.5
Creatinine 98.1 112.3 46.3 78.4
Kynurenic acid 8.3 12.0 5.3 7.7
Methionine 6.9 3.5 3.1 3.4
Arginine 6.0 3.9 3.3 3.1
Indole-3-lactic acida 10.1 15.4 1.9 1.9
Tryptophan 4.9 3.3 2.2 2.2
Tyrosinec 4.2 2.3 4.1 2.1
Malatec 3.0 3.2 2.7 3.9
Asparagine 5.2 3.4 4.4 4.4
Threoninec 2.4 1.6 2.1 2.2
Uric acid 1.9 1.5 2.3 2.3
Isoleucineb 9.9 4.7 3.1 2.8
Hexoses 3.2 2.0 1.1 2.4
Lysophosphatidylcholine (C20:4)a 2.2 3.6 1.3 3.2
Unknowna 3.1 3.2 2.8 1.3
Myristic acid (C14:0)a 4.1 1.6 0.8 0.7
Glucose-6-phosphatea 1.4 2.6 0.5 1.3
Unknowna 2.8 2.1 2.4 2.3
Aspartatea 2.7 1.3 2.0 1.2
Cytosine 1.8 1.2 2.1 2.1
alpha-Tocopherol 1.1 2.0 1.0 1.2
Roxithromycin 
Feces Cecum content 
 
Metabolite
LD HD LD HD
Creatinine 179.6 108.9 106.6 82.2
Taurine 44.3 19.7 14.4 15.8
Allantoin 27.9 12.1 19.7 29.3
Taurocholic acid 15.7 6.1 33.0 14.2
Malate 3.2 2.7 2.1 2.9
Isoleucinec 6.8 8.7 5.7 5.4
Methionine 4.1 3.5 3.0 3.8
Unknown 2.7 2.5 3.9 5.7
Tryptophan 3.1 4.4 2.6 3.0
Phosphatea 3.7 1.1 1.4 1.3
Arginine 3.3 3.2 2.7 3.3
Tyrosineb 2.3 2.2 2.4 2.5
Uric acid 1.9 1.5 3.6 3.6
Glucose 2.6 2.9 2.1 1.3
Hexoses 2.5 1.8 1.6 1.8
Asparagine 3.0 3.8 3.4 2.9
Kynurenic acida 9.2 8.9 2.9 2.7
Ketoleucinea 2.9 3.0 1.8 3.4
Threoninec 1.1 1.5 2.5 2.1
Leucine 7.5 6.2 5.4 4.6
Indole-3-lactic acid 1.9 1.7 1.9 2.3
Indole-3-acetic acida 0.5 0.5 0.5 0.7
Lysophosphatidylcholine (C20:4)a 1.4 1.0 NA 3.6
Phenylalaninea 3.5 3.1 4.7 3.6
Unknowna 2.0 0.9 1.6 1.7
Roxithromycin 
Feces Cecum content 
 
Fig. 3. PCAs of tested antibiotics and heatmap of top25 metabolites of feces for roxithromycin. Metabolite 
concentration changes in feces and cecum content of male (m) and female (f) Crl:Wi(Han) rats (N=5 per group) 
dosed with roxithromycin (200 and 400 mg/kg bw/d) for 28 days. Statistically significant changes (Welch-t- test; p 
< .05) are shown in bold, red boxes mean upregulation and blue boxes downregulation. The intensity of the color 
corresponds to the magnitude of the fold change. “NA” indicates that for this analyte, treatment and/or analysis 
groups there are no contrasts available. a just in top25 of feces; in cecum content, males: glucose, ornithine, 
leucine, glutamine, serine, phenylalanine, phosphatidylcholine (C18:0,C20:4), lysine; in cecum content, females: 
serine, glutamine, ornithine, hexoses, aspartate, lysine, an unknown metabolite. b measured with LC-MS/MS and 
LC-MS. c measured with GC–MS. 
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MALE ANIMALS FEMALE ANIMALS 
        Feces                              Cecum Content        Feces                                Cecum content 
         
Treatment group  Control    Vancomycin    Streptomycin    Roxithromycin 
Dose level                  ○ Low dose   ● High dose 
Metabolite
LD HD LD HD
Pantothenic acid 102.1 19.8 61.8 20.2
Cholic acida 2.0 3.3 1.3 0.5
Biotin 1.3 8.7 3.7 1.9
Valine 8.0 32.8 1.9 13.0
Taurine 8.2 199.5 9.7 42.6
Isoleucinec 6.3 15.2 2.0 6.6
Succinate 1.3 19.7 1.4 6.4
Kynurenic acid 32.2 21.0 15.7 14.1
Uracil 21.7 2.1 17.0 2.6
Indole-3-lactic acida 30.7 25.6 1.7 2.0
Choline plasmalogen (C18-
vinyl,C20:4)
1.5 2.4 1.3 3.2
Threonineb 0.8 9.9 1.8 8.2
Salicylic acida 2.2 1.3 0.9 0.6
Glucosaminea 1.7 4.1 1.3 2.1
Unknowna 1.6 3.2 2.3 4.1
Cysteine 4.0 9.6 2.4 5.5
Malateb 0.9 7.3 1.2 20.4
Leucinea 3.5 12.7 1.6 3.2
Glycochenodeoxycholic acida 0.8 0.5 0.4 0.2
Glycerola 4.7 1.8 1.5 1.3
erythro-Sphingosine (d18:1) 1.1 2.4 2.0 3.2
Ethanolamine plasmalogen 
(C39:5)a
0.6 2.5 0.5 1.6
Elaidic acid (C18:trans[9]1)a NA 1.7 NA 8.1
Phosphate 2.8 0.7 2.6 1.8
Glucose 1.0 4.0 0.5 0.7
Streptomycin sulfate 
Feces Cecum content 
Metabolite
LD HD LD HD
Taurine 0.8 32.2 0.5 19.4
Kynurenic acid 23.5 24.0 6.8 6.9
Valine 1.1 8.3 0.8 11.6
Sphingomyelin (d18:1,C16:0)a 2.5 8.7 NA NA
Cysteine 3.8 8.4 2.2 5.2
Isoleucinea,b 1.3 2.8 0.8 4.5
Taurocholic acida 4.5 4.5 3.8 2.3
Cholic acida 7.7 2.9 2.9 0.8
Spermidine 3.8 4.7 2.1 3.2
dihomo-gamma-Linolenic acid 
(C20:cis[8,11,14]3)
1.2 2.9 1.6 4.7
Leucinea 1.5 4.5 0.8 3.0
Unknown 1.8 3.6 1.5 2.1
Glycerol 1.1 2.3 2.3 4.7
Glucosaminea 1.7 2.6 0.8 1.0
Glycerol-3-phosphate 1.6 2.3 1.9 3.3
Sphingomyelin (d18:2,C18:0) 0.6 1.7 0.9 2.8
Pantothenic acida 1.3 2.2 0.8 2.8
Tyrosinea,b 1.1 1.1 0.8 2.2
Uracila 1.2 1.1 0.7 1.0
TAG (C16:0,C18:1,C18:3) 1.8 5.4 3.2 4.5
DAG (C18:1,C18:2) 1.1 2.7 1.1 1.8
Unknowna 1.6 1.8 1.0 1.1
4-Hydroxyphenylpyruvatea 0.8 0.9 0.9 1.3
Glycochenodeoxycholic acida 0.7 0.8 0.9 0.6
Unknown 1.3 3.5 1.6 3.0
Streptomycin sulfate 
Feces Cecum content 
 
Fig. 4. PCAs of tested antibiotics and heatmap of top25 metabolites of feces for streptomycin. Metabolite 
concentration changes in feces and cecum content of male (m) and female (f) Crl:Wi(Han) rats (N=5 per group) 
dosed with Streptromycin (100 and 450 mg/kg bw/d) for 28 days. Statistically significant changes (Welch-t- test; p 
< 0.05) are shown in bold, red boxes mean upregulation and blue boxes downregulation. The intensity of the color 
corresponds to the magnitude of the fold change. “NA” indicates that for this analyte, treatment and/or analysis 
groups there are no contrasts available. a just in top25 of feces; statistically significantly in cecum content, males: 
spermidine, an unknown metabolite; in cecum content, females: TAG (C16:0,C18:2), erythro-sphingosine (d18:1), 
TAG (C18:1,C18:2,C18:3), TAG (C18:2,C18:2), TAG (C18:1,C18:2), docosapentaenoic acid 
(C22:cis[7,10,13,16,19]5), uric acid. b measured with LC-MS/MS and LC-MS. c measured with GC–MS. 
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Overall comparison of statistically significantly metabolite changes 
The analysis of the top25 metabolites showed the most important metabolites that drive the 
separation of the treatments in the PCA. Independent from the PCA, a separate analysis was 
performed to compare similar metabolite changes as well as only downregulated 
metabolites in the different dose groups and target tissues.  
The metabolite profiles of the feces after antibiotic treatment for both sexes were screened 
for overlapping metabolites and compared to metabolite changes in cecum content (see 
Table 5). Eight metabolites in the male groups and seven metabolites in the female group 
were found to be significantly changed in all dose groups. Two metabolites were 
significantly changed in both sexes: kynurenic acid, which was increased, and stearic acid, 
which was decreased compared to controls. In the male group, all other metabolites were 
upregulated (lipids, amino acids and citrate in feces) whereas in the female group three 
more metabolites were downregulated (lipids). In all female groups, beta-sitosterol as well 
as taurocholic acid were upregulated. Only in the LD group of vancomycin, taurocholic 
acid was downregulated. 
Further, the decreased metabolites in feces for both sexes were evaluated and compared. 
Table 6 shows statistically significantly decreased metabolites in feces after the treatment 
with each of the antibiotics for males and females of LD and HD. Vancomycin treatment 
led to the highest number of significant changes, closely followed by roxithromycin and 
then streptomycin. In general, female animals showed a higher number of significantly 
decreased metabolites. The majority of these belong to the class of complex lipids, fatty 
acids and related compounds. After vancomycin treatment, feces of both sexes showed a 
decrease of glutamate, 5-oxoproline, IAA, 18-hydroxy-11-deoxycorticosterone, alpha-
tocopherol and coenzyme Q9 and Q10. 18-hydroxy-11-deoxycorticosterone was also 
decreased after roxithromycin treatment as well as coenzyme 9. In vancomycin treated 
males 4-hydroxyphenylpyruvate was decreased, in females salicylic acid, heptadecanoic 
acid (C17:0) and an unknown metabolite were decreased. In males of roxithromycin 
treatment IAA was decreased, and in females myo-inositol, myristic acid (C14:0), behenic 
acid (C22:0), erythro-sphingosine (d18:1), ceramide (d18:1, C24:0), 3-hydroxybutyrate, 
coenzyme Q10 and alpha-tocopherol. In females but not in males, octadecanol, lignoceric 
acid (C24:0), heptadecanoic acid (C17:0), eicosanoic acid (C20:0) and behenic acid (C22:0) 
were decreased after streptomycin treatment. 
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Table 5 Overall comparison of metabolite changes after antibiotic treatment found in the metabolite profiles of feces compared to cecum content. Metabolite concentration 
changes in feces of male and female Crl:Wi(Han) rats (N=5 per group) dosed with vancomycin (50 and 400 mg/kg bw/d), roxithromycin (200 and 400 (600) mg/kg bw/d) and 
streptomycin (100 and 450 mg/kg bw/d) for 28 days. Statistically significant changes (Welch-t-test; p < .05) are shown in bold, blue boxes mean downregulation, red boxes 
upregulation. The intensity of the color cor- responds to the magnitude of the fold change. 
LD HD LD HD LD HD LD HD LD HD LD HD 
Methionine 1.66 2.20 5.27 2.68 1.29 2.24 2.21 2.50 3.93 3.62 1.75 1.58
Cysteine 5.02 4.09 1.96 2.91 4.02 9.56 4.30 5.73 1.75 3.14 2.35 5.53
Asparagine 4.13 6.07 5.15 3.40 1.73 2.74 3.88 5.52 4.40 4.40 1.35 2.03
Kynurenic acid 12.06 9.10 8.29 12.00 32.15 21.01 7.21 6.01 5.33 7.69 15.72 14.11
Linoleic acid (C18:cis[9,12]2) 5.82 7.09 4.09 2.64 4.00 2.66 3.77 3.34 1.35 0.98 1.77 2.26
Oleic acid (C18:cis[9]1) 3.61 4.23 2.78 2.12 3.12 2.91 2.44 2.59 1.67 1.46 1.66 2.56
Stearic acid (C18:0) 0.28 0.34 0.31 0.30 0.40 0.40 0.27 0.34 0.35 0.35 0.43 0.47
Citrate 4.02 5.92 3.25 3.81 2.20 1.86 0.69 1.18 1.19 0.82 1.09 0.93
Roxithromycin Streptomycin
Cecum contentMetabolite
(Male animals) Vancomycin Roxithromycin Streptomycin
Feces
Vancomycin
 
LD HD LD HD LD HD LD HD LD HD LD HD 
Kynurenic acid 9.73 12.29 9.17 8.88 23.48 24.01 3.47 4.50 2.91 2.71 6.81 6.85
Taurocholic acid 0.20 92.60 15.70 6.13 4.48 4.53 0.07 31.21 32.97 14.23 3.81 2.27
Stearic acid (C18:0) 0.15 0.13 0.11 0.19 0.19 0.19 0.17 0.19 0.17 0.20 0.24 0.24
Octadecanol 0.31 0.19 0.28 0.32 0.53 0.39 0.30 0.25 0.35 0.35 0.60 0.47
Heptadecanoic acid (C17:0) 0.60 0.37 0.35 0.51 0.62 0.55 0.80 0.65 0.61 0.73 0.96 0.97
Eicosanoic acid (C20:0) 0.32 0.27 0.33 0.49 0.58 0.40 0.39 0.42 0.42 0.56 0.92 0.74
beta-Sitosterol 5.07 3.79 1.85 1.42 1.63 1.66 5.23 3.47 1.61 1.45 1.63 1.91
Metabolites
(Female animals)
Feces Cecum content
Vancomycin Roxithromycin Streptomycin Vancomycin Roxithromycin Streptomycin
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Table 6 Heatmap of statistically significantly decreased values of metabolite changes in feces after treatment with antibiotics. Metabolite concentration changes in feces of male 
(m) and female (f) Crl:Wi(Han) rats (N=5 per group) dosed with vancomycin (50 and 400 mg/kg bw/d), roxithromycin (200 and 400 (600) mg/kg bw/d) and streptomycin (100 
and 450 mg/kg bw/d) for 28 days. Statistically significant changes (Welch-t-test; p < .05) are shown in bold, blue boxes mean down- regulation. The intensity of the blue color 
corresponds to the magnitude of the fold change. 
Metabolite Metabolite class
f, LD m, LD f, HD m, HD f, LD m, LD f, HD m, HD f, LD m, LD f, HD m, HD
Glutamate 0.20 0.16 0.11 0.24 Amino acids
4-Hydroxyphenylpyruvate 0.56 0.30 0.56 0.40
5-Oxoproline 0.48 0.35 0.35 0.43 Amino acids related
Indole-3-acetic acid 0.12 0.18 0.10 0.08 0.54 0.11 0.50 0.26
myo-Inositol 0.20 1.20 0.30 1.58 Carbohydrates and related 
17-Methyloctadecanoic acid 0.41 0.70 0.58 0.70 Complex lipids, fatty acids and related
Behenic acid (C22:0) 0.60 0.82 0.50 1.01 0.61 1.26 0.47 0.81
Ceramide (d18:1,C24:0) 0.71 0.83 0.70 0.62
Cholic acid 0.29 0.42 0.46 0.22
Eicosaenoic acid (C20:1) No 02 0.48 0.58 0.34 0.46
Eicosanoic acid (C20:0) 0.32 0.31 0.27 0.39 0.33 0.64 0.49 0.36 0.40 0.45 0.58 0.79
erythro-Sphingosine (d18:1) 0.39 0.54 0.60 0.74
Glycerol-3-phosphate, polar fraction 0.39 0.33 0.27 0.38
Heptadecanoic acid (C17:0) 0.37 1.02 0.60 0.98 0.35 0.79 0.51 0.79 0.62 1.44 0.55 1.07
Hexadecanol 0.29 0.13 0.21 0.10 0.33 0.43 0.46 0.32
Isopalmitic acid (C16:0) 0.34 0.45 0.25 0.50
Lignoceric acid (C24:0) 0.44 0.71 0.53 0.60 0.58 1.07 0.59 0.79
Myristic acid (C14:0) 0.33 1.64 0.24 4.05
Octadecanol 0.31 0.20 0.19 0.16 0.28 0.48 0.32 0.30 0.53 0.65 0.39 0.80
Palmitic acid (C16:0) 0.61 0.68 0.50 0.77 0.42 1.01 0.73 0.58
Sphingomyelin (d18:2,C18:0) 0.51 0.45 0.54 0.48 0.56 0.65 0.62 0.63
Stearic acid (C18:0) 0.15 0.28 0.13 0.34 0.19 0.40 0.19 0.40
Tricosanoic acid (C23:0) 0.54 0.56 0.42 0.91
Unknown lipid 0.41 0.89 0.42 1.41
Unknown lipid 0.49 0.60 0.45 0.50
3-Hydroxybutyrate 0.60 0.73 0.48 1.22 Energy metabolism 
18-Hydroxy-11-deoxycorticosterone 0.60 0.73 0.46 0.67 0.64 0.65 0.48 0.68 Hormones, signal substances and related
Salicylic acid 0.36 0.41 0.50 0.41 Miscellaneous
alpha-Tocopherol 0.50 0.57 0.41 0.55 0.60 1.95 0.66 1.10 Vitamins, cofactors and related
Coenzyme Q9 0.33 0.62 0.46 0.60 0.68 0.89 0.39 0.85
Coenzyme Q10 0.34 0.58 0.49 0.64 0.40 0.85 0.60 0.78
Vancomycin Roxithromycin Streptomycin
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DISCUSSION 
Impact of antibiotics on the metabolite profile of gut tissue and content 
The metabolite profile of different matrices of the gut after antibiotic treatment was 
analyzed to 1) evaluate gut microbiota metabolite changes observed at different dose levels 
and in different sexes, and 2) to identify the best tissue matrix for further investigations 
regarding an assessment of metabolic effects of new compounds with antibiotic activity. 
The metabolite profiles of sampled gut matrices (i.e. jejunum, ileum, rinsed cecum, colon, 
rectum) were different from each other, but were not affected by treatment (see 
supplementary material). Feces and cecum content of treated animals had significantly 
different metabolome profiles compared to the control. There was no dose-dependency 
regarding absolute numbers of altered metabolites. However, a dose-dependency could be 
observed for vancomycin and streptomycin in feces and cecum content.  
Overall, the number of significantly upregulated metabolites was higher than the number of 
downregulated metabolites. This observation together with the nature of the metabolites 
that were upregulated suggests that due to the loss of gut bacteria certain food components 
were not used. Decreases in metabolite levels are likely due to a community shift and/or an 
imbalanced usage of nutrients. The metabolite changes in the feces and cecum content were 
similar, except for the roxithromycin female group where cecum content showed about 
10% more upregulated and about 7% less downregulated metabolites than in feces in both 
dose groups. This overall similar patterns of metabolic changes in feces and cecum content 
is in line with the findings of Li et al. who reported that the gut community in rats is similar 
in cecum content and feces (Li et al., 2017).  
It is well known that the sex has an impact on plasma metabolite profiles and in general we 
observed significant differences between sexes (Strauss et al., 2009). In cecum and feces 
however, only minor differences between male and female samples were observed with this 
targeted analysis which is a first indication that regarding the analyzed metabolites there is 
no significant sex difference in the metabolic output of the microbiome in these matrices.  
The profile strength showed that vancomycin, which is not systemically bioavailable, had 
the most profound effect on the metabolome of feces and cecum content followed by 
roxithromycin, while streptomycin had a comparably modest effect. This reflects the 
activity spectra of the antibiotics applied. Vancomycin, a glycopeptide antibiotic with a 
spectrum of activity against Gram-positive organisms has a profound effect on the gut 
microbiome in humans (Auwera et al., 1996; Lund et al., 2000; Vrieze et al., 2014). 
Roxithromycin, a bioavailable macrolide antibiotic with a narrow spectrum affecting Gram-
positive bacteria and some Gram-negative bacteria, showed in an investigation with 
volunteers no significant change of the community but a decrease of the total number of 
enterobacteria (Pecquet et al., 1991). In our study, the least changes in the metabolome 
were observed after streptomycin treatment. This poorly bioavailable antibiotic belonging 
to the class of aminoglycosides is only effective against aerobic organisms but not 
anaerobic bacteria that dominate the gut microbiome (The Human Microbiome Project 
Consortium, 2012). In another study, in which mice received a single dose of 20 mg 
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streptomycin an overall decrease in diversity and increase of Ruminococcaceae and 
Bacteroidaceae was observed (Lichtman et al., 2016). 
The differences of the activity spectra and similarities of both matrices also emerge from 
both the calculation of the profile strength and the PCA where both feces and cecum 
content from males and females showed a similar pattern: streptomycin having the lowest 
treatment-related effects compared to vancomycin and roxithromycin. Especially 
vancomycin showed a dose-dependent effect over all groups and both matrices. Whether 
the limited or even absent dose-response behavior for the changes observed in feces and 
cecum for streptomycin and roxithromycin can be ascribed to saturation of the dose-
response behavior at the dose levels tested and/or to other explanations remains to be 
established. 
 
Metabolite changes  
With a ranking for both matrices and sexes of 25 metabolites with the highest loading in 
PC1, 2 and 3 the most important metabolites that drive the separation were identified (see 
Figure 2, Figure 3, and Figure 4). For all three antibiotic treatments, the metabolites with 
the highest loadings were almost all considerably upregulated for both dose groups and in 
both matrices. Furthermore, male and female animals showed a significant overlap of 
metabolites in feces and cecum content. With a separate analysis, the downregulated 
metabolites in the feces of males and females were analyzed. Additionally, the metabolites 
were analyzed which were altered after all treatments in feces and cecum content of male 
and female animals in the same direction. These results are discussed in detail in the 
following sections. 
 
Vancomycin 
Compared to roxithromycin and streptomycin, vancomycin has the most profound effect on 
the metabolites in both matrices in both sexes. The 25 metabolites with the highest loadings 
in feces were all upregulated except for cholic acid in the HD of cecum content samples 
which was downregulated. Highly upregulated values could be observed for creatinine and 
trans-4-hydroxyproline. Creatinine and creatine, that was also upregulated, were increased 
due to an antibiotic elimination of microbes that produce enzymes known to degrade these 
metabolites (Romick-Rosendale et al., 2009; Wyss and Kaddurah-Daouk, 2000). It was also 
shown that creatine and creatinine were elevated in feces of germfree mice (Marcobal et al., 
2013). Various TAGs were also increased. Vancomycin is known to disrupt the bile acid 
metabolism resulting in the increase of cholic acid. Hence, the regulation of TAGs and 
other fatty acids was altered (Ridlon et al., 2006; Vrieze et al., 2014) and also the loss of 
bacteria, and with this their lipases could lead to an increase of TAGs and result in a 
decrease of free lipids. Various amino acids were upregulated in both matrices and sexes. A 
decrease could only be observed for glutamate. This is contrary to findings of Yap et al. 
who found a marked depletion of a range of amino acids in feces of mice after vancomycin 
treatment (Yap et al., 2008). Since the dose level was similar but the application period 
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lasted just for two days, it is possible that in the present study after a four-week treatment 
the gut microbiota were far more affected so that amino acids from the food could no 
longer be used efficiently by the remaining microbes. Moreover, the interspecies variability 
might contribute to the differences. Another metabolite, i.e. pantothenic acid, that can be 
derived from either the food or the microbes, was also increased. Some microbial species 
need pantothenic acid also for growth, and a loss of these microbes would explain an 
increase of this vitamin (Van Eldere et al., 1996).  
The decrease of metabolites belonging to the class of complex lipids, fatty acids and 18-
hydroxy-11-deoxycorticosterone could be due to the disruption of the bile acid metabolism 
or, regarding the lipids, a decrease of microbial lipases. Also alpha-tocopherol, which is 
present in the bile, was decreased (Hofmann, 1999). Feces samples showed a decrease of 5-
oxoproline that can be further metabolized to glutamate, which was also decreased. In the 
phenylalanine/tyrosine catabolic pathway tyrosine is further metabolized to 4-
hydroxyphenylpyruvate by the tyrosine aminotransferase (Gertsman et al., 2015). Since 
phenylalanine was significantly increased this pathway seemed to be disrupted. Similarly, 
in the tryptophan metabolism tryptophan is further metabolized to IAA. Whereas 
tryptophan was found to be increased, the level of IAA was significantly decreased 
(Gertsman et al., 2015). In conclusion, the increase of amino acids is due to the loss of 
microbes that normally utilize these metabolites. Generally, as described by Neis et al., 
amino acids can be either utilized by microorganisms, or catabolized through different 
pathways (Neis et al., 2015). Besides that, quinones coenzyme Q9 and Q10 were decreased. 
In general, quinones are produced and used by microorganisms as electron carriers that are 
essential for cellular respiration (Collins and Jones, 1981). Here again, a decrease of these 
metabolites could be explained with a substantial loss of microorganisms.  
 
Roxithromycin 
Roxithromycin, a narrow spectrum antibiotic that affects Gram-positive bacteria and some 
Gram-negative bacteria, in general does not lead to a significant change of the anaerobic 
and aerobic community but resulta in a decrease of the total number of enterobacteria 
(Koopman et al., 1987; Pecquet et al., 1991). This was also reflected in the less altered 
metabolite profile and less significantly upregulated metabolites compared to the effects 
induced by vancomycin. Furthermore, both in feces and cecum content no dose dependency 
was observed. In both matrices of males and females, allantoin, taurine, taurocholic acid, 
creatinine and isoleucine were significantly upregulated. Allantoin is a metabolic 
intermediate in microbes, that is produced from uric acid and serves as a nitrogen source 
(Ma et al., 2016). A loss or reduction of microorganisms, especially enterobacteria, 
probably led to an increase of allantoin as well as of malate, creatinine and amino acids. 
Taurocholic acid, a primary bile acid, was highly increased pointing at a disruption of the 
bacterial bile acid metabolism. Normally, primary bile acids are further metabolized to 
secondary bile acids and partly deconjugated.  
Microbiome-related metabolite changes in the intestinal tract 
77 
In the feces of the male group, a more important role than in cecum content was observed 
for the following metabolites: ILA, lysophosphatidylcholine, myristic acid, glucose-6-
phosphate and aspartate. However, all of them were just significantly upregulated in the LD 
group of feces samples. In in vitro experiments, ILA was hypothesized to be produced by 
human and not microbial cells because human cells did not complete the conversion of 
indolepyruvate to indole-3-carboxaldehyde and probably secrete indolepyruvate and ILA 
back to circulation (Gertsman et al., 2015). This suggests that increased levels of ILA can 
be of mammalian origin. Also in the female group ILA was slightly increased in the feces 
but not significantly in cecum content. Also derived from the tryptophan pathway is IAA, 
which was downregulated just in the top25 of feces, but only significantly in the cecum 
content of the LD. In both sexes, fatty acids and lipids were probably increased due to the 
disruption of the bile acid metabolism. Besides fatty acids and amino acids which were not 
observed in the top25 metabolites of feces but in cecum content, also ornithine was 
increased. Ornithine serves as a H-acceptor in the catabolic pathway of microbes (Davila et 
al., 2013). Similar to vancomycin, most of the decreased metabolites belong to the class of 
complex lipids and fatty acids which could be altered due to a decrease of microbial lipases 
or the disruption of the bile acid metabolism. This could be also true for 18-hydroxy-11-
deoxycorticosterone and alpha-tocopherol that were decreased in feces of female animals. 
Interestingly, more lipids as well as coenzyme Q10 were decreased in female animals, 
whereas IAA was significantly decreased only in male animals. Coenzyme 9 was decreased 
in both sexes. These metabolites were also found to be decreased after vancomycin 
treatment as discussed before. 
 
Streptomycin 
Treatment with streptomycin showed in PC1 versus PC3 but not PC2 a separation from the 
control for the HD groups and a slight separation of the LD group. In general, streptomycin 
showed modest effects on the metabolite profile which was also reflected by the low profile 
strength. This could result from its activity only spectra against aerobic but not anaerobic 
organisms, which dominate the gut microbiota (The Human Microbiome Project 
Consortium, 2012). However, a change or depletion of aerobic bacteria can result in a shift 
of the anaerobes as shown in a study reported by Lichtman et al., who observed an overall 
decrease in microbial diversity and increase of Ruminococcaceae and Bacteroidaceae upon 
treatment of mice with 20 mg streptomycin (Lichtman et al., 2016).  
Regarding the metabolites with the highest loadings in both matrices of males and females 
a significant increase was observed for kynurenic acid and cysteine. Also, an increase of 
amino acids could be observed, especially for the HD. The HD seemed to be more effective 
and hence could have wiped out more communities responsible for the metabolism of these 
amino acids.  
In the male group, pantothenic acid was significantly upregulated in cecum content and 
feces but interestingly, higher upregulated in the LD and not significantly altered in female 
groups. As for vancomycin treatment, an excess of pantothenic acid could be also derived 
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from a loss of microbes (Van Eldere et al., 1996). Interestingly, spermidine, which was 
found to be upregulated in the gut content, was decreased in the plasma after antibiotic 
treatment with aminoglycosides in our previous study (Behr et al., 2017). This polyamine is 
generated from precursor amino acids by the microbes and in low amounts by normal 
colonocytes (Davila et al., 2013; Ramezani et al., 2015). We suggest that spermidine is not 
absorbed or produced in higher rates, respectively, and hence could accumulate in the gut. 
Uracil was found to a higher extent in the LD. Uracil is normally absorbed in the small 
intestine through specific nucleoside transporters (Moran-Ramos et al., 2017). Due to 
perturbations of the upper part of the intestine and in the bile acid metabolism, the 
transporters and metabolizing enzymes might be downregulated. The effect of streptomycin 
on the bile acid metabolism as well as on the steroid and eicosanoid metabolism was earlier 
described by Antunes et al. (Antunes et al., 2011). In our study, we could also observe 
changes for cholic acid, taurocholic acid and glycochenodeoxycholic acid both in females 
and males. Interestingly, more changes of increased lipids and TAGs, especially for cecum 
content, could be observed in female animals. Thus, whereas stearic acid was decreased in 
both sexes, even more decreased metabolites were found in the female groups. This 
indicates that the lipid metabolism, including the microbial lipases, in females is more 
affected after antibiotic treatment and might suggest a sex-specific reaction or alteration of 
the host-microbial co-metabolism. In a study of Markle et al., sex-specific differences in the 
composition of the microbiome of cecum content were found at puberty and were most 
apparent in adult mice (Markle et al., 2013). Due to sex-specific changes in the plasma 
metabolome caused by a subset of glycerophospholipid and sphingolipid metabolites – not 
observed for the germfree mice – the authors assumed that the microbiome plays a role in 
regulating sex-specific features of the host metabolic profile.  
 
In both sexes and in all dose groups of vancomycin, roxithromycin and streptomycin, 
stearic acid was decreased and kynurenic acid was highly increased. Kynurenic acid can 
either be found in the diet or is made from tryptophan and enters the kynurenine pathway 
which is the most tryptophan- consuming metabolic pathway in mammalian and microbial 
cells (Peters, 1991). However, tryptophan levels were also slightly increased in the 
vancomycin and roxithromycin groups but not in the streptomycin groups. The decrease of 
stearic acid could result from the disruption of the lipid metabolism, including the microbial 
lipases, which cleave the TAGs into free fatty acids. 
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CONCLUSION 
The results of the present paper show that metabolic profiling allows a first assessment if 
and to what extent the gut microbiota is affected by a substance. It was possible to 
distinguish three antibiotics with each a different activity spectra from each other in feces 
and cecum content. In gut tissue, no treatment-related effect could be observed. In line with 
the activity spectra of the antibiotics tested, vancomycin showed the most profound effect 
on the metabolite profile, followed by roxithromycin and then by streptomycin for which 
changes were modest. Vancomycin showed also a clear separation of the LD and HD 
group. In general, for all antibiotics the largest changes were observed for the classes of 
lipids, bile acids and amino acids. Regarding gender-related effects, with this targeted 
analysis all dose groups of the three antibiotics had just minor differences in the top25 
metabolites between male and female samples. Furthermore, feces and cecum content 
showed just subtle differences of their metabolite profile within each treatment group. 
Concluding, taking other samples than feces does not add any extra information. Thus, as a 
non-invasive sampling method, feces provide a suitable matrix for studies on metabolism 
by the gut microbiota. 
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ABSTRACT 
The importance of the gut microorganisms and their wide range of interactions with the 
host are well-acknowledged. In this study, lincomycin and clindamycin were used to 
modulate microbial communities of Wistar rats to gain a comprehensive understanding of 
the implications of microbiome alterations. A metabolomics approach and taxonomic 
profiling were applied to characterize the effects of these antibiotics on the functionality of 
the microbiome and to identify microbiome-related metabolites. After treatment, the 
diversity of the microbial community was drastically reduced. Bacteroidetes and 
Verrucomicrobia were drastically reduced, Tenericutes and Deferribacteres completely 
disappeared, while abundance of Firmicutes and Proteobacteria were highly increased. 
Changes in plasma and feces metabolites were observed for metabolites belonging mainly 
to the class of complex lipids, fatty acids and related metabolites as well as amino acids and 
related compounds. Bile acid metabolism was markedly affected: taurocholic acid, 
glycochenodeoxycholic acid and cholic acid presented abrupt changes showing a specific 
metabolite pattern indicating disruption of the microbial community. In both plasma and 
feces taurocholic acid was highly upregulated upon treatment whereas 
glycochenodeoxycholic acid was downregulated. Cholic acid was upregulated in feces but 
downregulated in plasma. These results show that changes in the gut microbial community 
lead to alterations of the metabolic profile in blood and feces of the host and can be used to 
identify potentially microbiome-related metabolites. This implies that metabolomics could 
be a suitable tool to estimate the extent of changes induced in the intestinal microbiome 
with respect to consequences for the host. 
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ABBREVIATIONS  
ANCOM analysis of composition of microbiomes 
BSH  bile salt hydrolase 
GC  gas chromatography 
DAG  diacylglycerine 
GF  germ-free 
IBD  inflammatory bowel disease 
LC  liquid chromatography 
LD  low dose 
MOA  mode of action 
MS  mass spectrometry 
OECD  Organisation for Economic Co-operation and Development 
PCA  principal component analysis 
PCoA  principal coordinate analysis 
SPE  solid phase extraction 
TAG  triacylglycerol 
 
 
INTRODUCTION 
The gut microbiome has gained a lot of attention in the last years, becoming a rapidly 
growing field of study. It is increasingly recognized as a critical component in human 
development, health and disease and it is gaining a spot in fields such as oncology, 
toxicology, pharmacology, neurology and many others. Next generation sequencing and the 
development of metagenomic tools allow to characterize the gut microorganisms and have 
shed light on their importance for the host system (Gilbert et al., 2016). Although the 
fundamental role of the microbiome in the well-being of the host is clear, science is now 
dealing with a bigger challenge: i.e. understanding the mechanisms by which this process is 
driven. Integrative approaches that not only asses the composition of the gut microbiome 
but also its functionality must be implemented to unravel the complex dynamics of host-
microbiome interactions (Bäumler and Sperandio, 2016). There are high intra- and 
interspecies variabilities regarding the composition of the microbiome, however, there are 
also indications that the functionality in terms of gene activity and metabolic output of the 
microbes have a lower variability (Cho and Blaser, 2012; McCoy et al., 2017) which 
supports assessing functional microbial changes with metabolomics approaches. Currently, 
metabolomics is increasingly used to study the gut microbiome since matrices like urine, 
blood or feces can be screened, which also enables a longitudinal study design and the 
analysis of metabolic fluxes. Recent research has demonstrated the large impact the gut 
microbiome has on mammalian blood metabolites, suggesting a major interplay between 
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bacterial and mammalian metabolism (Wikoff et al., 2009). Metabolites produced or 
modified by the gut microbiota can be absorbed across the intestinal cell wall and can 
therefore be detected in plasma. Numerous circulating molecules have been determined to 
arise exclusively in the presence of gut microflora (Wikoff et al., 2009).  
Initial investigations demonstrated the identification of different modes of action (MoAs) or 
adverse outcomes after substance treatment using plasma metabolomics in rats (van 
Ravenzwaay et al., 2007). It was noted that the chemicals or diseases that produce a 
specific form of toxicity, generally through a shared mode of action, produced a subset of 
common specific metabolite changes. Such a common set of consistently regulated 
metabolites can be used to establish metabolic patterns specific for certain toxicities (Kamp 
et al., 2012; Mattes et al., 2014). Using this approach, microbiome-related metabolites in 
plasma could previously be identified after antibiotic treatment and specific metabolite 
patterns could be established in the MetaMap®Tox (Behr et al., 2017), a metabolomics 
database for the identification and prediction of toxicological modes of action (MoAs) of 
new test substances. 
 
In a previous study, we performed metabolite profiling of different matrices of the gut of 
rats, after antibiotic treatment in order to evaluate metabolite changes observed at different 
dose levels and in different sexes, and to identify the best tissue matrix for further 
investigations. The results of this targeted analysis showed that the metabolic profiles of 
male and female animals in the gut microbiome are comparable and that taking other 
samples (e.g. from different regions of the gastrointestinal tract) than feces did not add any 
extra information (Behr et al, submitted). Besides, the metabolites found in feces were 
similar to those in cecum content indicating that feces sampling for in vitro incubations 
could provide a suitable non-invasive method for studying microbiome related metabolites 
and metabolism. 
In this study, we analyzed the same metabolites in both plasma and feces to evaluate the 
effect of gut microbial changes on the plasma metabolome. Assessing the metabolite 
changes in the feces after the administration of lincosamides can support the evaluation of 
the antibiotics effects on the microbiome regarding its functionality. The aim of this study 
was to establish specific plasma metabolome patterns for the effects of lincosamides on the 
microbiome using the MetaMap®Tox database, and to identify potential microbiome-
associated or -derived metabolites in plasma based on changes of the gut core diversity of 
lincosamides-treated rats. Therefore, the feces metabolome was evaluated after the 
antibiotic treatment to aid in the establishment of more accurate plasma patterns and to gain 
a more comprehensive understanding of the effects and dynamics of microbiome 
alterations. 
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Figure 1 Schematic presentation of the study design for metabolite profiling in plasma and feces of antibiotic 
treated rats and the corresponding community analysis. Clindamycin and lincomycin were administered orally for 
28 days to rats. Blood samples were taken after 7, 14 and 28 days for metabolite profiling. Feces samples were 
taken at the last day of the study for metabolite profiling and targeted metagenomics analysis. The aim was to 
identify metabolites related to gut microbial changes seen in the community analysis due to antibiotic treatment 
and to establish specific plasma metabolome patterns in the MetaMap®Tox database. 
 
 
MATERIALS AND METHODS 
Three independent studies were performed according to the Organisation for Economic Co-
operation and Development (OECD) 407 protocol. Animal handling, treatment, and clinical 
examinations have been described earlier (Kamp et al., 2012; Strauss et al., 2012; van 
Ravenzwaay et al., 2012, 2010, 2007). 
 
Ethics statement 
The studies were approved by the BASF Animal Welfare Body, with the permission of the 
local authority, the Landesuntersuchungsamt Rheinland-Pfalz (approval number 23 177-
07/G 13-3-016). The study was performed in an AAALAC-approved (Association for 
Assessment and Accreditation of Laboratory Animal Care International) laboratory in 
accordance with the German Animal Welfare Act and the effective European Council 
Directive.  
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Animals and Maintenance Conditions 
Briefly, male and female Wistar rats (CrI:WI(Han)) were supplied by Charles River, 
Germany, and were 70 ±1 days old at the beginning of the studies. The animals (5 rats per 
sex and cage in one group) were maintained in an air-conditioned room at a temperature of 
20 to 24°C, a relative humidity of 30 to 70%, and a 12 hour light / 12 hour dark cycle. 
Ground Kliba mouse/rat maintenance diet “GLP” was supplied by Provimi Kliba SA, 
Kaiseraugst, Switzerland. Diet and drinking water were available ad libitum (except 16 - 20 
hours before sampling) and regularly assayed for chemical contaminants and the presence 
of microorganisms. 
 
Treatment of animals with compounds 
The antibiotics were administered daily by gavage to each treatment group consisting of 
five rats per group and sex. Clindamycin was prepared in ultrapure water and given at 
concentrations of 200 mg/kg body weight. Lincomycin was given at 300 mg/kg body 
weight in water containing 0.5% carboxymethyl cellulose (CMC). Dose-levels were 
selected according the literature data (Gray et al., 1972, 1971, 1966, 1964).To examine that 
the effect of CMC does not interfere with metabolite changes in the plasma patterns arisen 
from antibiotic treatment, 10 animals per sex received 10 ml/kg bw/d drinking water 
containing 0.5% CMC. The standard procedure for the evaluation of test substance-related 
effects in the MetaMap®Tox database is the comparison of the resulting values of the 
treatment groups against the baseline values of a diet control. This procedure has been used 
since 2004 resulting in a very extensive database of control values for the metabolites 
evaluated. As described in van Ravenzwaay et al (van Ravenzwaay et al., 2016), this gives 
us the ability to determine not only the statistical significance of regulated metabolites, but 
also allows the assessment if a particular metabolite value has ever been observed in control 
animals – providing a historical range of what is normal. The three substances 
(clindamycin, lincomycin and CMC) were each administered in separate studies, each with 
a diet control group of 10 animals per sex, to allow for such comparisons.  
 
Sampling of blood and feces for metabolite profiling 
Between 7:30 and 10:30 h, on study days 7, 14 and 28 blood samples were taken from the 
retro-orbital sinus in all rats under isoflurane anesthesia (1.0 ml K-EDTA blood). The blood 
samples were centrifuged (10 °C, 20,000 x g, 2 min) and the EDTA plasma was separated. 
The EDTA plasma samples were covered with nitrogen and frozen at -80 °C until 
metabolite profiling was performed.  
Feces samples were carefully removed during necropsy on day 28 from the rectum after a 
fasting period of 16 – 20 hours and one day after the last administration of the test 
substances. The samples were collected in pre-cooled (dry-ice) vials, immediately snap-
frozen in liquid nitrogen and stored at -80 °C until metabolite profiling or DNA extraction, 
respectively, was performed.  
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Clinical Examinations 
All animals were checked daily for any clinically abnormal signs and mortalities. Food 
consumption was determined on study days 6, 13 and 27. Body weight was determined 
before the start of the administration period in order to randomize the animals and on study 
days 6, 13 and 27. At the end of the treatment period, the animals were sacrificed by 
decapitation under isoflurane anesthesia. Metabolite profiling of plasma and feces samples 
as well as the gut microbial community analysis were performed for all control and treated 
animals.  
 
DNA extraction and bacterial 16S rRNA amplicon sequencing 
DNA was isolated from the fecal samples using InnuPREP stool DNA Kit (Analytik Jena) 
according to the manufacturer’s instructions. Based on observations made during the 
process, the incubation temperature for the cells’ lysis was lowered to 75°C. DNA yield and 
integrity were assessed using a Nanodrop. Samples were sent to IMGM® laboratories 
(Martinsried, Germany) for PCR, library preparation, and sequencing. DNA was amplified 
using 16S V3-V4 primers (Bakt_341F :5’-CCTACGGGNGGCWGCAG-3’ and Bakt_805r 
:5’-GACTACHVGGGTATCTAATCC-3’). Sequencing was performed on the Illumina 
MiSeq® next generation sequencing system (Illumina Inc.). Signals were processed to fastq 
files and the resulting 2 x 250 bp reads were demultiplexed using the MiSeq®Reporter 
software. 
 
Metabolite Profiling in plasma and feces  
For mass spectrometry-based metabolite profiling, plasma and feces samples were extracted 
by a proprietary method as described below. GC-MS (gas chromatography-mass 
spectrometry) and LC-MS/MS (liquid chromatography-MS/MS) were used for broad 
profiling (van Ravenzwaay et al., 2007). Proteins were removed from 60 µL plasma 
samples by precipitation using 200 µL acetonitrile. Subsequently, polar and non-polar 
fractions were separated for both GC-MS and LC-MS/MS analysis by adding water and a 
mixture of ethanol and dichloromethane (1:2, v:v). Feces samples were freeze dried and 
ground prior to extraction. Processed feces (5 mg) were extracted with a mixture of 
acetonitrile, water, ethanol and dichloromethane in a sample tube with a 3 mm stainless 
steel ball using a Bead Ruptor (Omni International Inc.). Phase separation was achieved by 
adding additional dichloromethane. For GC-MS analysis (CTC GC PAL, Agilent 6890 GC 
gas chromatograph, 5973 MSD mass spectrometer), the non-polar fraction was treated with 
methanol under acidic conditions to yield the fatty acid methyl esters derived from both 
free fatty acids and hydrolyzed complex lipids. The non-polar and polar fractions were 
further derivatized with O-methyl-hydroxylamine hydrochloride and pyridine to convert 
oxo-groups to O-methyl-oximes and subsequently with a silylating agent before analysis 
(Roessner et al., 2000). For LC-MS analysis, both fractions were reconstituted in 
appropriate solvent mixtures. HPLC was performed by gradient elution on reversed phase 
separation columns. Mass spectrometric detection technology was applied which allows 
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target and high sensitivity MRM (Multiple Reaction Monitoring) profiling in parallel to a 
full screen analysis as described in patent WO2003073464 (Walk and Dostler, 2003). For 
GC-MS the acquisition in scan mode m/z 15-600 for polar compounds and m/z 40-600 for 
lipid compounds was applied. For LC-MS MRM and a Q3 Scan of m/z 100-1000 was used. 
MRMs off all analytes were determined using solutions of the authentic standard.  
GC-MS conditions: CTC GC PAL, Agilent 6890 GC gas chromatograph, 5973 MSD mass 
spectrometer, gradient: 70 °C to 340 °C, carrier gas: helium, acquisition in scan mode m/z 
15-600 (polar compounds) / m/z 40-600 (lipid compounds). 
LC-MS conditions: Agilent 1100 HPLC System, AB Sciex API 4000 mass spectrometer, 
gradient elution for polar compounds with water / acetonitril / ammonium formate, gradient 
elution for lipid compounds with water / methanol / methyl tert-butyl ether / formic acid, 
MRM and Q3 Scan m/z 100-1000. 
 
For GC-MS and LC-MS/MS profiling, data were normalized to the median of reference 
samples which were derived from a pool formed from aliquots of all samples to account for 
inter- and intra-instrumental variation. In plasma, 224 semi-quantitative metabolites could 
be analyzed using the single peak signal of the respective metabolite and a normalization 
strategy according to the patent WO2007012643A1 (Walk et al., 2006) resulting in ratio 
values which represent the metabolite change of treated versus control animals, of which 
195 are chemically identified and 29 are structurally unknown. In feces, 208 semi-
quantitative metabolites could be analyzed, 177 of which are chemically identified and 31 
are structurally unknown. 
 
Statistics 
The data were analyzed by univariate and multivariate statistical methods. The sex- and 
day-stratified heteroscedastic t-test ("Welch test") was applied to compare metabolite levels 
of dose groups with respective controls. For all metabolites, changes were calculated as the 
ratio of the mean of metabolite levels in individual rats in a treatment group relative to 
mean of metabolite levels in rats in a matched control group (time point, dose level, and 
sex). Hereafter, these ratios are referred to as ‘relative abundance’ in plasma or feces. 
The p-values, t-values, and ratios of corresponding group medians were collected as 
metabolic profiles and fed into the MetaMap®Tox database (van Ravenzwaay et al., 2016). 
In the database, all treatment groups are compared to diet controls of the corresponding 
study. In this study, the profile strength of the metabolic profile is addressed. This 
parameter represents the rounded down average of absolute medians of t-values and does 
not only include the absolute number of significantly changed metabolites, but also the 
magnitude of the respective changes.  
Briefly, the best balance for finding the maximum number of truly regulated metabolites 
while minimizing the number of false positive regulated metabolites is obtained at a p value 
of 0.15. Therefore, for pattern recognition p values between 0.1 and 0.2 are used in the 
database for plasma. For a detailed description on the use of statistics in MetaMap®Tox see 
Impact of lincosamides on the bacterial composition and metabolite profile 
95 
van Ravenzwaay et al. (van Ravenzwaay et al., 2016). The patterns of the lincosamides 
were established using a p-value of 0.2. 
An in-house R script was written to check the completeness of the measured metabolite 
data. Metabolite profiles for which the database contained more than 50% of the missing 
values across the measured samples were removed from the analysis. As Singular Value 
Decomposition (SVD) PCA algorithm can only be performed on complete matrices all 
missing values are replaced by values computed using SVDimpute Algorithm as proposed 
by Troyanskaya et al. (Troyanskaya et al., 2001). PCA function from pcaMethods 
(Stacklies et al., 2007) R package version 1.70.0 was used with “UV” unit variance scaling 
option and center option set to “TRUE” to make the matrix mean centred. First 5 PCA axis 
was visualised using scatterD3 R package version 0.8.2. Whenever we write 
“significantly”, "statistically significantly” is meant. 
 
Bioinformatics 
Forward and reverse primers corresponding to the sequences 5’-
CCTACGGGNGGCWGCAG-3’ and 5’-GACTACHVGGGTATCTAATCC-3’ were 
trimmed from the raw reads using cutadapt (Martin, 2011) and forward/reverse read pairs 
that did not contain either primer were removed. A table of amplicon sequence variants 
(ASV) was obtained by denoising using QIIME2’s dada2 denoise-single command 
(Callahan et al., 2016; “QIIME2,” n.d.). A phylogenetic tree was built from the ASVs using 
QIIME2’s alignment mafft, alignment mask, phylogeny fasttree, and phylogeny midpoint-
root commands. Taxonomy was assigned to ASV sequences using sintax (Edgar, 2016) on 
version 128 of the SILVA Living Tree Project database (Yilmaz et al., 2014). Diversity 
analysis was performed using the diversity plugins from QIIME2 (Caporaso et al., 2010).  
Statistically significant changes of the microbial community up to the taxonomic family 
level were evaluated with analysis of composition of microbiomes (ANCOM) as 
implemented in QIIMES2’s composition plugin (Mandal et al., 2015).  
 
For establishing the pairwise Krona plots, two samples of interest (A and B) were selected 
and an average of each taxon (A + B)/2 was calculated, e.g. if A = 20% and B = 30% of 
Bacteroidetes; it shows up as 25% Bacteroidetes. The difference (diff) is calculated per taxa 
by subtracting B from A and reported as a difference in fraction of the total for that taxa 
with diff = (A – B)/(A+B). For A = 20% and B = 30%, the difference is -0.2. I.e. when the 
second sample contributes more, the difference is negative and represents the additional 
fraction of that taxa that B contributed. When the first sample contributes more, the 
difference is positive and represents the additional fraction of that taxa that A contributed. 
When taxa contributions are the same, the difference is 0.  
 
Establishment of specific metabolite patterns in MetaMap®Tox 
Patterns correlating to specific toxicological modes of action were established in 
MetaMap®Tox database as described before (Kamp et al., 2012). In the current study, 
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patterns were created based on the metabolic profiles of clindamycin and lincomycin. 
Briefly, metabolites which were statistically significantly regulated in the same direction 
(higher/lower levels compared to controls) for both substances were identified from the 
MetaMap®Tox database to establish a metabolite profile. After identification of the 
significantly changed metabolites and a consistency check through an expert panel of 
experienced toxicologists, the pattern was validated against the database and should 
identify compounds in the MetaMap®Tox with the same toxicological mode of action.  
 
 
RESULTS 
Clinical signs 
No clinical signs of toxicity or mortality were observed in any of the animals that received 
CMC or lincomycin. The group of female animals treated with clindamycin showed 
temporarily following relevant clinical signs salivation and semi closed eyelid (4 animals), 
and one of the animals presented fur piloerection. Similarly, males treated with 
clindamycin, showed slight salivation (all animals), semi closed eyelid (3 animals) and, two 
of them were in a general poor condition. Except for salivation, these findings were only 
observed in the individual animals on 1-3 days of the administration period of 28 days. 
Therefore, and in the absence of body weight effects, these observations were assessed as 
borderline effects of a marginal systemic toxicity of clindamycin at 200 mg/kg body 
weight. Relative changes in body weight and food consumption noted upon administration 
of the test compounds are shown in Table 1. Treated animals did not present any significant 
changes with respect to body weight when compared to the controls.  
 
 
Table 1 Relative changes in body weight and food consumption of male and female Crl:Wi(Han) rats (N = 5 per 
group) dosed for 28 days compared to the diet controls. Data were collected on study days 6, 13 and 27. Treated 
animals did not present any significant changes (p < 0.05) in body weight compared to the control groups (N = 10 
per group).  
m f m f
Clindamycin 6 0.97 0.99 1.30 0.80
13 0.95 0.98 1.12 1.19
27 0.94 1.00 0.99 1.16
Lincomycin 6 1.00 0.99 1.00 0.70
13 0.98 1.00 1.03 0.99
27 0.96 1.05 1.18 0.97
0.5% CMC 6 1.00 0.99 0.98 1.00
13 0.98 1.01 0.99 0.90
27 0.97 1.02 0.97 0.93
Compound Day
Body weight Food consumption
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Metabolite Profiling in plasma and feces 
Table 2 shows the percentage of altered metabolites of the metabolome analysis in plasma 
and feces of antibiotic-treated rats as well as the animals receiving 0.5% CMC compared to 
the diet control animals.  
Clindamycin treatment showed a significant effect on the plasma metabolite profiles in all 
the treated animals compared to the controls (see Table 2). Male animals exhibited a 
percentage of changed metabolites of 32% (day 7) and 28% at the end of the administration 
period (day 28). More down- than upregulated metabolites were observed. Females 
presented a balanced ratio of down- and upregulated metabolites on day 7 and day 28. At 
day 7, 25% of the total measured metabolites were altered, on day 14, the total changes 
increased to 34% due to a rise in upregulated metabolites. On the last day of treatment, the 
total amount of altered metabolites was 24%.  
The total amount of metabolite changes observed with lincomycin treatment was similar 
compared to clindamycin (see Table 2). The number of total significantly altered 
metabolites in males dropped from 32% on day 7 to 22% at the end of the study (day 28). 
In the female group, the percentage of changed metabolites also decreased from day 7 
(36%) to day 28 (28%). In general, in both sexes, the number of downregulated metabolites 
in plasma was higher than the number of upregulated metabolites. Females showed slightly 
higher percentage of total changes compared to the controls than male animals, especially 
on day 7. 
In the CMC group of male animals the percentage of changed metabolites fluctuated 
strongly over time and decreased from 32% to 19% compared to the diet control showing 
more upregulated than downregulated metabolites. Due to these inconsistent fluctuations in 
the plasma metabolites, the overall profile strength was evaluated to enable an assessment 
whether an effect is significant or in the range of normal biological fluctuations of the 
metabolome (see Table 3). 
 
Table 2 displays the percentages of changed metabolites in the feces of the treated animals 
compared to the diet controls on day 28. The values show that the antibiotics administered 
had a prominent impact on the feces metabolome. Around half of the total measured 
metabolites were significantly altered after lincomycin treatment in both males and females. 
Regarding clindamycin, males treated with this antibiotic exhibited 57% changed 
metabolites. Females expressed with 44% a lower number of total changes. In general, after 
lincosamides treatment the number of significantly upregulated metabolites in feces was at 
least three times higher than the downregulated ones.  
After CMC treatment the feces metabolome just showed only very minor changes (4-5%) 
compared to the diet control. 
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Table 2 Statistically significantly downregulated (blue) and upregulated (red) measured metabolites compared to 
the diet controls in plasma (day 7, 14 and 28, p < 0.2) and feces (day 28, p < 0.05) of male and female Wistar rats 
after antibiotic treatment with clindamycin, lincomycin and 0.5% CMC for 28 days. 
Feces Feces
7 d 14 d 28 d 28 d 7 d 14 d 28 d 28 d
Total metabolites 212 212 211 182 219 218 218 180
% down 24.5 16.0 16.1 14.3 12.8 12.8 12.8 11.7
% up 7.5 9.0 12.3 42.9 12.3 21.6 11.0 32.8
% total 32.1 25.0 28.4 57.1 25.1 34.4 23.9 44.4
Feces Feces
7 d 14 d 28 d 28 d 7 d 14 d 28 d 28 d
Total metabolites 214 212 214 183 219 216 217 180
% down 21.5 26.4 16.8 8.2 22.8 19.0 14.7 9.4
% up 10.3 6.1 5.1 43.7 13.2 11.6 12.9 40.6
% total 31.8 32.5 22.0 51.9 36.1 30.6 27.6 50.0
Feces Feces
7 d 14 d 28 d 28 d 7 d 14 d 28 d 28 d
Total metabolites 218 218 219 200 212 212 219 199
% down 12.4 12.8 5.0 1.0 12.7 5.7 19.6 3.5
% up 19.3 16.1 14.2 3.5 9.0 12.7 8.7 0.5
% total 31.7 28.9 19.2 4.5 21.7 18.4 28.3 4.0
Clindamycin, males Clindamycin, females
Plasma Plasma
Lincomycin, males Lincomycin, females 
Plasma Plasma
0.5% CMC, males 0.5% CMC, females 
Plasma Plasma
 
 
A Principle Component Analysis (PCA) was conducted to visualize treatment-related 
effects on the feces metabolites. The PCA demonstrated that CMC treatment clusters with 
the control animals and after 4 weeks of lincosamides administration a clear treatment-
related effect could be observed in the feces metabolome (see Figure 2). The main 
separation was driven by the treatment-related effect. The female group showed a 
separation of clindamycin and lincomycin in principal component 2. Taken together, these 
analyses show that the observed alterations of the metabolites in the feces is mainly driven 
by the treatment effect followed by the specific antibiotic applied (either lincomycin or 
clindamycin).  
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Figure 2 Treatment effect of clindamycin and lincomycin on the feces metabolome of male animals (a) and female 
animals (b). PCAs of fecal metabolic profiles of male (N = 29) and female (N = 28) control animals, male and 
female animals dosed with clindamycin (200 mg/kg bw/d) and lincomycin (300 mg/kg bw/d) (N = 5 per group, 
except female group of clindamycin with N = 4) and animals receiving 0.5% CMC (N = 10 for females, N = 7 for 
males) for 28 days. Feces samples were taken on study 28 after overnight fasting. 
 
The profile strength of each metabolic profile was calculated in the MetaMap®Tox 
database (see Table 3) to evaluate the magnitude of the changes which reflects the impact 
of a treatment on the metabolome compared to the diet control of the study. In the feces, 
lincosamides treatment showed both in males and females a profound effect (lincomycin 
with 3.54 for females and 4.05 for males, and clindamycin with 3.80 for females and 3.96 
for males) whereas the profile strength of CMC treatment was below 1.0. The profile 
strength of the plasma metabolome in both sexes was for lincosamides treatment 0.9-1.0. 
For CMC treatment the profile strength was in the range of other control groups in the 
database (0.85 for males and 0.7 for females).  
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Table 3 Profile strength of the metabolite profile in plasma and feces of male and female Wistar rats after 
treatment with clindamycin, lincomycin and 0.5 % CMC. 
males females males females males females
Plasma 1.06 0.93 0.97 1.02 0.85 0.70
Feces 3.96 3.80 4.05 3.54 0.83 0.87
Clindamycin Lincomycin 0.5% CMC
 
 
Specific plasma metabolite patterns of lincosamides 
Numerous studies have demonstrated that the gut microbiota influences the host metabolic 
phenotype. The microorganisms present in the intestine produce or modify different 
metabolites. These metabolites can be (re-)absorbed into the system and consequently can 
be detected in the plasma. Thus, in the present study, specific plasma metabolome patterns 
were established to characterize the effects of the lincosamides antibiotics on the 
functionality of the microbiome. Therefore, each metabolite value of a treated group was 
evaluated against the value of the diet control of the corresponding study and expressed as a 
relative (fold-change) value of the control.  
 
Plasma metabolite pattern in male animals 
A plasma pattern for the effect of lincosamides on the male microbiome was established 
and validated in MetaMap®Tox (see Figure 3). This pattern consists in a total of 12 plasma 
altered metabolites. Ten of these metabolites were significantly decreased and two were 
increased (i.e. 3-hydroxybutyrate and taurocholic acid) after the antibiotics administration 
compared to the control group. Noteworthy, 9 of the 12 downregulated metabolites were 
complex lipids, fatty acids and related metabolites.  
Significant changes were also seen in amino acids and energy metabolism. At all three time 
points (day 7, 14, 28) and for both lincosamides tested, cholic acid and 
glycochenodeoxycholic acid in plasma were profoundly decreased. In contrast, taurocholic 
acid presented highly elevated levels. The highest relative abundance in plasma was 
reached on day 7 where the values for lincomycin showed a 7.82-fold and 4.40-fold 
increase compared to the controls, respectively. On day 28, the relative abundance in 
plasma for taurocholic acid dropped to 4.22 (lincomycin) and 2.60 (clindamycin). Another 
significantly increased metabolite noted after lincosamides treatment was 3-
hydroxybutyrate, with concentrations in plasma increased towards the end of the 
administration period: 1.31 after clindamycin and 1.19 after lincomycin treatment. Other 
metabolites belonging to the class of complex lipids, fatty acids and related, such as 
arachidonic acid, heptadecanoic acid and diacylglycerol (DAG), were shown to be 
significantly decreased at most time points. 
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Metabolite Direction Metabolite class
7 d 14 d 28 d 7 d 14 d 28 d
Tyrosine ↓ 0.81 0.75 0.90 0.82 0.84 0.93
Glycine ↓ 0.76 0.81 0.88 0.62 0.62 0.92
Taurocholic acid ↑ 4.40 3.12 2.60 7.82 6.36 4.22
Glycochenodeoxycholic acid ↓ 0.00 0.01 NA 0.00 0.01 0.03
Cholic acid ↓ 0.00 0.04 0.00 0.00 0.00 0.01
DAG (C18:1,C18:2) ↓ 0.80 0.92 0.81 0.72 0.69 0.93
Arachidonic acid (C20:cis[5,8,11,14]4)↓ 0.73 0.80 0.96 0.75 0.74 0.97
Heptadecanoic acid (C17:0) ↓ 0.82 0.78 0.76 1.00 0.74 0.79
Lysophosphatidylcholine (C20:4) ↓ 0.97 0.83 0.85 0.91 0.86 1.04
Lysophosphatidylcholine (C17:0) ↓ 0.86 0.89 0.83 0.99 0.89 0.93
Unknown metabolite ↓ 0.83 0.87 0.92 0.96 0.94 0.91
3-Hydroxybutyrate ↑ 1.18 1.50 1.31 1.06 1.09 1.19 Energy metabolism and related metabolites
Clindamycin Lincomycin
Amino acids
Complex lipids, fatty acids and related 
metabolites
 
Figure 3 Heatmap of statistically significantly increased and decreased values of metabolite changes after 
treatment with lincosamides of male animals (Welch t test; p < 0.2). Metabolite concentration changes relative to 
the diet controls of each study (N = 10 per group) in plasma of male Crl/Wi(Han) rats (N = 5 per group) dosed 
with lincomycin (300 mg/kg bw/d) or clindamycin (200 mg/kg bw/d) for 28 days. Blood samples were taken on 
study days 7, 14 and 28 after overnight fasting: figures in red boxes are significantly increased and those in blue 
boxes significantly decreased metabolite value changes. The intensity of the color corresponds to the magnitude of 
the fold change. "NA" indicates that for this analyte, treatment and/or analysis groups there are no contrasts 
available. 
 
Plasma metabolite pattern in female animals 
A plasma metabolome pattern was also created for the female animals treated with 
lincosamides. This pattern contains ten metabolites that showed to be altered after the 
antibiotics treatment (see Figure 4). Six metabolites were significantly decreased and four 
significantly increased compared to the diet control group. Changes were seen in amino 
acids and related metabolites, carbohydrates and related metabolites, complex lipids, fatty 
acids and related metabolites, energy metabolism and related and in miscellaneous 
metabolites. As in the male pattern, cholic acid and glycochenodeoxycholic acid were 
remarkably decreased at all the time points (day 7, 14, 28). The relative abundance in 
plasma ranged from 0.02 on day 7 to 0.01 on day 28 (clindamycin) and from undetectable 
concentrations on day 14 to 0.06 on the last day of the study (lincomycin). Also, similar to 
the male pattern, the values of taurocholic acid and 2-hydroxybutyrate were significantly 
increased. Particularly after lincomycin treatment, taurocholic acid was highly upregulated 
exhibiting its highest value at day 7 (4.12). However, at the last day of the study the relative 
plasma concentrations of taurocholic were similar for both antibiotics; 1.83 (lincomycin) 
and 1.84 (clindamycin). 2-Hydroxybutyrate was 3.80-fold increased in plasma after 
clindamycin administration, dropping on day 28 to an 1.93-fold increase. Lincomycin 
treatment caused a significant increase of 2-hydroxybutyrate on day 7 (1.23) and day 14 
(1.57). Regarding the amino acids and related metabolites, the female group showed a 
significant increase in glutamate during days 7 and 14. Additionally, low relative 
abundance in plasma was found for 3-hydroxyindole, ranging from 0.06 on day 7 to 0.33 on 
day 28 (lincomycin) and from 0.46 on day 7 to 0.17 on day 14. High levels of glucuronic 
acid were also observed after treatment with both antibiotics. 17-hydroxypregnenolone, a 
steroid hormone, was found to be strongly decreased after clindamycin administration and 
dropped to undetectable levels after lincomycin treatment. Besides, the concentrations of 
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hippuric acid were clearly decreased with both substances over all the times points, except 
for day 28 of lincomycin, where this metabolite was singularly upregulated. Relative 
plasma values of hippuric acid ranged from 0.07 at day 7 to 0.12 on day 28 (clindamycin) 
and from 0.33 at day 7 to 0.75 on day 14 with a followed increased to 1.96 at day 28 
(lincomycin). 
 
Metabolite Direction Metabolite class
7 d 14 d 28 d 7 d 14 d 28 d
Glycine ↓ 0.78 0.85 0.91 0.64 0.68 1.01
Glutamate ↑ 1.23 1.41 1.04 1.31 1.21 1.15
3-Hydroxyindole ↓ 0.46 0.17 0.09 0.06 0.04 0.33 Amino acids related metabolites
Glucuronic acid ↑ 1.55 1.51 1.35 1.59 1.39 1.72 Carbohydrates and related metabolites
Taurocholic acid ↑ 1.44 1.55 1.84 4.12 3.29 1.83
Glycochenodeoxycholic acid ↓ 0.07 0.11 0.21 0.16 0.04 0.18
Cholic acid ↓ 0.02 0.03 0.01 0.01 0.00 0.06
2-Hydroxybutyrate ↑ 2.28 3.08 1.93 1.23 1.57 1.04 Energy metabolism and related metabolites
17-Hydroxypregnenolone ↓ 0.01 0.11 0.08 0.00 0.00 0.00 Hormones
Hippuric acid ↓ 0.07 0.13 0.12 0.33 0.75 1.96 Miscellaneous
Clindamycin Lincomycin
Amino acids
Complex lipids, fatty acids and related 
metabolites
 
Figure 4 Heatmap of statistically significantly increased and decreased values of metabolite changes after 
treatment with lincosamides of female animals (Welch t test; p < 0.2). Metabolite concentration changes relative to 
the diet controls of each study (N = 10 per group) in plasma of female Crl/Wi(Han) rats (N = 5 per group) dosed 
with lincomycin (300 mg/kg bw/d) or clindamycin (200 mg/kg bw/d) for 28 days. Blood samples were taken on 
study days 7, 14 and 28 after overnight fasting: figures in red boxes are significantly increased and those in blue 
boxes significantly decreased metabolite value changes compared to controls. The intensity of the color 
corresponds to the magnitude of the fold change. 
 
Significant altered metabolites in feces and plasma  
Table 4 shows an overall comparison of significant altered metabolites after lincosamides 
treatment where significant increased and decreased plasma metabolites were compared 
with the changes in feces. Feces metabolites that were found to be altered more than 5-fold 
were also included in the table.  
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Table 4 Overall comparison of significant altered metabolites after lincosamides treatment. Statistically significant 
increased and decreased plasma metabolites were compared with the changes in feces. Additionally, feces 
metabolites that were found altered more than 5-fold were included in the table and marked with *. Arrows 
indicate the direction of regulation. "NA" indicates that for this analyte, treatment and/or analysis groups there are 
no contrasts available. 
♂ ♀ ♂ ♀
Glutamate ↑ ↑
Glycine ↓ ↓ ↑ ↑
Taurine ↑* ↑*
Tryptophan ↑* ↑*
Tyrosine ↓ ↑* ↑*
3-Hydroxyindole ↓ NA
Indole-3-lactic acid ↑*
Kynurenic acid ↑* ↑*
Creatine ↑* ↑*
Creatinine ↑* ↑*
Hippuric acid ↓ NA
Cholic acid ↓ ↓ ↑* ↑*
Glycochenodeoxycholic acid ↓ ↓ ↓*
Taurocholic acid ↑ ↑ ↑* ↑*
4-Hydroxysphinganine (t18:0, Phytosphingosine) ↑* ↑*
Arachidonic acid (C20:cis[5,8,11,14]4) ↓
DAG (C18:1,C18:2) ↓ ↑ ↑
Heptadecanoic acid (C17:0) ↓ ↓ ↓
Hexadecanol ↓* ↓*
Linoleic acid (C18:cis[9,12]2) ↑*
Lysophosphatidylcholine (C17:0) ↓
Lysophosphatidylcholine (C20:4) ↓
TAG (C16:0,C18:2) ↑* ↑*
TAG (C18:1,C18:2) ↑* ↑*
TAG (C18:2,C18:2) ↑* ↑*
TAG (C16:0,C18:1,C18:3) ↑* ↑*
TAG (C18:1,C18:2,C18:3) ↑* ↑*
Unknown metabolite I ↓
Unknown metabolite II ↑* ↑*
Glucuronic acid ↑ ↑ ↑
Xylitol ↑* ↑*
3-Hydroxybutyrate ↑ ↑* ↑*
2-Hydroxybutyrate ↑ ↑* ↑*
17-Hydroxypregnenolone ↓ NA NA
Amino acids
and related
metabolites
Bile acids
Complex lipids,
fatty acids
and related
metabolites
Others
FecesPlasmaMetabolite Class
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Community analysis of the gut microbiome 
To characterize the changes in the gut microbiota composition after lincosamides 
administration, 16S ribosomal RNA gene sequencing was performed. DNA was extracted 
from feces samples collected at the last day of the study (day 28) from the control and 
treated animals, and an analysis of bacterial taxonomic units was carried out.  
A clear treatment-related effect for both antibiotics on the gut microbiome was revealed by 
a principal coordinate analysis (PCoA) of weighted UniFrac distances (see Figure 5). The 
main separation on Axis 1 was driven by the treatment. Community structures of treated 
animals, both male and female, clustered together and were clearly separated from the 
cluster of the community composition of the control groups, which clustered with the CMC 
treated animals.  
 
 
Figure 5 Principal coordinate analysis (PCoA) of the gut microbial community showing a treatment-related effect 
of clindamycin and lincomycin versus the vehicle carboxymethylcellulose (CMC, 0.5%) and control groups in the 
gut microbial composition of male and female animals. Feces samples were taken on day 28 of the study, DNA 
was extracted and the 16S ribosomal RNA gene was sequenced. PCoA was calculated using weighted UniFrac 
distance on the denoised dataset obtained from the dada2 workflow. 
 
To dig deeper into the changes observed in the PCoA, an analysis of alpha and beta 
diversity was performed. To assess alpha diversity, effective species number was calculated 
for each sample by taking the exponential of Shannon-Weiner index (Chao et al., 2010). 
Effective species is a standardized diversity unit that represents the amount of diversity in a 
population of evenly distributed species. Effective species number for each sample was 
visualized and Kruskal-Wallis statistics were calculated using the diversity plugin of 
QIIME2 (see Supplementary Material). Analysis of effective species number by treatment 
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showed that despite appearing similar on the PCoA, CMC seemed to slightly increase the 
diversity from around 80 effective species to 100, however this change was not significant 
after testing using Kruskal-Wallis. The diversity decline in antibiotic treated samples was 
similar for both antibiotics very pronounced; decreasing the effective species to fewer than 
20 (Kruskal-Wallis, q < 0.01).  
For beta diversity, a PERMANOVA analysis (Anderson, 2017) of weighted UniFrac 
distance was performed using the diversity plugin in QIIME2 to reveal that CMC had no 
effect on the females’ microbiome (F = 1.3, p = 0.182) and just a minor, yet significant, 
effect on the males’ microbiome (F = 1.9, p = 0.036). However, the microbial composition 
was substantially changed for both males and females upon treatment with lincomycin (F > 
53.9, p < 0.002) or clindamycin (F > 46.5, p < 0.003) as compared to the controls (see 
Suplementary Material). Both antibiotics demonstrated similar drastic alterations of the gut 
microbiome at the phylum level (see Figure 6). The microbial community of control 
animals was composed mainly by Firmicutes (~45-48%) and Bacteroidetes (~40-44%), 
followed by Verrucomicrobia (7-9%), unidentified bacteria (~3%), Proteobacteria (~0.8%), 
Tenericutes (~0.2%) and Deferribacteres (~0.02-0.04%). After 28 days of clindamycin and 
lincomycin administration the gut bacterial community was composed by a high percentage 
of Firmicutes (more than 90% in lincomycin and 80% in clindamycin) followed by a low 
relative proportion of Proteobacteria (3% lincomycin, 15% clindamycin) and other 
unidentified phyla (1.5-2% lincomycin, 3-4% clindamycin). Bacteroidetes (< 0.015%) and 
Verrucomicrobia (< 0.1%) were drastically reduced. Deferribacteres and Tenericutes were 
completely wiped out in the antibiotic-treated animals, while the proportions of Firmicutes 
proportions were twice as compared to the control groups. Additionally, the levels of 
Proteobacteria were greatly increased in the treated groups.  
 
(a) 
 
 (b) 
 
Figure 6 Relative abundance of gut microbes at phylum level of control animals (N = 30 males and N = 28 
females) and after 0.5% CMC (N = 9 males and N = 10 females), clindamycin and lincomycin treatment (N = 5 
per group and sex, except female group of clindamycin with N = 4) in male (a) and female animals (b). Feces 
samples were taken on day 28 of the study. Male and female Crl:Wi(Han) rats were dosed with 0.5% CMC, 
lincomycin (300 mg/kg bw/d) and clindamycin (200 mg/kg bw/d), respectively, for 28 days. 
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The CMC group showed slight differences in composition between male and female 
animals which could also be observed in the PCoA. (see supplementary material). In male 
animals there was a slight decrease of Bacteroidetes (~3%), Proteobacteria, Tenericutes, 
Verrucomicrobia and an increase of Firmicutes (~7%). In comparison, the female animals 
just showed a slight decrease of Verrucomicrobia (~6%) and an increase of ~4% of 
Bacteroidetes. Taken together, these results demonstrate an evident effect of clindamycin 
and lincomycin on the gut microbial diversity and taxa proportions but no or just minor 
changes after CMC treatment.  
For a deeper analysis, pairwise Krona plots were established to show the differences 
between groups with a color code from 1 (pink) meaning an increase after treatment; to -1 
(green) meaning a decrease after treatment. More information is available in the materials 
and methods section. Since the PCoA of the microbial gut community showed no obvious 
differences between male and female animals, the pairwise Krona plots were established 
with the combined data of male and female animals (see Figure 7). After CMC treatment, 
the male group showed a decrease in the bacteria of the order Rhodospirillales (family 
unassigned). In both male and female animals, lincosamides treatment lead to an increase or 
decrease, respectively, of 10 to 16 different bacterial families mainly deriving from 
Firmicutes and Bacteroidetes (see Supplementary Material).  
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a) Control vs 0.5% CMC b) Control vs clindamycin 
 
c) Control vs lincomycin  
Figure 7 Pairwise Krona plots showing the difference (diff) of the 
microbial composition up to family level after 0.5% CMC (a), 
clindamycin (b) and lincomycin (c) treatment. The percentage is the 
average of each family over control and treatment. When taxa 
contributions are the same, the difference is 0. Pink color means a 
decrease, yellow an increase of the bacterial family compared to the 
bacterial composition of the control animals. Feces samples were taken 
on day 28 of the study, DNA was extracted and the 16S ribosomal RNA 
gene was sequenced. Core diversity analysis was obtained by denoising 
the raw reads using dada2 workflow. Male and female Crl:Wi(Han) rats 
(N = 5 per group) were dosed with 0.5% CMC, lincomycin (300 mg/kg 
bw/d) and clindamycin (200 mg/kg bw/d), respectively, for 28 days.  
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DISCUSSION 
Microorganisms present in the gastrointestinal tract have the capacity to synthesize or 
modify different metabolites. These metabolites can be taken up into the host system and 
consequently can be detected in plasma. However, even though the effects of the 
microorganisms in the host metabolic phenotype is recognized, little is known about the 
mechanisms and consequences of these host-microbe interactions.  
In the present study, a shift of the microbiome was induced by the administration of two 
antibiotics, i.e. lincomycin and clindamycin, which belong to the class of lincosamides. 
Lincosamides were chosen due to their broad-spectrum activity against microbes and their 
low systemic toxicity in the host. Several studies have demonstrated that lincosamides do 
not induce organ/systemic toxicity even at high doses in long-term toxicity studies (Gray et 
al., 1972, 1971, 1966, 1964). In our study, treated animals showed no significant alteration 
in food consumption and body weight compared to control animals. Clinical symptoms, in 
particular salivation, found after the administration of clindamycin were probably an acute 
response to the administration treatment (gavage, potential bad taste, slight irritant effects) 
rather than a form of systemic toxicity identifiable by metabolomics. The temporarily 
observed clinical findings (semi-closed eyelid, piloerection and general poor condition) on 
maximum of 3 days during the administration period of 28 days were assessed as borderline 
effects of slight systemic toxicity, which are in the absence of any body weight effect 
unlikely identifiable by metabolomics. For these reasons, it can be assumed that the plasma 
metabolome changes caused by these antibiotics were the result of their effect on the 
microbial functionality.  
CMC, which is widely used in toxicity studies as a vehicle, has been reported  to have an 
effect on the microbiome and is suggested to be associated with the development of 
inflammatory bowel disease (IBD) (Chassaing et al., 2015; Martino et al., 2017). Therefore, 
a separate group for each sex received 0.5% CMC to identify potential significant shifts in 
microbiome communities as well as in the metabolome. CMC treatment showed no effect 
on the fecal microbiome composition and virtually no effect on the fecal metabolome. 
Moreover, the plasma pattern strength, 0.7 – 0.85, is in the range of control values. Given 
these facts it is concluded that CMC has no relevant biological effect on the microbiome 
nor on the fecal and plasma metabolome.  
The profile strength, which reflects the impact of a treatment on the overall metabolome 
regarding the magnitude of change, showed that in plasma the lincosamides treatment had 
no strong effect regarding the overall metabolite profile. However, minor changes in tightly 
controlled metabolites or just few metabolites that are highly up- or downregulated, are not 
reflected in this evaluation. Though, they are detected in the process of establishing the 
specific plasma metabolome patterns. Even though the profile strength was around 1.0 in 
plasma, however, lincosamides treatment had a strong effect on the gut microbiome, as 
clearly shown by both the high number of total changes of metabolites (44-57%) and the 
high values of the feces profile strength (3.5-4.0). This implies that only a fraction of the 
fecal metabolome changes has an influence on the plasma metabolome, given the fact that 
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the same metabolites were measured in both samples. Since in this study the aim was to 
establish metabolome patterns of the plasma metabolites, changes of relevant metabolites in 
the lincosamides patterns were established.  
 
Impact of lincosamides on the gut microbiome and specific plasma metabolome 
patterns 
Specific plasma metabolome patterns were established in the MetaMap®Tox database to 
characterize the effects of the lincosamides antibiotics on the functionality of the gut 
microbiome. These patterns were created I) with the aim of identifying microbiome-related 
or -associated metabolites, and II) as a first step towards future identification of substances 
with similar effects on the microbiome in the MetaMap®Tox database, and. Different 
classes of antibiotics provide different patterns of microbiota alterations because of their 
different spectrum and antibacterial targets. In our previous study, it has been demonstrated 
that antibiotic class-specific changes in the plasma metabolome of rats can be detected 
(Behr et al., 2017).  
In the present study, specific plasma metabolome patterns (for male and female animals) 
were established in the database for the influence of lincosamides antibiotics on the gut 
microbiome. These patterns are composed by potentially gut microbiome-related 
metabolites, which are believed to be either produced or further modified by the intestinal 
microbial communities.  
The community analysis showed no significant differences between male and female 
control animals and female animals treated with CMC. Male animals treated with CMC 
showed a decrease of Rhodospirillales. However, due to the minor relative abundance of 
these Proteobacteria, the PCoA did not show a clear separation of CMC treated males from 
the control animals. After lincosamides treatment, the community analysis confirmed that at 
the compositional level the bacterial community was markedly affected and consequently 
the changes observed in the metabolome could be linked to a disruption on the gut 
microbiome. Lincosamides are particularly active against anaerobes, e.g. Bacteroidetes, 
which are the main colonizers of the gastrointestinal tract. This is consistent with the 
depletion of Bacteroidetes observed in this study. In line with our findings, in other studies 
levels of species belonging to Bacteroidetes significantly decreased whereas levels of 
Proteobacteria and Firmicutes markedly increased after exposure, and the total bacterial 
diversity was reduced compared to control animals (Hornish et al., 1987; Sun and Hsi, 
1973). The diversity analysis presented here was carried out to demonstrate alterations in 
the gut microbiota that could be linked to the metabolic changes observed in the plasma and 
feces profiles. A deeper exploration into more specific taxonomic groups (e.g. genera or 
species) and their metabolic functionality was beyond the aims of the present study but will 
be performed in the future using data from studies with antibiotics having different activity 
spectra to allow a broad correlation analysis and an integration of these data into systems 
biology models. 
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Identification of key metabolites in MetaMap®Tox  
The plasma metabolome patterns for lincosamides showed changes of metabolites 
belonging mainly to the classes amino acids and related metabolites, bile acids and complex 
lipids, fatty acids and related metabolites. Some of the metabolites were found to be altered 
in both plasma and feces, which strengthens their linkage with the microbiome. Feces are 
composed by a large quantity of gut bacteria and their metabolic products. Lincosamides 
exerted a substantial effect on the feces metabolome of rats. The number of significantly 
upregulated metabolites, contrary to the observation in plasma, was much higher than the 
number of downregulated metabolites suggesting that either the lack of bacterial enzymes is 
causing an accumulation of these metabolites in the gut or the outgrowth of the 
communities not affected by the antibiotics is producing more of certain compounds. From 
the principal component analysis (PCA) clear treatment-related effects were revealed in the 
metabolite profile of feces after the antibiotics administration. An overall comparison of 
significant altered metabolites after lincosamides treatment where significant increased and 
decreased plasma metabolites were compared with the changes are shown in Table 4, where 
also feces metabolites that were found to be altered more than 5-fold were included. In the 
following sections amino acids and related as well as bile acids as key metabolites of the 
plasma patterns from different metabolite classes are discussed in detail. 
 
Amino acids and related metabolites 
Amino acids and proteins as an essential part of the diet reach the intestinal tract, and a 
considerable part reaches the colon encountering bacterial communities which make use of 
them for their metabolic processes. Studies in germ-free (GF) and conventionalized mice 
have demonstrated that the gut microbiota not just affects the bioavailability of host’s 
amino acids but also alters the distribution of free amino acids in the GI tract (Macfarlane et 
al., 1988; Whitt and Demoss, 1975). After 28 days of lincosamides antibiotics exposure our 
metabolomics analysis revealed that several amino acids fluctuated after treatment. The 
plasma metabolic profiles showed that the amino acids glycine and tyrosine were present in 
lower concentrations compared to the controls while glutamate was found in higher 
concentrations. Conversely, in feces glycine, tyrosine, glutamate, taurine and tryptophan 
were significantly upregulated. On the one hand, lower levels in plasma accompanied by 
higher levels in feces suggest that these amino acids accumulated in the intestine and, with 
the exception of glutamate, were not absorbed into the system. Glycine, more likely as a 
consequence of bacterial impairment, could not be further metabolized and therefore 
accumulated in the intestine as indicated by its elevated levels in feces. On the other hand, 
due to less bacterial polysaccharide degradation, energy metabolism in the rat could have 
switched to amino acid and lipid metabolism. This could explain a decrease of amino acids 
and lipids, and an increase of glutamate in plasma which is produced by transferring 
excessive ammonia to alpha-ketoglutarat. Furthermore, critical for the whole-body 
metabolism, a decrease in glycine levels was observed in plasma. Given the importance and 
the wide range of metabolic pathways, e.g. the glutamatergic system, in which glycine is 
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involved, a change in the concentration of this amino acid could have consequences for the 
host’s well-being (Lechner, 2006). Creatine and creatinine, indole-derivates and hippuric 
acid were already identified as key metabolites and described in detail in our previous 
studies (Behr et al., 2017) (Behr et al, submitted). 
 
Bile acids 
After lincosamides treatment, primary bile acids were highly altered in both male and 
female animals in plasm and feces. In both matrices the taurine conjugated bile acid, 
taurocholic acid, was highly upregulated. The glycine conjugated glycochenodeoxycholic 
acid was downregulated in both plasma and feces. Plasma levels of glycochenodeoxycholic 
acid were particularly low, reaching undetectable levels. Cholic acid, however, presented an 
opposite pattern: it was upregulated in feces and downregulated in plasma. Similar 
perturbations of the bile acid pool after antibiotic treatment were already reported in 
different studies and associated with Clostridium difficile colonization (Cepa et al., 2018; 
Swann et al., 2011; Theriot et al., 2015). Increased levels of taurine conjugated bile acids 
and a decrease in glycine conjugated bile acids are generally observed as a consequence of 
gut microbiome impairments. In a metagenomic study it was shown that Firmicutes 
deconjugated both glycine and taurine bile acids, while Bacteroidetes were only capable of 
deconjugating taurine derivates (Jones et al., 2008). In rats, almost all the bile acids are 
conjugated with taurine rather than glycine, which implies that taurine conjugation 
dominates at physiological concentrations (Killenberg and Jordan, 1978). The community 
analysis after the administration of clindamycin and lincomycin revealed a depletion of 
Bacteroidetes and an increase of Firmicutes. This is consistent with the high levels of the 
conjugated taurocholic acid, due to the depletion of taurocholic acid-specific bile salt 
hydrolases (BSHs) exhibited by Bacteroidetes (Ridlon et al., 2006). The loss of 
Bacteroidetes-specific hydrolases that deconjugate taurocholic acid could account for the 
strikingly higher values of taurocholic acid observed in both plasma and feces. It is 
important to mention that taurocholic acid is transported actively from the intestine. Earlier 
studies have shown that taurocholic acid uptake is increased in the ileal epithelium of GF 
rats supporting the increased reabsorption which could be reflected in higher levels of this 
metabolite in plasma (Riottot and Sacquet, 1985). The increase of Firmicutes is in line with 
the decreased levels of glycochenodeoxycholic acid and the increased levels of glycine 
observed in feces. 
Cholic acid accumulated in the intestine and it can be hypothesized that it could not be 
further converted into secondary bile acids due to the loss of microorganisms with a 7α- 
dehydroxylation activity. Moreover, cholic acid is a hydrophobic bile acid which is not 
actively transported. Therefore, cholic acid is in general inefficiently absorbed by passive 
diffusion, and moreover could be excreted in higher amounts due to higher levels of fatty 
acids like the TAGs. The reabsorption via the enterohepatic pathway could be less efficient 
which could explain the lower levels of this metabolite observed in the plasma of 
lincosamides treated animals. 
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As already observed in our previous study, antibiotic treatment led to various significant 
alterations of lipids and fatty acids probably both due to the disruption of the bile acid 
metabolism and a decrease of microbial lipases or (Behr et al, submitted). Especially 
triacylglycerols (TAGs) were present at significantly higher levels in feces after the 
antibiotics administration. Another reason for these high levels in the intestine could be the 
TAG content in bacterial cells (Alvarez and Steinbüchel, 2003), which were destroyed by 
antibiotic treatment. In consequence these fatty acid triesters of glycerol could be released 
and could have led to an induction of bile acid production in the liver. 
The changes observed in the primary bile acids after lincosamides administration suggest 
that the gut microbiome has a strong influence on the bile acid metabolism. Since bile acids 
are reabsorbed from the intestine, an altered bile acid metabolism and the gut microbiota 
have the potential to influence the gut-liver axis, the immune system and other body 
systems. Altered bile acid metabolism has been associated with diseases beyond the 
gastrointestinal tract, such as the non-alcoholic fatty liver disease (NAFLD), drug-induced 
liver injury or cardiovascular dysfunction (Cepa et al., 2018; Fu et al., 2016; Khurana et al., 
2011). It is also conceivable that altered bile acid concentrations may affect the absorption 
of xenobiotics, with particular importance for pharmaceutical products. In the present 
study, the levels of secondary bile acids were not assessed. The measurement of these 
metabolites could be essential for achieving a comprehensive understanding of the interplay 
between bile acids and the gut microbiome.  
 
 
CONCLUSION 
In this study, specific plasma patterns for the lincosamides effects on the gut microbiome 
were established, potentially microbiome-derived or -associated metabolites in both plasma 
and feces could be identified and a profound impact of lincosamides on the bacterial 
communities was demonstrated. The diversity of the community was drastically narrowed 
down, and major shifts were observed in bacterial phyla. For example, Firmicutes 
represented greater than 80% of the total diversity in antibiotic-treated animals compared to 
around 40% in control animals. The vehicle CMC showed negligible effects on both the 
metabolome and microbial communities. Most changes could be observed in metabolites 
belonging to the class of bile acids, complex lipids, fatty acids and related metabolites, as 
well as amino acids and related metabolites. The principal component analysis showed a 
clear treatment-related effect on the feces metabolome, and most of the altered metabolites 
were increased. Taken together, it is demonstrated that the gut microbiota influences the 
host metabolic phenotype by producing or modifying some metabolites that can be taken up 
into the system and consequently be detected in plasma. The creation of metabolic patterns 
associated to different types of microbiome disruption represents the first step towards 
assessing the toxicological profiles of compounds or biologicals regarding the gut microbial 
communities. 
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ABSTRACT 
The bile acid-liver-gut microbiota axis plays an important role in the host’s health. The gut 
microbiota has an impact on the bile acid pool, but also the bile acids themselves can 
influence the gut microbiota composition. In this study, six antibiotics from five different 
classes (i.e. lincosamides, glycopeptides, macrolides, fluoroquinolones, aminoglycosides) 
were used to modulate microbial communities of Wistar rats to elucidate changes in the bile 
acid metabolism and to identify key metabolites in the bile acid pool related to gut 
microbial changes. 20 primary and secondary bile acids were analyzed in plasma and feces 
of control and treated animals. Antibiotics treatment induced significant changes in primary 
and secondary bile acids in both matrices. Taurine-conjugated primary bile acids 
significantly increased in plasma and feces. Contrary, cholic acid and most of the analyzed 
secondary bile acids significantly decreased in plasma, and cholic acid accumulated in the 
feces after treatment with all antibiotics but roxithromycin. Despite the different activity 
spectra of the antibiotics applied against gut microbes, the overall effect on the bile acid 
pool tended to be similar in both matrices except for streptomycin. These results show that 
changes in the gut microbial community affect the bile acid pool in plasma and feces and 
that changes in the bile acid profile can be indicative of alterations of the gut microbiome. 
Due to the important role of bile acids for the host, changes in the bile acid pool can have 
severe consequences for the host. 
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Key words: metabolomics; gut microbiome; bile acid profiling; repeated dose oral toxicity 
study; antibiotics; microbiome-related metabolites 
 
ABBREVIATIONS  
BSH  bile salt hydrolase 
GC  gas chromatography 
GF  germ-free  
HCA  hierarchical clustering analysis 
IBD  inflammatory bowel disease 
IBS  irritable bowel syndrome 
LC  liquid chromatography 
MS  mass spectrometry 
OECD  Organisation for Economic Co-operation and Development 
PCA  principal component analysis 
SBS  short bowel syndrome 
SPE  solid phase extraction 
 
 
INTRODUCTION 
The gut microbiome has a strong influence on mammalian blood metabolites, especially on 
components of the bile (Long et al., 2017). Bile acids, which are the major functional 
components of the bile, are important signaling molecules and distinctive representors of 
the tight interplay between microbes and the host. Via complex molecular mechanisms they 
can influence the gut-liver axis, the immune system and other systems of the body. It is also 
conceivable that altered bile acid concentrations may affect the absorption of other 
metabolites or xenobiotics which ultimately may lead to altered plasma concentrations. 
Primary bile acids are synthesized in the liver from cholesterol and are conjugated with 
either taurine or glycine (such as chenodeoxycholate (CDCA), tauro- and 
glycochenodeoxycholate (TCDCA, GCDCA), cholate (CA), tauro- and glycocholate (TCA, 
GCA), α- and β-muricholate and its taurine conjugate (α-, β-MCA and -TMCA)), thereby 
gaining their amphiphilic character, before they are secreted into the bile and finally into 
the small intestine to emulsify lipids into micelles and assist in nutrient absorption. Lipids 
are emulsified by bile salts for the optimal hydrolysis activity of endogenous or microbial 
lipases, e.g converting triacylglycerols to monoacyl- and diacylglycerols, fatty acids and 
glycerol. The majority of bile acids is actively reabsorbed in the ileum. A minor amount 
escapes reabsorption, reaches the colon and is partly excreted. When reaching the intestine, 
primary bile acids are further metabolized by unique microbial enzymes to unconjugated, 
secondary and tertiary bile acids (such as deoxycholate (DCA), tauro- and 
glycodeoxycholate (GDCA, TDCA), ω-muricholate (ω-MCA), hyodeoxycholate (HDCA), 
ursodeoxycholate (UDCA), tauro- and glycoursodeoxycholic acid (TUDCA, GUDCA), 
lithocholate (LCA), tauro- and glycolithocholic aicd (TLCA, GLCA)). The microorganisms 
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possess enzymes to modify these bile acids, for example bile salt hydrolase (BSH) that 
cleaves the peptide linkage between the amino acid and the primary bile acid. Furthermore, 
some microbes, mainly anaerobes, possess a 7α-dehydroxylation activity to convert primary 
bile acids into secondary bile acids (Ridlon et al., 2006). The bile acids can enter the 
enterohepatic circulation via active or passive transport, are recycled and re-conjugated in 
the liver, and then re-secreted into the bile and the intestine (see Figure 1).  
 
 
Although bile acids have a 
key role in lipid digestion and 
absorption, they are also 
recognized as important 
signaling molecules serving 
as ligands for numerous 
nuclear receptors, e.g. the 
farnesoid X receptor (FXR), 
the trans-membrane-bound G-
protein-coupled receptor 
(TGR5), the vitamin D 
receptor (VDR) and pregnane 
X receptor (PXR) 
(Makishima et al., 2002; 
Maruyama et al., 2002; Xie et 
al., 2001). Through binding to 
these receptors, bile acids can 
regulate genes involved in 
lipid and glucose metabolism, 
and energy homeostasis 
(Hylemon et al., 2009). 
Figure 1 Scheme of primary, secondary and tertiary bile acids that were 
measured in rat feces and plasma in this study. Primary bile acids are 
produced in the liver and conjugated with taurine or glycine, then 
excreted into the intestine and modified by microbes. The major part is 
actively reabsorbed in the intestine and the remaining bile acids are 
passively reabsorbed, entering the enterohepatic pathway.  
 
Regarding the mechanisms of bile acids binding to cytoplasmic and nuclear receptors they 
have been proposed to act in a way similar to that of hormones (Vítek and Haluzík, 2016). 
Perturbations of the bile acid pool are associated to several gastrointestinal diseases such as 
Clostridium difficile infection, irritable bowel syndrome (IBS), inflammatory bowel 
diseases (IBD), short bowel syndrome (SBS) and even colorectal cancer (Dior et al., 2016; 
Duboc et al., 2013; Pereira-Fantini et al., 2016; Theriot et al., 2015; Zou et al., 2017). 
Furthermore, via the enterohepatic circulation, an altered bile acid metabolism has an effect 
on the gut-liver axis and other body systems, and has been associated with several diseases 
beyond the gastrointestinal tract such as non-alcoholic fatty liver disease (NAFLD), drug-
induced liver injury (DILI), or cardiovascular dysfunction (Khurana et al., 2011; Mouzaki 
et al., 2016; Slopianka et al., 2017). 
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In a previous study, we performed metabolite profiling in plasma and feces of rats after 
lincosamides treatment in order to establish specific metabolite patterns in the 
MetaMap®Tox database and to identify key metabolites indicating gut microbial changes 
(Behr et al., 2018). The results showed that after treatment, primary bile acids were highly 
altered in both male and female animals in plasma and feces. However, the levels of other 
primary bile acids and secondary bile acids, which are known to be produced exclusively 
by the microbes in the gut, were not assessed. Therefore, in this study the aim was to 
further elucidate changes in the bile acid metabolism and to identify key metabolites related 
to gut microbial changes. Primary and secondary bile acids in plasma and feces of rats were 
analyzed after treatment with different classes of antibiotics. The evaluation of changes in 
the plasma and feces bile acid pool could help to gain a more comprehensive understanding 
of how microbial changes may influence the bile acid metabolism which, regarding the 
important role of these signaling molecules, can have far reaching consequences for the 
host. 
 
 
MATERIAL AND METHODS 
Three independent studies were performed according to the Organisation for Economic Co-
operation and Development (OECD) 407 protocol. Animal handling, treatment, and clinical 
examinations have been described earlier (Kamp et al., 2012; Strauss et al., 2012; van 
Ravenzwaay et al., 2012, 2010, 2007). 
 
Ethics statement 
The studies were approved by the BASF Animal Welfare Body, with the permission of the 
local authority, the Landesuntersuchungsamt Rheinland-Pfalz (approval number 23 177-
07/G 13-3-016). The study was performed in an AAALAC-approved (Association for 
Assessment and Accreditation of Laboratory Animal Care International) laboratory in 
accordance with the German Animal Welfare Act and the effective European Council 
Directive.  
 
Animals and maintenance conditions 
Briefly, male and female Wistar rats (CrI:WI(Han)) were supplied by Charles River, 
Germany, and were 70 ±1 days old at the beginning of the studies. The animals (5 rats per 
sex and cage in one group) were maintained in an air-conditioned room at a temperature of 
20 to 24°C, a relative humidity of 30 to 70%, and a 12 hour light / 12 hour dark cycle. 
Ground Kliba mouse/rat maintenance diet “GLP” was supplied by Provimi Kliba SA, 
Kaiseraugst, Switzerland. Diet and drinking water were available ad libitum (except 16 - 20 
hours before sampling) and regularly assayed for chemical contaminants and the presence 
of microorganisms. 
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Treatment of animals with compounds 
The antibiotics were administered daily by gavage using an appropriate vehicle to each 
treatment group consisting of five rats per group and sex, and metabolite and bile acid 
changes were compared with a dietary control group (10 rats per sex) (see Table 1). Dose 
levels of the antibiotics were selected in such a way that the dose would induce a clear 
effect on the targeted microbiome population, without causing systemic toxicity (Gray et 
al., 1972, 1971, 1966, 1964; Ho et al., 2015; Villa et al., 1988; von Keutz and Schlüter, 
1999; World Health Organization, 1997). To examine that the effect of the vehicle 
carboxymethylcellulose (CMC), which was used for the administration of some of the 
administered antibiotics with limited water solubility, does not interfere with metabolite 
changes in the plasma patterns arisen from antibiotic treatment, 10 animals per sex received 
10 ml/kg bw/d drinking water containing 0.5% CMC. The standard procedure for the 
evaluation of test substance-related effects in the MetaMap®Tox database is the 
comparison of the resulting values of the treatment groups against the baseline values of a 
diet control. This procedure has been used since 2004 resulting in a very extensive database 
of control values for the metabolites evaluated. As described in van Ravenzwaay et al. (van 
Ravenzwaay et al., 2016), this allows to determine not only the statistical significance of 
regulated metabolites, but also the assessment if a particular metabolite value has ever been 
observed in control animals – providing a historical range of what is normal. The 
substances were each administered in three separate and consecutive studies (study 1: 
vancomycin, streptomycin, roxithromycin, 0.5% CMC; study 2: sparfloxacin, lincomycin; 
study 3: clindamycin), each with a diet control group of 10 animals per sex, to allow for 
such comparisons. Dose-levels, routes of administration and form of preparation of the 
antibiotics are summarized in Table 1.  
 
Table 1 Compounds used, dose levels, form of preparation, and class of antibiotics. All compounds were 
administered orally by gavage. 
Treatment Dose/day Form of preparation Class of antibiotics
Clindamycin 200 mg/kg body weight in ultra-pure water Lincosamides
Lincomycin 300 mg/kg body weight in water containing 
0.5% CMCa 
Lincosamides
Roxithromycin 200 mg/kg body weight in water containing 
0.5% CMCa 
Macrolides
Sparfloxacin 200 mg/kg body weight in water containing 
0.5% CMCa 
Fluoroquinolones
Streptomycin 100 mg/kg body weight in water containing 
0.5% CMCa 
Aminoglycosides
Vancomycin 50 mg/kg body weight in ultra-pure water Glycopeptides
a carboxymethyl cellulose: Tylose CB30000    
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Sampling of blood and feces for bile acid profiling 
Between 7:30 and 10:30 h, on study days 7, 14 and 28 blood samples were taken from the 
retro-orbital sinus in all rats under isoflurane anesthesia (1.0 ml K-EDTA blood). The blood 
samples were centrifuged (10 °C, 20,000 x g, 2 min) and the EDTA plasma was separated. 
The EDTA plasma samples were covered with nitrogen and frozen at -80 °C until bile acid 
profiling was performed.  
Feces samples were carefully removed during necropsy on day 28 from the rectum after a 
fasting period of 16 – 20 hours and one day after the last administration of the test 
substances. The samples were collected in pre-cooled (dry-ice) vials, immediately snap-
frozen in liquid nitrogen and stored at -80 °C until bile acid profiling was performed.  
 
Clinical examinations 
All animals were checked daily for any clinically abnormal signs and mortalities. Food 
consumption was determined on study days 6, 13 and 27. Body weight was determined 
before the start of the administration period in order to randomize the animals and on study 
days 6, 13 and 27. At the end of the treatment period, the animals were sacrificed by 
decapitation under isoflurane anesthesia. Bile acid profiling of plasma and feces samples 
were performed for all control and treated animals.  
 
Bile acid profiling in plasma and feces  
Bile acid analysis was performed with a UHPLC–ESI-MS/MS consisting of a Waters 
Acquity UHPLC system coupled with an SCIEX 5500 Triple Quad™ LC-MS/MS system 
equipped with an ESI ion source which enabled the measurement of a total number of 20 
bile acids. To ensure accuracy and precision, the method provides seven calibration 
standards, a mixture of 3 isotope-labeled internal standards, and a quality control sample. 
Prior to analysis 5 mg of dried feces were extracted with 1 mL extraction solvent (ethanol 
[95%]/NaOH [0.1 N]) in an ultrasonic bath for 30 minutes following a 10 minute 
centrifugation (14,000 rpm, 4°C). The supernatant was removed and used for analysis. 10 
µl of plasma or extracted feces was added together with 10 μL of internal standards mixture 
onto filter spots suspended in the wells of a 96-well filter plate (PALL AcroPrep, PTFE 0.2 
µm) fixed on top of a deep-well plate and extracted with 100 μL methanol by shaking at 
600 rpm for 20 min on an Eppendorf ThermoMixer C (Eppendorf AG, Hamburg). Elution 
of the methanol extracts was performed by centrifugation (5,700 rpm, 5 min) into the lower 
receiving deep-well plate, which was then detached from the upper filter plate. After adding 
60 μL Milli-Q® water to the extracts and shaking briefly (600 rpm, 5 min), the sample plate 
was analyzed by LC-MS/MS. All target isobaric bile acids were baseline separated under 
ultrahigh pressure liquid chromatography (UPLC) conditions as described previously 
(Slopianka et al., 2017). Briefly, UPLC systems were used at a flow rate of 0.5 - 1 mL/min. 
Mobile phase A was water with 0.01% formic acid and 10mM ammonium acetate and 
mobile phase B was 30% (v/v) acetonitrile / methanol with 0.01% formic acid and 10mM 
ammonium acetate. The gradient program initially started at 35% B, increased to 100% B 
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in 3.5 min held at 100% B for 0.5 min, decreased to 35% B in 0.1 min, and then held at 
35% B for 0.9 min, enabling a short runtime of 5 min. Chromatographic separation was 
performed with a proprietary reversed- phased UHPLC analytical column (Biocrates Life 
Sciences AG, Innsbruck) kept at 50 °C. Chromatographic performance was enhanced with 
a SecurityGuard ULTRA Cartridge C28/ XB-C18 for 2.1 mm ID precolumn (Phenomenex 
Cat. No. AJ0- 8782). An injection volume of 5 μL was used. Mass spectrometric detection 
was accomplished with electrospray ionization in negative ion mode. Two MRM transitions 
are used for each target bile acid for semi-quantitative evaluation. 
 
Statistics 
The data were analyzed by univariate and multivariate statistical methods. The sex- and 
day-stratified heteroscedastic t-test ("Welch test") was applied to compare metabolite levels 
of dose groups with respective controls. For all metabolites, changes were calculated as the 
ratio of the median of metabolite levels in individual rats in a treatment group relative to 
median of metabolite levels in rats in a matched control group (time point and sex). 
Hereafter, these ratios are referred to as ‘relative abundance’ in plasma or feces. 
Principal Component Analysis (PCA) was done in SIMCA (Sartorius Stedim Biotech, 
Umetrics® Suite of Data Analytics Solutions, version 15) using the default software settings 
(UV-scaling, centering, removal of samples and metabolites with more than 50% missing 
values). For the PCA, log10-transformed, sex- and day-stratified data normalized to the 
median of the corresponding control were used as input. 
Hierarchical clustering analysis (HCA) was performed in TIBCO® Spotfire® (TIBCO 
Spotfire Inc., version 6.0) using t-values from the Welch test (see above for details) as 
input. Row (samples) and column (metabolites) clustering was done using Ward’s method 
for clustering with half square Euclidean distance measure based on Z-score normalized 
data where missing values were imputed as row average. Ratios are shown log10-
transformed. 
The term “significantly” is used to denote "statistically significantly” at the displayed p 
level. 
 
Figures 
Figure 1 showing the enterohepatic circulation in rats was created using Adobe Illustrator 
CS5. 
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RESULTS 
Clinical signs 
There were no mortalities in any of the treatment groups, except for one animal at the 
beginning of the study in the female group of streptomycin (not treatment-related). Animals 
treated with roxithromycin showed slight salivation immediately after administration. The 
group of female animals treated with clindamycin showed temporary clinical signs as 
indicated by salivation and semi closed eyelid (4 animals), and fur piloerection (1 animal). 
Similarly, males treated with clindamycin showed slight salivation (all animals), semi 
closed eyelid (3 animals), and two of them were in a general poor condition. Except for 
salivation, these findings were only observed in the individual animals for 1-3 days of the 
administration period of 28 days. In absence of changes in food consumption and body 
weight development, these clinical signs were assessed as borderline effects and not 
indicative of systemic organ toxicity. Relative changes in body weight and food 
consumption noted upon administration of the test compounds are shown in Table 2. 
Treated animals did not present any significant changes with respect to body weight when 
compared to the controls. 
 
Table 2 Relative changes in body weight and food consumption of male and female Crl:Wi(Han) rats (N = 5 per 
group) dosed for 28 days compared to the diet controls. Data were collected on study days 6, 13 and 27. Treated 
animals did not present any significant changes (p < 0.05) in body weight compared to the control groups (N = 10 
per group). 
m f m f
Clindamycin 6 0.97 0.99 1.30 0.80
13 0.95 0.98 1.12 1.19
27 0.94 1.00 0.99 1.16
Lincomycin 6 1.00 0.99 1.00 0.99
13 0.98 1.00 1.03 0.92
27 0.96 1.05 1.18 0.97
Roxithromycin 6 0.98 0.99 0.85 0.80
13 0.96 1.00 0.86 0.97
27 0.96 1.01 1.04 1.03
Sparfloxacin 6 0.96 0.98 0.94 0.77
13 0.94 0.99 0.97 1.01
27 0.94 0.99 1.01 0.99
Streptomycin 6 0.97 0.98 0.92 0.91
13 0.96 0.99 0.92 0.99
27 0.95 0.97 0.97 0.93
Vancomycin 6 0.99 0.98 0.88 0.85
13 0.97 1.00 0.93 0.92
27 0.95 1.00 0.93 0.95
Body weight Food consumption
Antibiotic Day
 
 
Bile acid profiling 
The bile acid profiling of feces and plasma samples showed significant changes of primary 
and secondary, conjugated and unconjugated bile acids in male and female animals (see 
Table 3). First, a principle component analysis (PCA) was conducted to visualize treatment-
related effects on the bile acid pool in feces and plasma of male and female animals (see 
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Figure 2). For both sexes, the PCA demonstrated that CMC treatment clusters with the 
control animals in plasma as well as in feces. Roxithromycin and streptomycin were the 
closest treatment groups to the controls in both matrices showing slight variability 
compared to the control. Clindamycin and lincomycin, both from the class of lincosamides, 
with a slight separation between each other but still clustering together, showed the most 
profound effects on the bile acid pool. In plasma, the main separation was driven by the 
treatment-related effect of lincomycin. Also, vancomycin and sparfloxacin showed a 
treatment-related effect and a separation from other classes of antibiotics. Separation in 
feces was more pronounced than in plasma, indicating a more profound effect of the 
antibiotics on fecal metabolite composition. 
 
 
 
Figure 2 Principal component analysis (PCA) of fecal and plasma metabolic profiles of control and treated female 
(f) and male (m) animals showing the trellis of results. Animals were dosed daily with antibiotics (clindamycin, 
lincomycin, vancomycin, streptomycin, roxithromycin, sparfloxacin) and 0.5% CMC for 28 days. Data shown by 
the plasma samples contain the metabolite profiles of all three sampling time points (day 7, 14 and 28). Feces were 
sampled at the end of the study. 
 
The PCA of each day of plasma sampling (day 7, 14 and 28) showed a decrease of 
variability in PC1 for lincomycin compared to control from day 7 to 28 of lincomycin in 
males and females (see Supplementary Materials S1 and S2). Further, the bile acid pool in 
both matrices did not show obvious differences between males and females (see 
Supplementary Materials S3 and S4). However, the separation of roxithromycin and 
streptomycin from the control was clearer in male animals, i.e. the treatment-related effect 
was stronger here.  
The hierarchical clustering analysis (HCA) of the bile acid pool in the feces showed a 
similar pattern as the PCA for male and female animals with a clustering of lincosamides 
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(clindamycin and lincomycin) having the most profound effect on the bile acid pool, 
followed by vancomycin and sparfloxacin, mild effects of streptomycin and roxithromycin, 
and no effect of CMC (see Figure 3). In plasma samples, the HCA showed in both sexes no 
or mild effects of the vehicle controls and streptomycin and the most profound effect of the 
lincosamides antibiotics. In the female animals, roxithromycin clusters with the vehicle 
control and streptomycin and, as seen in the feces samples, sparfloxacin with vancomycin, 
whereas roxithromycin showed clusters with the lincosamides antibiotics in the male 
animals. 
 
Table 3 shows changes in metabolite concentrations relative to the diet controls of primary 
and secondary bile acids on day 28 in feces and on day 7, 14 and 28 in plasma of antibiotic-
treated female and male rats. Taurine conjugated primary bile acids, i.e. TCDCA, TCA, α- 
and β-TMCA, were significantly increased in plasma and feces of antibiotic-treated rats 
except TCA in the streptomycin group. In contrast, many of the unconjugated and glycine 
conjugated bile acids, i.e. CDCA, GCDCA, GCA, α- and β- MCA, were significantly 
decreased. 
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c) 
 
d) 
Figure 3 Hierarchical clustering analysis (HCA) of fecal (a and b) and plasma (c and d) metabolic profiles of treated female (a and c) and male (b and d) animals compared to 
the control animals. The relative abundance (ratio) of bile acids in plasma or feces are log10-transformed. Animals were dosed daily with antibiotics (clindamycin, lincomycin, 
vancomycin, streptomycin, roxithromycin, sparfloxacin) and 0.5% CMC for 28 days. Data shown by the plasma samples contain the metabolite profiles of all three sampling 
time points (day 7, 14 and 28). Feces were sampled at the end of the study. 
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The effect appeared to be more pronounced in male animals. Also, the male group treated 
with 0.5% CMC showed a significant decrease in plasma levels on day 14 and 28 of 
CDCA, CA, α- and β- MCA, DCA, MCA and UDCA. However, no significant changes of 
these bile acids were observed in the feces.  
Primary bile acid cholic acid, CA, was highly upregulated in the feces upon antibiotic 
treatment, with the exception of animals treated with the macrolide antibiotic 
roxithromycin. Contrarily, plasma levels were significantly downregulated in female 
animals after lincosamides and roxithromycin treatment. In the other groups, the levels of 
CA were decreased, however, not significantly. Male animals showed significantly 
decreased plasma levels of CA in all treatment groups on at least one time point.  
With few exceptions, the secondary bile acids DCA, GDCA, TDCA, ω-MCA, HDCA, 
UDCA, LCA, GLCA and TLCA, were significantly downregulated in plasma and feces of 
male and female animals. The taurine conjugate TUDCA was significantly upregulated in 
feces of female and male animals treated with lincosamides and roxithromycin, and in 
males treated with sparfloxacin. Plasma and feces levels of streptomycin- and 
roxithromycin-treated animals showed an increase of TDCA, however, not always 
significantly upregulated. Further, contrary to the other treatments, TLCA was significantly 
upregulated in feces after roxithromycin treatment.  
Solely streptomycin showed an increase, which was significant in the female group, of ω-
MCA in feces and plasma. Compared to the other antibiotics treatments, upon streptomycin 
treatment the secondary bile acids were less affected, except for HDCA. 
Vancomycin treatment had a profound effect on the secondary bile acids in samples of 
males and females; the unconjugated and glycine conjugated primary bile acids were 
decreased compared to the diet control in male but not in female animals. 
The highest values of significant upregulation of the bile acids in both matrices, especially 
the taurine conjugates, were observed after lincosamide treatment. Here, primary bile acid 
TMCA in feces was up to 155-fold increased in females and up to 230-fold in males. 
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Table 3 Metabolite concentration changes relative to the diet controls of primary and secondary bile acids on day 
28 in feces (F28) and on day 7, 14 and 28 (P7, P14, P28) in plasma of antibiotic-treated female and male 
Crl/Wi(Han) rats (N = 5 per group). Figures in red boxes are significantly increased and those in blue boxes 
significantly decreased metabolite value changes (Welch t test). The intensity of the color corresponds to the 
magnitude of the fold change and p-value, bold numbers have a ratio <0.5 or >2. "NA" indicates that for this 
analyte, treatment and/or analysis groups there are no contrasts available. Abbreviations: CDCA 
chenodeoxycholate, GCDCA glycochenodeoxycholate, TCDCA taurochenodeoxycholate, CA cholate, GCA 
glycocholate, TCA taurocholate, aMCA muricholate (alpha), bMCA muricholate, TMCA(a+b) tauromuricholate 
acid (a+b), DCA deoxycholate, GDCA glycodeoxycholate, TDCA taurodeoxycholate, wMCA muricholate, 
HDCA hyodeoxycholate, UDCA ursodeoxycholate, TUDCA tauroursodeoxycholate, GUDCA 
glycoursodeoxycholic acid, LCA lithocholate, GLCA glycolithocholic aicd, TLCA taurolithocholic aicd. 
ratio < 1 and p-value < 0.01ratio > 1 and p-value < 0.01
ratio > 1 and 0.01 ≤ p-value < 0.05
ratio > 1 and 0.05 ≤ p-value < 0.10 ratio < 1 and 0.05 ≤ p-value < 0.10
ratio < 1 and  0.01 ≤ p-value < 0.05
 
FEMALES
Bile acids F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28
CDCA 0.3 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.9 0.0 0.1 0.1 0.5 0.3 0.2 0.4 17.6 0.4 1.7 0.2 4.3 0.2 0.4 0.0 NA 0.5 2.0 0.1
GCDCA 2.7 0.6 0.4 0.8 0.5 0.7 0.1 0.7 0.4 0.4 0.4 0.2 1.3 0.5 0.3 1.6 0.6 1.3 0.9 1.0 1.0 0.4 0.9 0.6 0.7 0.4 1.2 0.7
TCDCA 35.0 1.4 1.0 1.5 4.5 2.3 1.1 1.0 1.4 1.7 1.5 1.8 2.3 1.2 1.4 1.8 1.2 1.2 1.3 2.6 1.0 1.9 2.4 2.6 0.6 0.9 1.1 1.2
CA 18.6 0.0 0.0 0.0 25.0 0.0 0.0 0.1 0.5 0.0 0.0 0.1 27.4 1.1 0.5 0.3 8.3 0.5 1.0 0.1 19.5 0.2 0.6 0.1 0.7 0.5 2.3 0.1
GCA 1.7 0.4 0.3 0.2 1.2 0.6 0.1 0.3 0.2 0.4 0.3 0.1 1.9 1.0 0.5 2.0 1.1 3.6 0.7 0.6 2.7 0.5 1.5 0.7 1.0 0.8 1.5 0.7
TCA 47.4 1.3 1.0 1.6 28.0 4.1 3.7 1.5 2.4 2.6 5.5 3.1 5.0 2.6 3.2 1.7 2.1 1.7 3.0 2.1 4.2 2.0 7.0 3.8 1.0 1.1 2.3 1.6
α-MCA 0.6 0.0 0.1 0.1 0.2 0.0 0.1 0.7 0.2 0.2 0.1 0.6 0.7 0.2 0.6 3.0 0.4 1.0 0.4 0.4 0.2 0.4 0.1 0.3 0.5 1.7 0.1
β-MCA 2.4 0.1 0.3 0.4 0.9 0.0 0.1 0.7 1.3 0.7 1.3 2.3 0.3 1.5 1.2 0.3 1.1 1.9 1.8 0.8 0.5 0.5 1.0 1.4 0.3 1.2 2.3 0.7
(α+β)-TMCA 155.8 2.0 1.4 2.4 90.8 3.8 3.2 2.9 10.1 1.9 2.9 2.4 7.1 1.7 1.7 1.9 1.9 1.6 2.4 2.6 2.9 3.1 4.0 3.6 0.8 1.0 1.4 1.6
DCA 0.0 0.4 0.0 0.0 0.0 0.3 0.0 0.1 0.5 0.8 0.6 0.9 0.0 0.1 0.0 0.1 1.1 0.7 0.7 1.2 0.0 0.0 0.4 0.0 0.9 0.9 1.4 1.1
GDCA 0.6 0.0 NA 0.1 1.5 0.1 0.0 NA NA 0.5 0.4 0.1 NA 0.1 0.3 0.5 0.4 1.5 1.0 0.5 0.3 0.0 0.1 0.0 1.8 0.7 1.9 0.3
TDCA 0.2 0.0 0.0 0.0 0.5 0.0 NA 0.1 9.4 2.3 3.1 1.9 0.3 0.1 0.2 0.0 2.3 1.7 1.6 2.1 0.2 0.0 0.0 0.0 1.2 1.3 2.2 1.5
ω-MCA 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.8 1.2 0.6 1.5 0.0 0.2 0.0 0.0 2.1 2.2 1.5 2.5 0.0 0.0 0.0 0.1 0.5 1.1 1.3 1.0
HDCA 0.0 0.0 0.0 NA 0.0 0.0 NA NA 0.1 0.1 0.0 0.1 0.0 0.1 0.0 NA 0.2 0.2 0.3 0.3 0.0 0.0 0.0 0.0 2.2 0.5 1.8 0.9
UDCA 0.0 0.1 0.3 0.0 0.1 NA 0.0 0.1 NA 0.1 0.1 0.5 0.3 0.4 0.6 0.2 NA 1.7 0.2 0.2 NA 0.2 0.1 0.3 NA 0.4 2.3 0.3
TUDCA 22.6 6.9 NA NA 5.4 NA 2.9 NA 3.4 9.0 1.2 NA 2.1 NA 10.3 NA 1.8 2.8 NA NA 0.5 3.6 1.8 NA 0.3 7.8 1.8 NA
GUDCA 2.8 0.1 1.0 NA 2.4 NA NA NA 1.4 1.8 0.6 1.1 1.0 NA NA NA 0.9 1.6 0.6 1.0 1.4 1.7 1.2 3.3 2.3 1.1 1.1 1.3
LCA 0.0 1.0 NA NA 0.0 9.5 NA 0.2 0.2 0.7 0.5 0.7 0.2 0.1 0.0 13.1 0.4 0.7 0.4 0.7 0.0 0.1 10.7 0.1 0.7 0.8 0.8 0.8
GLCA 0.5 0.5 0.3 0.7 2.7 7.5 NA NA 0.4 0.3 0.3 0.5 8.2 NA 0.9 0.7 0.4 0.5 0.3 0.2 0.2 0.6 0.2 0.2 0.5 0.6 0.6 0.5
TLCA 0.1 0.0 NA 0.0 0.3 NA 0.0 0.2 3.3 0.7 0.8 1.4 0.3 NA 1.1 0.1 0.6 1.1 0.8 1.0 0.4 0.0 0.0 0.0 0.4 0.8 1.1 1.0
MALES
Bile acids F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28 F28 P7 P14 P28
CDCA 0.1 0.0 0.1 0.0 NA 0.0 NA 0.0 NA 0.0 0.0 0.1 NA 0.0 0.3 0.9 0.6 0.6 0.0 0.4 1.0 0.1 0.2 0.2 NA 0.7 0.5 0.4
GCDCA 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.7 0.4 0.1 0.1 2.9 0.1 0.1 0.4 0.7 0.4 0.1 0.3 1.5 0.3 0.3 0.4 1.0 1.8 0.7 0.5
TCDCA 13.6 2.5 1.5 1.2 13.4 5.0 2.6 1.7 1.5 2.1 2.0 2.3 5.0 3.9 3.6 2.1 1.2 2.5 2.3 2.7 3.0 2.7 3.2 3.0 1.1 1.3 1.2 0.9
CA 19.9 0.0 0.0 0.0 48.3 0.0 0.0 0.0 0.6 0.0 0.0 0.0 22.7 0.1 0.9 0.9 3.7 0.7 0.0 0.2 38.7 0.1 0.1 0.1 1.1 0.4 0.4 0.2
GCA 0.5 0.2 0.3 0.2 3.2 0.3 0.2 0.2 0.2 0.2 0.1 0.1 1.6 0.4 0.6 0.7 0.3 1.5 0.3 0.3 1.4 0.4 0.4 0.2 1.0 1.7 0.8 0.3
TCA 90.8 4.7 2.9 4.6 62.0 7.8 6.8 4.7 1.6 3.4 2.2 3.8 8.3 8.0 5.3 3.1 1.1 4.5 3.3 2.7 7.4 2.5 2.7 2.6 0.7 1.0 1.0 0.7
α-MCA 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.1 0.0 0.1 0.2 0.0 0.4 0.7 2.4 1.1 0.0 0.3 0.7 0.1 0.1 0.2 1.1 0.9 0.3 0.5
β-MCA 0.9 0.1 0.3 0.4 1.0 0.1 0.1 0.3 0.8 0.2 0.0 0.2 0.4 0.3 1.9 1.1 2.8 1.9 0.5 0.9 0.5 0.2 0.2 0.4 1.0 0.9 0.5 0.4
(α+β)-TMCA 192.7 5.0 2.6 4.0 227.9 5.9 5.9 3.9 8.0 3.6 2.7 3.0 16.9 4.2 5.0 2.3 1.8 3.0 2.6 2.6 3.9 1.9 2.7 3.1 0.7 1.3 0.9 0.9
DCA 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.1 0.2 0.0 0.0 0.2 0.0 1.6 0.6 0.1 0.3 0.0 0.0 0.2 0.0 1.1 0.8 0.6 0.3
GDCA NA 0.0 0.0 0.0 0.6 0.0 NA 0.0 0.5 0.1 0.0 0.1 2.7 0.0 0.0 0.1 0.2 0.2 0.1 0.1 0.3 0.0 0.0 0.1 1.1 1.8 0.5 0.4
TDCA 0.1 0.0 0.0 0.0 NA 0.0 NA 0.0 4.6 2.5 1.2 2.1 0.2 0.1 0.0 0.0 0.6 1.7 1.4 1.5 0.1 0.0 0.0 0.0 1.0 1.2 1.1 0.6
ω-MCA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.4 0.4 0.0 0.0 0.0 NA 1.8 3.2 0.4 0.8 0.0 0.0 0.0 0.0 1.1 1.6 0.3 0.5
HDCA 0.0 0.0 0.0 0.0 0.0 0.0 NA NA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 NA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.2 0.6 0.2
UDCA 0.0 0.0 0.3 0.0 0.0 0.0 NA 0.0 NA 0.0 0.1 0.0 0.0 0.1 1.2 1.2 NA 1.6 0.2 0.4 NA 0.1 0.1 0.2 NA 0.8 0.4 0.6
TUDCA 28.3 0.2 0.6 0.7 29.0 NA 3.0 1.7 2.2 1.2 0.6 9.3 NA 7.8 1.8 1.0 2.0 NA 0.6 2.9 1.2 NA 0.8 0.4 0.9 NA 0.3
GUDCA 2.3 NA 1.0 0.3 0.8 NA 0.2 0.9 NA 0.5 1.4 0.6 1.6 NA 0.3 1.3 0.5 1.1 1.2 0.9 1.4 0.4 16.3 10.1 0.7 0.6 4.2 1.1
LCA 0.0 0.5 1.5 0.3 0.0 0.1 0.2 0.3 0.3 0.6 6.5 0.5 0.0 0.2 9.7 0.3 0.9 0.7 0.3 0.4 0.1 0.3 28.0 0.2 1.5 1.6 1.1 0.6
GLCA 0.4 0.1 0.8 0.4 1.3 0.1 NA NA 1.6 0.3 0.9 0.7 1.3 0.2 NA 1.9 1.4 0.4 0.2 0.8 0.9 0.5 1.6 4.4 1.2 0.8 1.2 0.4
TLCA 0.3 0.2 0.1 0.2 NA 0.2 NA 0.3 3.1 1.1 0.7 0.6 0.7 0.3 0.3 0.2 1.7 0.7 0.4 0.5 NA 0.1 0.2 1.6 2.5 1.1 1.1 0.6
Vancomycin 0.5% CMC 
Vancomycin 0.5% CMC 
Antibiotics Vehicle
Clindamycin Lincomycin Roxithromycin Sparfloxacin
Clindamycin Lincomycin Roxithromycin Sparfloxacin Streptomycin
Streptomycin
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DISCUSSION 
Upon treatment with antibiotics possessing different activity spectra and bioavailabilities, 
feces and plasma samples showed significant changes of primary and secondary, 
conjugated and unconjugated bile acids in male and female animals. Whereas lincosamides, 
roxithromycin and sparfloxacin are bioavailable, streptomycin is poorly and vancomycin 
non-bioavailable after oral administration (Arimori et al., 1998; Brown and Riviere, 1991; 
Derrick and Reilly, 1983; Geraci et al., 1956; Musther et al., 2014). 
The PCA and HCA show clear treatment-related effects with no effects of the vehicle CMC 
clustering with control animals, slight effects of streptomycin and roxithromycin, followed 
by clear effects of vancomycin and sparfloxacin and strongest effects of the lincosamides 
antibiotics. However, in the HCA plasma samples showed differences between genders in 
the clustering of antibiotics. In the female animals, roxithromycin showed a slight effect as 
observed in the feces samples, whereas it showed a similar pattern and clustering with the 
lincosamides antibiotics.  
As in our last study, we observed significant changes of the primary bile acids TCA and CA 
in both plasma and feces (Behr et al., 2018). In general, it was shown that in rat plasma the 
majority of conjugated bile acids are taurine derivates (García-Cañaveras et al., 2012). We 
hypothesized that the antibiotics-induced loss of microbes possessing specific bile salt 
hydrolases that deconjugate taurine conjugates could account for the strikingly higher 
values of taurocholic acid observed in both plasma and feces, with the exception of the 
streptomycin group. Bacteroidetes exhibit taurocholic acid-specific bile salt hydrolases 
(BSHs) (Ridlon et al., 2006) and the depletion of these microbes was consistent with the 
high levels of the conjugated taurocholic acid. Further, taurocholic acid is transported 
actively from the intestine and it was shown that taurocholic acid uptake is increased in the 
ileal epithelium of GF rats (Riottot and Sacquet, 1985). The antibiotic treatment could have 
led to an increased reabsorption and eventually in higher levels of this metabolite in plasma. 
Other taurine conjugated bile acids, TCDCA, and α- and β-TMCA, were significantly 
increased in plasma and feces of antibiotic-treated rats except for the streptomycin group, 
which will be discussed below. In a study with germ-free mice, cytochrome P450 
expression and activity associated with bile acid metabolism and drug detoxification 
mechanisms were analyzed in liver microsomes during a colonization process of these mice 
(Claus et al., 2011). The analysis revealed the involvement of gut microbiota in CYP8b1 
induction and the consecutive regulation of the TCA/TMCA ratio. Also, significant 
overexpression of nuclear receptors was observed at the end of the colonization process 
which implies that the gut microbiome plays an important role in the endogenous 
xenobiotic detoxification pathways. Primary bile acid CA was highly upregulated in the 
feces, with the exception of animals treated with the macrolide antibiotic roxithromycin. 
Cholic acid is not actively transported and inefficiently absorbed by passive diffusion and 
could have accumulated in the intestine due to the loss of microorganisms with a 7α-
dehydroxylation activity which would have transformed CA to DCA. Contrary to the feces, 
many treatments caused downregulated levels of CA in plasma, as well as many of the 
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unconjugated and glycine conjugated bile acids, i.e. CDCA, GCDCA, GCA, α- and β- 
MCA, were significantly decreased. There seemed to be slight sex differences since the 
effect was more pronounced in male animals. Firmicutes are able to deconjugate both 
taurine and glycine, which was in line with the decreased levels of glycochenodeoxycholic 
acid in feces, probably due to the lack of Firmicutes. Unconjugated bile acids have a central 
role in the metabolic homeostasis of the gastrointestinal tract and can activate nuclear 
receptors as FXR, PXR, CAR, VDR and TGR5 (Huttenhower et al., 2012; Hylemon et al., 
2009; Thomas et al., 2008). Furthermore, they are in general important for controlling the 
microbial population and the integrity of the intestinal barrier function (Jia et al., 2018; 
Vavassori et al., 2009). 
Secondary bile acids and their conjugates DCA, GDCA, TDCA, ω-MCA, HDCA, UDCA, 
LCA, GLCA and TLCA were significantly downregulated in plasma and feces of male and 
female animals due to the loss of intestinal bacteria which transform the primary into 
secondary bile acids by unique microbial enzymes. For example, the bile salt hydrolase 
(BSH) cleaves the peptide linkage between the amino acid and the primary bile acid. 
Furthermore, mainly anaerobic bacteria possess a 7α- dehydroxylation activity to convert 
primary into secondary bile acids (Ridlon et al., 2006). However, again the taurine 
conjugated bile acid TUDCA accumulated in feces of female and male animals treated with 
lincosamides and roxithromycin, and in males treated with sparfloxacin. In the female 
group, TUDCA was also upregulated, however, not significantly. Important to note here is 
that there are indications that UDCA and its conjugated derivates can be produced by the 
liver of mice and could therefore be considered primary bile acids (Selwyn et al., 2015).  
Regarding the overall alteration of the bile acid pool in plasma and feces, streptomycin and 
roxithromycin appeared to differ from the other treatments. Streptomycin, a poorly 
bioavailable aminoglycoside, has in contrast to the other antibiotics poor activity against 
obligate anaerobic and most gram-positive bacteria. However, the majority of the intestinal 
microbes belongs to the obligate anaerobes. Contrary to the other treatments, TLCA, in 
high levels considered as a promoter of colon cancer (Farhana et al., 2016), was 
significantly upregulated in feces after roxithromycin treatment. Similar results for 
macrolides compared to other classes of antibiotics were observed in a study with rats (Li et 
al., 2017). Interestingly, compared to other macrolide antibiotics, roxithromycin and its 
main metabolite were reported to exhibit a very poor affinity for rat liver cytochrome P-450 
even at high doses (i.e. 500 and 1,000 mg/kg p.o.) and a decreased ability to induce liver 
cytochrome P-450 PCNE, an isozyme implicated in drug associations involving some 
macrolide antibiotics (Delaforge et al., 1988). Therefore, it could be assumed that 
roxithromycin did not interfere with liver cytochromes and xenobiotic metabolisms and that 
consequently unique changes in the bile acid pool are due to changes of the gut 
microbiome.  
Vancomycin, which is used for the treatment of severe Clostridium difficile infections 
(CDI), showed a profound effect on the secondary bile acids. Vancomycin treatment is 
reported to deplete microbial members responsible for converting primary bile acids into 
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secondary bile acid which reduces the resistance to Clostridium difficile colonization 
(Theriot et al., 2015). It is a non-bioavailable antibiotic, i.e. changes in the bile acid pool 
were highly likely induced by changes of the gut microbial composition or the loss of bile 
acid-metabolizing microbes. 
In a recent study, the vehicle control 0.5% CMC showed no significant changes in the 
microbial community of the rat feces (Behr et al., 2018). Moreover, in this study, the bile 
acid profiling showed also no significant changes in the feces of both sexes and in plasma 
of females. However, the male group treated with CMC showed a slight but significant 
decrease in plasma on two-time points of CDCA, CA, α- and β- MCA, DCA, MCA and 
UDCA. In the literature, there are only few studies on CMC and its potential effect on the 
bile acid pool. Anderson et al. reported an increase of bile acids in the feces of human 
volunteers consuming 15 g CMC daily for 23 days but no changes in plasma biochemistry 
(Anderson et al., 1986). In another study broiler chickens fed CMC diet excreted more bile 
acids in the feces and the total aerobic and anaerobic microbial counts small intestine 
significantly increased (Smits et al., 1998). The authors hypothesized that CMC decreases 
apparent lipid digestibility by reducing the concentration of bile acids in the chyme which 
may further contribute to malabsorption of lipids. Since feces were shown to be a more 
sensitive matrix for bile acid changes caused by antibiotics than plasma, it could have been 
expected that such changes should have also shown up in the feces. Nevertheless, if CMC 
would have had an exclusive effect in the upper parts of the intestinal tract, then this may 
have been unnoticed in the present study. Further studies on the impact of CMC on the gut 
microbiome and bile acid alterations in the small intestine should be performed since no 
changes in the feces could be observed.  
Summarizing, this study shows that antibiotics have a profound impact on the bile acid 
metabolism via alterations of the intestinal microbiota - in particular shown by the poorly or 
non-bioavailable antibiotics streptomycin and vancomycin - and potential feedback 
mechanisms regarding the bile acid production in the liver. The impact of the antibiotic 
treatment was stronger in the feces indicating a clearer and more profound effect of the 
antibiotics on fecal metabolite composition. Although different classes of antibiotics with 
different activity spectra against gut microbes were applied, they induced an increase of 
taurine-conjugated primary bile acids in both plasma and feces. Contrary, cholic acid and 
most of the secondary bile acids were significantly downregulated in plasma whereas cholic 
acid accumulated in the feces. This accumulation was not seen for roxithromycin indicating 
a different mode of action for the macrolide antibiotic.  
Not only could changes in the gut microbiome lead to alterations of the bile acid pool (Jia et 
al., 2018) but also the bile acids themselves can influence the composition of the microbiota 
(Ridlon et al., 2014). Bile acids are essential to make compounds (natural and xenobiotic) 
more bioavailable, and hence increase absorption. An alteration of the bile acid pool, 
therefore, is highly likely to have an effect on bioavailability and absorption and this could 
potentially lead to altered plasma concentrations of both endogenous metabolites, the 
metabolome, as well as xenobiotics. Additionally, bile acids themselves interact with 
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nuclear receptors (Makishima et al., 2002; Maruyama et al., 2002; Xie et al., 2001). Here 
too, an alteration in the concentration of bile acids is expected to have an effect in terms of 
reduced or increased gene activation. This may impact the cytochrome P450 expression and 
could interfere with drug detoxification mechanisms, finally leading to either a 
detoxification or toxification of a compound of interest. Regarding the points mentioned 
above changes of the bile acid pool might have implications for affecting the gut-liver axis, 
the immune system and other systems of the body. 
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OVERVIEW OF THE RESULTS AND MAIN FINDINGS 
The gut microbiome plays an important role in health and disease of the host, and can be 
influenced by factors such as diet, the host condition, environmental chemical exposure and 
drugs [1–4]. In the last years, omics technologies as metagenomics, metaproteomics and 
metabolomics shown to be promising tools towards a mechanistic understanding of the gut 
microbiome, providing a holistic view of the host and its microbiome. Integrative 
approaches that not only asses the composition of the gut microbiome but also its 
functionality have been implemented to unravel the complex dynamics of host-microbiome 
interactions [5]. Compared with metagenomic approaches, which face the difficulty of high 
intra- and interspecies variabilities regarding the composition of the microbiome, a 
metabolome analysis offers the advantage to elucidate the functionality, in terms of gene 
activity and metabolic output of the microbes, with a lower variability [6–8]. In this 
mechanistically focused project, the aim was to elucidate interactions between gut microbes 
and the host by applying metabolomics and taxonomic profiling, thereby assessing 
functional microbial changes and the consequences for the host organism.  
Chapter 2 presented the first investigation of the mammalian-microbiome co-metabolism 
of endogenous metabolites by analyzing the plasma of antibiotic-treated Wistar rats. To 
identify plasma metabolites related to microbiome changes due to antibiotic treatment, 
broad-spectrum antibiotics belonging to the class of aminoglycosides (neomycin, 
gentamicin), fluoroquinolones (moxifloxacin, levofloxacin) and tetracyclines (doxycycline, 
tetracycline) were applied. These were administered orally for 28 days to male rats, and 
blood was sampled for metabolic profiling after 7, 14 and 28 days. Whereas 
aminoglycosides are poorly bioavailable after oral administration, the other two classes can 
be absorbed from the gut [9–13]. For each class of antibiotics specific plasma metabolome 
patterns could be established in the MetaMap®Tox database and first key metabolites 
(hippuric acid, indole-3-acetic acid, indole-3-propionic acid, 3-indoxylsulfate and glycerol) 
could be identified, indicating a change of the gut microbiome. However, for the 
tetracycline and fluoroquinolone antibiotics, a possible influence of systemic toxicity had to 
be taken into account when evaluating their effects on the plasma metabolome due to their 
bioavailability.  
With this study design it could be shown that gut microbial changes lead to changes in the 
plasma metabolome, therefore further experimental studies were set up to elucidate this 
interaction. Consequently, three antibiotics (vancomycin, streptomycin and roxithromycin) 
from different classes were administered orally to rats with a subsequent metabolic 
profiling in feces, cecum content and gut tissue (jejunum, ileum, cecum, colon and rectum) 
analyzing the same set of metabolites as before in plasma (Chapter 3). After antibiotic 
treatment, metabolite changes observed at different dose levels and in both sexes were 
evaluated. Treatment-related effects could be observed in the metabolite profile of feces 
and cecum content, but not in the different gut tissues. The most relevant changes in 
metabolite values were comparable in feces and cecum content and also among sexes. The 
metabolite profile showed compound specific effects on the microbiome, in line with the 
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activity spectra of the antibiotics tested. Vancomycin showed the largest effects in the feces 
and cecum metabolome, followed by roxithromycin and then by streptomycin for which 
changes were modest. For all antibiotics the largest changes were observed for the classes 
of lipids, bile acids, amino acids and amino acid related metabolites. In general, it has to be 
noted that analysis was targeted. An untargeted analysis or a broader range of metabolites, 
e.g. including the analysis of short chain fatty acids (SCFAs), may have revealed significant 
differences between matrices and possibly even sexes. 
With our targeted analysis, we identified feces as the best matrix for further investigations 
regarding an assessment of metabolic effects of new compounds with antibiotic activity. 
Thus, it offers the advantage of being a non-invasive sampling method, also enabling a 
longitudinal study design. However, this matrix only partially reflects the metabolite profile 
of the gut content, since the upper part, i.e. the small intestine, shows distinct differences in 
the composition of the microbial composition [14] which may considerably differ regarding 
the metabolite profile. For our metabolome studies, it requires overnight-fasted animals for 
the blood sampling and then the animals do not have content in the small intestine, so this 
matrix was not included in the studies.  
In Chapter 4, we applied lincomycin and clindamycin, another class of antibiotics known 
to show no or low systemic toxicity after oral administration, and modulated microbial 
communities of Wistar rats to gain a comprehensive understanding of the implications of 
microbiome alterations. A metabolomics approach and taxonomic profiling were applied to 
characterize the effects of these antibiotics on the functionality and composition of the 
microbiome and to identify microbiome-related metabolites. After treatment, the diversity 
of the microbial community was drastically reduced. Whereas other phyla disappeared, the 
abundance of Firmicutes and Proteobacteria was highly increased. Again, most changes in 
plasma and feces metabolites were observed for metabolites belonging to the class of 
complex lipids, fatty acids and related metabolites as well as amino acids and related 
compounds. The three analyzed primary bile acids (taurocholic acid, 
glycochenodeoxycholic acid and cholic acid) were markedly affected and displayed 
diverging results. In both plasma and feces taurocholic acid was highly upregulated upon 
treatment, whereas glycochenodeoxycholic acid was downregulated. Interestingly, cholic 
acid was upregulated in feces, however, it was downregulated in plasma. Taking into 
account that quantitatively the most pronounced changes were related to bile acids, it can be 
stated that the gut microbiome plays a very important role in the composition of the bile 
acid pool because secondary bile acids are exclusively formed by bacterial enzymes.  
Since a change of the gut microbiota can impact the bile acid pool, we used six antibiotics 
from five different classes (lincosamides, glycopeptides, macrolides, fluoroquinolones, 
aminoglycosides) and modulated microbial communities of Wistar rats to elucidate changes 
in the bile acid metabolism related to gut microbial changes (Chapter 5). The results 
showed that changes in the gut microbial community affected the bile acid pool in plasma 
and feces of the host, and that bile acid profiling can be indicative for an alteration of the 
gut microbiome. After treatment, significant changes of primary and secondary bile acids in 
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both matrices of treated animals could be observed. For cholic acid and taurocholic acid, as 
discussed in Chapter 4, there was an increase of taurine-conjugated primary bile acids in 
both plasma and feces. Contrary, cholic acid and most of the analyzed secondary bile acids 
were found to be significantly downregulated in plasma whereas cholic acid accumulated in 
the feces. Although different classes of antibiotics with different activity spectra against gut 
microbes were applied, the overall effect on the bile acid pool tended to be similar in both 
matrices. However, streptomycin showed less significant changes, probably because it is 
not active against obligate anaerobes. Since the bile acid-liver-gut microbiota axis plays an 
important role in the host’s health, e.g. via activation or inactivation of nuclear receptors in 
the liver or intestine, an alteration of the bile acid pool might have implications for 
toxicological evaluations regarding the gut-liver axis, the immune system and other body 
functions known to be influenced by the gut microbiota and needs to be further 
investigated. 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
In this project, the aim was to obtain detailed insight in the mammalian-microbiome co-
metabolism of endogenous metabolites and the extent to which the microbiome influences 
the plasma metabolome observed with the help of the MetaMap®Tox database. To elucidate 
this interaction, antibiotics as well as vehicle and diet controls were used to modulate the 
microbial communities of Wistar-rats. After 28-day oral administration, metabolomic 
analyses of plasma, gut tissue and content (feces and cecum-content) were performed. 
Additionally, DNA was extracted from rat feces and the 16S subunit was sequenced to 
perform a core diversity analysis. In the following, the applied methods and their results, as 
well as their limitations and suggestions for improvements are pointed out. The techniques 
used, i.e. metabolomics and taxonomic profiling, are discussed in more depth and bridged 
to statistical evaluations and metagenomic databases. The last section then elucidates the 
xenobiotic metabolic capacity of the gut microbiome, gives future perspectives for research 
and closes with a conclusion. 
 
Metabolomics, key metabolites and (systemic) effect of antibiotics 
Within the context of the omics technology, metabolomics is the analysis of small 
endogenous molecules such as carbohydrates, amino acids, nucleic acids or fatty acids and 
their derivatives resulting from biochemical pathways [15]. These metabolites, in its 
entirety called the metabolome, can be measured in biological samples, for example, urine 
or plasma as a matrix. Compared to other omics technologies, metabolomics, is from a 
statistical perspective, more powerful in detecting robust effects [16] and the use of 
sensitive LC-MS and GC-MS techniques offers the possibility to detect a broad range of 
metabolites. In the past years it has been shown that metabolomics can serve as a powerful 
tool in risk assessment, e.g. as a read-across tool, and in toxicological research [17,18]. 
Besides the targeted analysis of metabolites used here, there is also the possibility to 
perform an untargeted analysis. This does not provide quantitative results but normalized 
peak height of the metabolites can be considered semi-quantitative [19]. The advantage is 
that with the untargeted method, relative changes of metabolites in samples can be readily 
revealed which would lead to important findings. In contrast to the untargeted method, with 
our targeted analysis we analyzed about 200 metabolites in feces and plasma and identified 
a range of key metabolites indicating a change of the gut microbiome (Chapter 2-5). 
However, to depict a more precise picture of gut microbial changes, and with this of 
interindividual or sex-specific effects, the following classes of metabolites may be useful to 
gain new insights and could be additionally measured: short chain fatty acids (SCFAs), 
choline metabolites, phenolic, benzoyl and phenyl derivates, polyphenols and flavonoids, 
vitamins, and polyamines [20–27]. Other valuable analytes might be dietary carbohydrates 
and complex glycoconjugates since they are more and more playing a role in the research of 
how to maintain or restore a healthy gut microbiome [28]. 
The metabolome data in the MetaMap®Tox database is based on blood sampling and 
subsequent metabolic profiling of more than 200 metabolites after 7, 14 and 28 days of test 
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substance treatment in a 28-day toxicity study in rats. To use metabolomics in toxicology as 
a screening tool, various metabolite patterns for different toxicological targets and mode of 
actions (MoAs) were established in the MetaMap®Tox database, with the aim to identify 
and predict the toxicological MoA of new test substances, e.g. in the liver, kidney, thyroid, 
testes, blood, nervous system and endocrine system [29]. In other words, this means that 
changes of the endogenous metabolites, derived from the organs affected by a compound, 
are analyzed. In the last years, however, research has demonstrated that gut microbiome-
derived metabolites and co-metabolites can be found in the host’s blood [25]. Hence, the 
challenge of this project was that oral administration of a bioavailable substance can cause 
changes in both endogenous, and gut microbiome-derived or -associated metabolites in 
plasma. After antibiotic treatment with tetracyclines, fluoroquinolones, macrolides and 
lincosamides, which are absorbed from the gastrointestinal tract, a possible influence of 
systemic toxicity had to be taken into account when evaluating their effects on the plasma 
metabolome (Chapters 2, 4, 5). Dose levels used in these studies were carefully chosen, to 
avoid systemic toxicity, while being high enough to induce an effect on the microbiota. For 
these reasons, it is assumed that the plasma metabolome changes caused by these 
antibiotics in our studies, in the absence of effects on body weight development or clinical 
signs over a longer period of time, were primarily the result of their effect on the microbial 
functionality. To strengthen the correctness of pure microbiome-related metabolite 
identification, we applied a) aminoglycosides and vancomycin because these antibiotics are 
poorly or not absorbed at all from gut, and b) performed a metabolic profiling in different 
matrices of the gut to analyze the same metabolites as before in plasma in the immediate 
surrounding matrix of the bacteria. We observed that the metabolite profile was not only 
dependent on the bioavailability and the potential systemic effect but also on the 
bactericidal/-static efficacy spectrum of the antibiotics. These factors led to specific 
changes in the metabolite patterns which could be clearly observed when evaluating the 
metabolome of the gut content (Chapter 3). Still, using these differences of the metabolite 
patterns is an opportunity to identify and characterize substances that may have antibiotic 
properties and affect specific phyla or species of the gut microbiome. 
In Chapter 2, three metabolites, of which relative abundances in plasma from male rats 
were decreased after antibiotic treatment in all patterns (tetracyclines, fluoroquinolones, 
aminoglycosides), could be identified as key metabolites: indole-3-acetic acid (IAA), 
hippuric acid and glycerol. Since these metabolites could be found in the aminoglycoside 
pattern, it is highly likely that these metabolites are derived from the microbiota. Indole-3-
acetic acid, a protein-bound uremic solute, is generated either from bacterial indole 
production or from dietary tryptophan degradation by both endogenous and bacterial cells, 
e.g. Clostridium sporogenes, Clostridium bartlettii and Escherichia coli [30]. In antibiotic-
treated rats, the tryptophan metabolism appeared to be significantly altered because levels 
of indole-containing substances like 3-indoxylsulfate and IAA were decreased both in urine 
and feces whereas tryptophan and tryptamine levels were increased significantly in feces 
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[22]. Likewise, after lincosamides treatment, indole derivatives were significantly altered in 
plasma (Chapter 4). 
Another significantly decreased key metabolite in plasma, hippuric acid (HA), is produced 
by the microbes via benzoate by metabolizing aromatic compounds and polyphenols. 
Benzoate is then conjugated with glycine in the liver, kidney and intestine by bacteria as 
Clostridium difficile, F. prausnitzii, Bifidobacterium, Subdoligranulum, Lactobacillus [31–
34]. Bacterial suppression by antibiotics reduces the excretion of hippuric acid in blood, 
urine and feces of rodents [21,22,24] and in germ-free animals the plasma and urinary 
concentrations of hippuric acid were found to be reduced [25,26]. We could not analyze 
HA in the feces, however, benzoate levels in the surrounding gut tissue as well as in the gut 
content did not show any significant changes. Furthermore, the plasma metabolic profiles 
of many antibiotic-treated animals showed that the amino acid glycine was present in lower 
concentrations compared to the controls and conversely significantly upregulated in the 
feces. This indicates that glycine, more likely as a consequence of bacterial impairment, 
could not be further metabolized. However, this does not explain the accumulation in the 
intestine. Thus, we suggest that the significant decrease of hippuric acid in plasma is not 
due to the lack of benzoic acid but rather to a decrease of glycine in the host’s system. 
Given the importance and the wide range of metabolic pathways, e.g. the glutamatergic 
system, in which glycine is involved, a change in the concentration of this amino acid could 
have consequences for the host’s well-being [35].  
Besides significant changes of amino acids and related metabolites, complex lipids, fatty 
acids and related metabolites including glycerol were generally affected in both feces and 
plasma, also depending on the class of antibiotics (Chapter 2-5). All three primary bile 
acids, which were measured in the metabolome analysis, showed profound alterations after 
antibiotic treatment (Chapter 4). Therefore, an additional method was set up to analyze a 
set of 20 bile acids in plasma and feces of antibiotic-treated rats (Chapter 5). Since an 
altered bile acid pool may affect the absorption or excretion of (endogenous) metabolites or 
xenobiotics, or induce changes in activation or inactivation of nuclear receptors in the liver 
or intestine, this could lead to altered plasma concentrations, a detoxification or toxification 
of xenobiotics, or as a secondary effect to a change of endogenous metabolites, the 
metabolome, e.g. in plasma. The changes of plasma or feces levels of certain metabolites, 
reflecting the regulation of tricacylglycerols and other fatty acids, due to changes in the bile 
acid pool were described in Chapter 3 and 4. As presented in Chapter 5, all tested 
antibiotics had a profound impact on the bile acid metabolism via alterations of the 
intestinal microbiota - in particular shown for the poorly or non-bioavailable antibiotics 
streptomycin and vancomycin - and potential feedback mechanisms regarding the bile acid 
production in the liver. All five classes of antibiotics induced an increase of taurine-
conjugated primary bile acids in both plasma and feces, and a significant downregulation of 
secondary bile acids. Interestingly, cholic acid was downregulated in plasma but 
accumulated in the feces after antibiotic treatment, with the exception of roxithromycin 
which indicates a different mode of action for this macrolide antibiotic. Since cholic acid 
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accumulated in the intestine, it can be hypothesized that it could not be further converted 
into secondary bile acids due to the loss of microorganisms with a 7α-dehydroxylation 
activity. It can be assumed that since cholic acid is not actively transported and in general 
inefficiently absorbed by passive diffusion, it accumulates in the gut as seen for other fatty 
acids like the tricacylglycerols. In general, it was shown that the majority of conjugated bile 
acids in rat plasma are taurine derivatives [36]. If the liver produces more taurine-
conjugates, which accumulated in plasma and feces, in relation to cholic acid, then this 
could account for the significantly lower plasma values of cholic acid. Summarizing, the 
bile acids demonstrated to be valuable key metabolites regarding changes of the gut 
microbial communities. Moreover, the bile acids reflect the tight interaction between 
microbial metabolism and host, directly affecting for example nuclear receptors in the liver 
which play a very important role in the field of pharmacology and toxicology.  
As mentioned above, we performed a metabolic profiling in different matrices of the gut to 
analyze the same metabolites, as before in plasma, in the immediate surrounding matrix of 
the bacteria (Chapter 3). Whereas the metabolite profiles of sampled gut matrices (i.e. 
jejunum, ileum, rinsed cecum, colon, rectum) did not show treatment-related effects, feces 
and cecum content of treated animals had significantly different metabolome profiles 
compared to the control. As no clear changes between feces and cecum content could be 
observed in the overall metabolite profile, thus indicating the potential to profit from having 
a non-invasive sampling method, we analyzed feces samples for all subsequent projects. 
Furthermore, it was shown that the metabolite profile can be correlated with changes in the 
gut microbial community analyzed in this matrix and comparisons could be drawn with in 
vitro incubations which are normally based on feces samples. Recently, in a study 
examining more than 1000 metabolites in human feces from 786 individuals from a 
population-based twin study, the fecal metabolome was found to be only modestly 
influenced by host genetics but largely reflected the gut microbial composition [37]. In our 
studies, compared to plasma, feces were shown to be a more sensitive matrix for 
metabolome changes caused by antibiotics and thus it can be expected that changes should 
first show up in the feces. Interestingly, in our targeted analysis, feces and cecum content 
from male and female animals showed a similar metabolite profile. This was somewhat 
surprising as for plasma metabolite profiles, it is well known that sex has a profound impact 
and in general significant differences between sexes, also in untreated controls are observed 
[38]. However, in the current analysis of the feces metabolome, steroids and 
catecholamines were not measured and these analyte levels could be different between the 
sexes. Nonetheless, the very similar metabolite profiles - containing about 200 metabolites - 
led to the conclusion that there are no significant differences between sexes regarding the 
gut microbial communities. This finding will be discussed below where the microbial 
communities of male and female animals will be compared.  
In general, the possibility that potential systemic toxicity can occur after oral treatment 
aggravates the distinction between endogenous and microbiome-derived or -associated 
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metabolites and had to be taken to account when evaluating the metabolome. The long-term 
effect of many antibiotics on the host or even the mode of action on the host’s cells are not 
well-known or at least not yet proven. For example, the US Food and Drug Administration 
(FDA) announced in 2008 severe side effects of fluoroquinolone antibiotics as tendon 
rupture and irreversible nerve damage, and reported a few years later the fluoroquinolone-
associated disability (FQAD) [39]. Since mitochondria show some similarities to bacteria, 
mitochondrial toxicity may affect the mammalian cells but in the meantime also epigenetic 
changes seem to play a role [40,41]. Short-term and long-term consequences of antibiotic 
use on the human microbiome are now an evolving field of research related to diseases such 
as malnutrition, obesity, diabetes, infection, and even a short-term treatment is associated to 
have adverse effects on the host’s health [42]. Yet, in modern industrial animal farming, 
low doses of antibiotics are used to enhance growth and prevent diseases, and this practice 
is considered to be, in part, responsible for drug resistance of human pathogenic bacteria, 
thereby increasing the epidemic risks. The mechanisms behind the growth promoting 
properties of antibiotics are still not well-known and remain to be (urgently) elucidated 
which would enable the targeted development of alternatives to substitute antibiotics. 
 
Taxonomic profiling  
The analysis of ribosomal RNA gene sequences yields a description of a microbial 
community in terms of species richness, structure, composition, and members of microbial 
communities [43]. To assess the effects of the antibiotics, possessing different activity 
spectra, on the gut microbial composition, a taxonomic profiling was done. Therefore, a 
16S rRNA profiling and an amplicon sequencing were performed to characterize the 
taxonomic structure of a microbial community. Compared to a metagenomic approach, e.g. 
shotgun metagenomics that aims to characterize whole genomes, the analysis of the 16S 
rRNA gene provides a relatively rapid and cost-effective method for assessing the bacterial 
diversity and abundance. However, the 16S rRNA profiling entails limitations which are 
discussed in the following.  
The community analysis performed in this project delivered qualitative data, i.e. the 
obtained abundance of microbial taxa or operational taxonomic units (OTUs) is a relative 
value of the sample sequence library rather than an absolute value of the total bacteria cell 
count. If microbial cell numbers vary considerably between samples, the relative profiling 
might have implications for correlation analyses of, e.g. bacterial species with (semi-
)quantitative data such as metabolome data [44]. Quantitative microbiome profiling (QMP) 
of bacterial loads can be assessed by quantitative polymerase chain reaction (qPCR), 
downsized to an even sampling depth, or flow cytometry, and defined as the ratio between 
sample size and microbial load, as described by Vandeputte et al. to provide more power in 
assessing variation within and between individuals [45]. It was shown that correlation 
analyses built upon quantitative data increased the detection of true bacterial associations 
(sensitivity) and decreased the false positive correlation rates. As compared to our studies, 
the differences between the individuals, or a healthy versus a patient cohort, are expected to 
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be more subtle than the differences in microbial communities of antibiotic-treated versus 
non-treated animals. Bender et al. showed that the relative abundance has a stronger impact 
on variability than does absolute biomass, suggesting that it is feasible to detect differences 
in bacterial populations in very low-biomass samples [46]. Still, for a subsequent 
correlation analysis of our results between microbial and metabolite changes, this potential 
confounder has to be taken into account.  
Another confounder in the analysis of 16S rRNA data is 16S gene copy number (GCNs). 
Since different bacteria contain different numbers of GCNs, sequence variant counts are 
biased towards clades with a higher number of GCNs [47]. Louca et al. systemically 
evaluated the predictability of public sequenced genome data sets and recommended 
against correcting for 16S GCNs in microbiome analyses unless certain requirements are 
fulfilled [47]. However, regarding our results of the rat gut microbiome, many operational 
taxonomic units (OTUs) are still not assigned in the databases. Thus, correcting for 16S 
GCNs would probably lead to a higher bias in the results than when they would be analysed 
without 16S GCNs as it was performed.  
Others suggest, due to the reduction of phylogenetic resolution by the limited read length of 
second-generation sequencing platforms, the enrichment of 16S rRNA genes from 
metagenomic samples with a hybridization capture approach [48]. Further, high-throughput 
methods for assessing community structure in terms of biomass are lacking. Kleiner et al. 
showed with metaproteomics-based methods that assessment of species biomass 
contributions adds an important dimension to the analysis of microbial community structure 
[49]. They assessed the microbial community structure using protein abundance as a 
measure for biomass contributions of individual populations and observed high variabilities 
in results when comparing the metaproteomics approach and 16S rRNA gene amplicon 
sequencing [49].  
In general, with potentially conflicting associations of clinical outcomes, regarding for 
example genomic and functional predictions, it was demonstrated how important the 
experimental design and execution on reproducibility and robustness of microbiome studies 
is [46,50]. Technical and methodological variation, for example due to different sample 
storage, DNA extraction protocols, primer choice, library preparation, and laboratory 
conditions have a great impact on metagenomic analyses and thus on the inferred microbial 
composition [50–53]. In a recent review of Knight et al., the best practices for performing a 
microbiome study are discussed, including experimental design, choice of molecular 
analysis technology, methods for data analysis and the integration of multiple omics data 
sets [54]. The authors inter alia suggest to replace operational taxonomic unit-based 
analyses with new methods that are based on exact sequence variants and methods for 
integrating metagenomic and metabolomic data [54]. Summarizing, the standardization of 
protocols for microbiome studies is essential to minimize biases in the results in order to 
enable the comparison of data between different studies and to allow drawing clear 
conclusions about the role of the microbiome in health and disease.  
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To characterize the changes in the gut microbiota composition, 16S rRNA gene sequencing 
was performed from the isolated bacterial DNA in feces taken from Wistar rats on day 28 
of the studies. Figure 1 shows a principal coordinate analysis (PCoA) of weighted UniFrac 
distances of the gut microbial community of female and male rats after treatment with 
different antibiotics (vancomycin, streptomycin, sparfloxacin, roxithromycin, lincomycin 
and clindamycin), a restricted diet control, vehicle controls (carboxymethylcellulose (CMC, 
0.5%) and corn oil), and the control groups of the four independent studies. A clear 
treatment-related effect could be observed for all antibiotics except streptomycin, which 
shows a weak separation, on the gut microbiome and the main separation on Axis 1 was 
driven by the treatment.  
 
 
 
 
 
Figure 1 Principal Coordinate Analysis (PCoA) of the gut microbial community showing the treatment-related 
effect of antibiotics applied for the studies (vancomycin, streptomycin, sparfloxacin, roxithromycin, lincomycin 
and clindamycin) versus the restricted diet control, the vehicles carboxymethylcellulose (CMC, 0.5%) and corn 
oil, and the control groups in the gut microbial composition of male and female animals. Feces samples were taken 
on day 28 of the studies, bacterial DNA was extracted and the 16S ribosomal RNA gene was sequenced. PCoA 
was calculated using weighted UniFrac distance on the denoised dataset obtained from the dada2 workflow. 
 
As already seen in the metabolome (Chapters 3 and 5), the effect of streptomycin was not 
as pronounced as the effects of the other antibiotics. Streptomycin is not active against 
obligate anaerobe bacteria, i.e. the majority of the intestinal microbes were not affected 
which was reflected in the taxonomic and metabolomic results. An analysis of both the gut 
microbial community and the metabolome from the small intestinal content would probably 
show clear alterations compared to control animals. Furthermore, changes in the bile acid 
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pool could be more distinct since the active uptake of 95% of the bile acids takes place in 
the ileum which is the connection between small and large intestine. 
Community structures of control groups, vehicle controls and restricted diet controls 
clustered together, as well as lincomycin and clindamycin from the lincosamides antibiotics 
(Chapter 4) and surprisingly vancomycin, a glycopeptide drug, and sparfloxacin, a 
fluoroquinolone drug. Since vancomycin is not bioavailable after oral administration but 
sparfloaxcin is, a comparison of the feces and plasma metabolome as well as an analysis if 
metabolites and specific genera correlate, could help to identify more microbiome-derived 
or -associated metabolites and to gain new insights into metabolic pathways. 
In general, community structures of both male and female animals clustered together. 
Interestingly, the same observation was made when comparing the metabolome of cecum 
content and feces (Chapter 3). Only for animals treated with streptomycin, sex differences 
were observed, especially in cecum content. In females, lipids and triacylglycerols were 
stronger increased compared to males. As mentioned above, an analysis of the small 
intestine where lipid and bile acid metabolism predominates could reveal a sex-specific 
reaction as shown in a study of Markle et al., were sex-specific differences in the 
composition of the microbiome of cecum content were found at puberty and were most 
apparent in adult mice [55]. Therefore, the differences of both alpha and beta diversity were 
assessed for a deeper analysis of sex-specific effects between control and treated groups. 
Alpha diversity describes the within-sample diversity using the OTUs whereas the beta 
diversity calculates a pairwise sample dissimilarity and represents either a similarity or a 
distance between the samples. As described in Chapter 4, alpha diversity and effective 
species number was calculated for each sample by taking the exponential of Shannon-
Wiener index [56], and for the effective species number Kruskal-Wallis statistics were 
calculated using the diversity plugin of QIIME2. The Kruskal-Wallis (H) test is a 
nonparametric test that determines if there are statistically significant differences between 
two or more groups. This statistical test was ran to test for differences in effective species 
which is a measure of species diversity that accounts for the evenness and number of 
species where the H value is essentially a measure of effect size. Usually, the H value is 
reported with the p/q values. The q-value is the p-value after correcting for multiple testing 
to reduce the chance of false positives. Table 1 shows the differences in alpha diversity of 
female versus male animals treated with vehicles (CMC and corn oil), antibiotics 
(roxithromycin, streptomycin, vancomycin, lincomycin and clindamycin) and control 
animals (diet control and 20% reduced diet). A minor significant difference after testing 
using Kruskal- Wallis was only seen for the roxithromycin group and the control group 
with single caging.  
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Table 1 Differences in alpha diversity of female versus male animals treated with vehicles (CMC and corn 
oil), antibiotics (roxithromycin, streptomycin, vancomycin, lincomycin and clindamycin) and control animals 
(diet control and 20% reduced diet). Effective species number (Chao et al., 2010) was calculated for each 
sample by taking the exponential of Shannon-Weiner index and Kruskal-Wallis statistics were calculated using 
the diversity plugin of QIIME2. The last column indicates where the p value is < 0.05 (*) or < 0.01 (**). 
Females Males H p-value q-value Significance
Vehicle control (0.5% CMC) Vehicle control (0.5% CMC) 2.940 0.086 0.115
Diet control (study 1) Diet control (study 1) 1.651 0.199 0.249
Roxithromycin Roxithromycin 3.863 0.049 0.068 *
Streptomycin Streptomycin 0.167 0.683 0.731
Vancomycin Vancomycin 0.966 0.326 0.384
Diet control (study 2) Diet control (study 2) 0.334 0.248 0.304
Vehicle control (corn oil) Vehicle control (corn oil) 1.776 0.183 0.232
Lincomycin Lincomycin 1.120 0.290 0.347
Sparfloxacin Sparfloxacin 1.421 0.233 0.287
Diet control (single caging) Diet control (single caging) 3.938 0.047 0.066 *
Diet control (study 3) Diet control (study 3) 0.060 0.806 0.833
Restricted diet (20%) Restricted diet (20%) 1.320 0.251 0.307
Clindamycin Clindamycin 3.810 0.051 0.070
Diet control (study 4) Diet control (study 4) 2.063 0.151 0.193
 
Table 2 shows the PERMANOVA analysis [57] of weighted UniFrac distance for the beta 
diversity which was performed using the diversity plugin in QIIME2. Pseudo F values 
compare the total sum of squared dissimilarities (or ranked dissimilarities) among objects 
belonging to different groups to that of objects belonging to the same group [58]. Larger F-
ratios indicate more pronounced group separation, however, the significance of this ratio is 
usually of more interest than its magnitude [58].  
 
Table 2 Pairwise PERMANOVA results from QIIME2 beta group significance. Diet control animals of study 1, 
2 and 4 and the vehicle controls (CMC and corn oil) show a minor, yet significant, difference between male and 
female animals, as well as roxithromycin and clindamycin. The last column indicates where the p value is < 0.05 
(*) or < 0.01 (**). 
Females Males Sample Size Permutations pseudo-F p-value q-value Significance
Vehicle control (0.5% CMC) Vehicle control (0.5% CMC) 19 999 4.867 0.001 0.001 **
Diet control (study 1) Diet control (study 1) 20 999 2.715 0.001 0.001 **
Roxithromycin Roxithromycin 20 999 3.487 0.018 0.020 *
Streptomycin Streptomycin 19 999 1.643 0.125 0.129
Vancomycin Vancomycin 20 999 1.481 0.071 0.075
Diet control (study 2) Diet control (study 2) 18 999 2.536 0.012 0.014 *
Vehicle control (corn oil) Vehicle control (corn oil) 18 999 3.443 0.001 0.001 **
Lincomycin Lincomycin 20 999 1.356 0.246 0.249
Sparfloxacin Sparfloxacin 18 999 1.336 0.270 0.271
Diet control (single caging) Diet control (single caging) 10 999 1.316 0.174 0.179
Diet control (study 3) Diet control (study 3) 19 999 1.447 0.145 0.150
Restricted diet (20%) Restricted diet (20%) 10 999 2.015 0.058 0.062
Clindamycin Clindamycin 17 999 5.082 0.001 0.001 **
Diet control (study 4) Diet control (study 4) 20 999 2.140 0.028 0.031 *  
 
The q-value was described above but is calculated differently. Diet control animals of study 
1, 2 and 4 and the vehicle controls (CMC and corn oil) showed a minor, yet significant 
difference (F=2.1 - 4.9, p< 0.05) between male and female animals, as well as 
roxithromycin and clindamycin (F=3.5 - 5.1, p< 0.05). However, when comparing F values 
here to F values of treated groups versus control groups where F is about 50, the 
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differences, as shown in the PCoA, were marginal. Furthermore, as discussed above, feces 
and cecum content from male and female animals showed a very similar metabolite profile. 
This led to the assumption that there were no significant differences between sexes 
regarding the gut microbial communities which could be demonstrated with this evaluation. 
 
Further, genetic factors and interindividual differences of the animals as well as the DNA 
extraction method could lead to a variability of control animals between independently 
conducted studies. To elucidate the variability between the control groups of male and 
female animals of the four studies, the same analyses of alpha and beta diversity were 
performed. Since the conducted studies were highly standardized regarding age, diet, 
handling and treatment of the animals, we assumed a low variability between the controls. 
As seen in Table 3, the controls showed a minor, yet significant, difference in alpha 
diversity between study control 1,2 and 3 versus study control 4 of female animals, and 
between study control 1 and 4 versus study control 3 of male animals.  
The PERMANOVA analysis in Table 4 for the beta diversity of weighted UniFrac distance 
revealed that almost all diet control groups showed minor, yet significant, differences when 
compared to each other both in the male animals (F=1.8 - 3.3, p< 0.05) and the female 
animals (F=2.2 - 5.3, p< 0.05). However, as observed for the comparison of male versus 
female community, the F value was very low. That means the differences between the 
control groups, as also shown in the PCoA, were minor. Since the highest variability arises 
from the 16S rRNA taxonomic profiling due to the DNA extraction step [50], the variability 
from the genetic background and potential interindividual differences of the Wistar rats in 
our studies can be considered to be negligible.  
 
Table 3 Differences in alpha diversity of the diet controls from study 1, 2,3 and 4 of female and male animals. 
Effective species number (Chao et al., 2010) was calculated for each sample by taking the exponential of 
Shannon-Weiner index and Kruskal-Wallis statistics were calculated using the diversity plugin of QIIME2. The 
last column indicates where the p value is < 0.05 (*) or < 0.01 (**).  
Group 1 Group 2 H p-value q-value Significance
Diet control (study 1, n=10) Diet control (study 2, n=8) 0.284 0.594 0.650
" Diet control (study 3, n=9) 0.667 0.414 0.473
" Diet control (study 4, n=10) 10.080 0.001 0.003 **
Diet control (study 2, n=8) Diet control (study 3, n=9) 0.083 0.773 0.805
" Diet control (study 4, n=10) 6.189 0.013 0.020 *
Diet control (study 3, n=9) Diet control (study 4, n=10) 4.167 0.041 0.058 *
Diet control (study 1, n=10) Diet control (study 2, n=10) 0.206 0.650 0.702
" Diet control (study 3, n=10) 0.006 0.940 0.940 **
" Diet control (study 4, n=10) 1.286 0.257 0.313
Diet control (study 2, n=10) Diet control (study 3, n=10) 0.280 0.597 0.650
" Diet control (study 4, n=10) 0.463 0.496 0.555
Diet control (study 3, n=10) Diet control (study 4, n=10) 0.015 0.903 0.912 *
Fe
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Table 4 Pairwise PERMANOVA results from QIIME2 beta group significance. Diet control animals of study 1, 
2, 3 and 4 show a minor, yet significant, difference between study 1 and 4, 2 and 4, and 3 and 4 of female 
animals, as well as study 1 and 3, and 3 and 4 of male animals. The last column indicates where the p value is < 
0.05 (*) or < 0.01 (**). 
Group1 Group2 Sample Size Permutations pseudo-F p-value q-value Significance
Diet control (study 1) Diet control (study 2) 18 999 3.871 0.002 0.003 **
" Diet control (study 3) 19 999 2.213 0.003 0.004 **
" Diet control (study 4) 20 999 5.337 0.001 0.001 **
Diet control (study 2) Diet control (study 3) 17 999 1.556 0.122 0.127
" Diet control (study 4) 18 999 2.918 0.014 0.016 *
Diet control (study 3) Diet control (study 4) 19 999 3.867 0.004 0.005 **
Diet control (study 1) Diet control (study 2) 20 999 1.170 0.296 0.297
" Diet control (study 3) 20 999 1.789 0.045 0.049 *
" Diet control (study 4) 20 999 2.581 0.014 0.016 *
Diet control (study 2) Diet control (study 3) 20 999 1.823 0.026 0.029 *
" Diet control (study 4) 20 999 3.301 0.001 0.001 **
Diet control (study 3) Diet control (study 4) 20 999 1.953 0.026 0.029 *
Fe
m
al
es
M
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The data obtained from the four studies with diet controls, vehicle controls and antibiotics 
having different activity spectra allows a broad correlation analysis and possibly an 
integration of these data into new systems biology models linking species to specific 
metabolites. Therefore, a deeper exploration into more specific taxonomic groups (e.g. 
genera or species) and their metabolic functionality has to be performed in the future. Yet, 
it has to be noted that the datasets and metagenomic information of the rodent gut need 
further improvement and characterization: while over 1500 species have been isolated and 
cultured from the human gut, e.g. only around 100 species have been cultured from mice 
strains [6,59–61]. Since the feces turned out to be a more sensitive matrix than plasma 
regarding changes in the metabolome, the correlation analyses should be based upon these 
data and then linked to the results of the plasma metabolomics. This could allow the 
estimation of the extent of changes induced in the microbiome with respect to consequences 
for the host and could enable the identification of more relevant key metabolites derived 
from the gut microbiome. 
. 
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FUTURE PERSPECTIVES  
The gut microbiome uses its genome to fulfil important functions for its host such as the 
extraction of calories from otherwise indigestible components of the diet, synthesis of 
essential vitamins and amino acids, bile acid and lipid metabolism, support of the 
development of the immune system, maintenance of the energy balance, prevention of 
infections, and many others [5,62–69]. As diverse as these functions of the gut microbiome 
in the body are, as diverse is the field of research. Hereafter, the following facets of gut 
microbial research directions will be briefly addressed: I) the gut-brain axis, II) the gut and 
immune system, III) the gut in health and disease, IV) effects of xenobiotics on the gut 
microbiome, V) effects of the gut microbiome on xenobiotics including effects on their 
metabolism and systemic bioavailability, VI) availability and suitability of in vitro models, 
and VII) including the gut microbiota in ADME and PBK models. The relevance of the gut 
microbiome in these fields will be set in context with toxicology, pharmacology and the use 
of metabolomics, and finally the section closes with VIII) a conclusion by summarizing the 
main findings of this thesis and how it contributed to this field of research. 
 
I) The gut-brain axis 
Between the gut microbiome and the brain exists a bi-directional crosstalk through the gut-
brain axis which can influence for example behavior, serotonin metabolism, intestinal 
gluconeogenesis, the blood-brain barrier, or appetite regulation [70]. The gut itself is 
embedded in the enteric nervous system (ENS) and can communicate with the central 
nervous system (CNS), for example via the vagus nerve to the brain. Various diseases, e.g. 
Alzheimer’s disease, autism spectrum disorder, and depression are associated with 
alterations in gut microbial composition, diversity and the metabolites derived from the gut 
microbiota. For example, increased levels of short chain fatty acids as well as ammonia 
were observed in children with autism spectrum disorder, however, a causative role of the 
gut microbiome remains to be determined [71]. In general, microbiome-derived or -
associated metabolites are constantly sensed by immune cells and enteric glial cells which 
can lead to a secretion of neuro-modulatory signaling molecules affecting the CNS [72]. 
There are various experimental models for these neurological diseases, such as chronic 
antibiotics treatment and germ-free animal models, fecal microbiome transplantations from 
human patients or animal models into antibiotic-treated- or germ-free animals, co-housing 
of animal models with naive or specifically colonized controls, treatment with prebiotics 
(constituents in food that induce the growth or activity of beneficial microbes), probiotics 
(live microorganisms intended to provide health benefits), synbiotics (combination of pre- 
and probiotics), or postbiotics (byproducts of probiotic metabolism) to colonize the gut with 
selected microbiome of choice, and application of culturomics methodologies to isolate 
potential disease-relevant bacterial strains [72]. Elucidating the mechanisms behind the 
complex crosstalk could help to discover for example new drug candidates for patients 
suffering from neurodegenerative diseases such as Parkinson's and Alzheimer's disease or 
multiple sclerosis, which are of major public health concern. Pro-, pre-, post- and synbiotics 
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could be promising health ingredients able to modulate gut microbiota composition and 
thereby delaying or preventing the onset or progression of these diseases. There is a need to 
systematically identify the pathogenic mechanisms, to characterize gut community and 
functional changes and, on this basis, develop a concept for a targeted, e.g. nutritional, 
intervention. 
 
II) The gut and immune system 
The gut microbiome plays a crucial role in the development and homeostasis of the host 
mammalian immune system, especially during infancy. The microbes communicate with 
the host cells, locally and systemically, via metabolites. For instance, short-chain fatty acids 
have broad effects on the immune system and can directly or indirectly act on local or 
resident antigen-presenting cells to decrease inflammatory responses associated with 
neuroinflammation and allergic airway disease [73]. As research demonstrated, there are 
several microbes having well-characterized effects on particular immune functions [74,75]. 
The current mechanistic understanding reveals a complex interplay since microbial 
interactions with immunity are affected by co-variables as location, timing, and context 
[76]. Caesarean sections and a critical period during early infancy regarding the 
development of the immune system are associated with persistent defects in the 
development and training of specific immune subsets due to the disruption of microbiome-
host interactions, which can lead to the development of diseases later on, e.g. diabetes, 
allergy, asthma or inflammatory bowel disease [42,77]. As already stated above, antibiotic 
use, especially during this “window of opportunity”, can have short-term and long-term 
consequences on the human microbiome and thus on the host immune system [42]. 
Therefore, elucidating the mechanisms of the host-microbe interactions, especially in this 
vulnerable period of time, is essential to prevent these diseases, to develop alternative 
therapeutic approaches and to critically reconsider the often excessive and imprudent use of 
antibiotics.  
 
III) The gut in health and disease 
A shift or perturbations of the microbiome, especially during the first years of life, have 
been associated with diseases such as Crohn’s disease, colon cancer, diabetes, allergies, 
Alzheimer’s and Parkinson’s disease, depression, stroke, and many more [2]. As described 
above, microbes and their metabolites have the potential to affect the host organism in a 
detrimental or beneficial way. The findings of associations between these microbes/their 
metabolites and diseases, or prevention from disease, can be used to develop new 
therapeutic strategies for diverse purposes. For example, fecal microbiota transplants from a 
healthy donor have outstanding efficacy in treating Clostridium difficile infections [78]. 
Regarding obesity, studies in germ-free mice receiving fecal microbiota transplants from 
conventionally raised mice have provided the most compelling evidence establishing the 
causal link between gut microbes and energy harvest from the diet and energy storage in the 
host [79]. Another aspect is the importance of the gut microbiome in the treatment of 
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cancer. It is hypothesized that there exists a cross-reactivity between microbial and tumor 
antigens shaping T cell repertoires and/or microbial products stimulating pattern 
recognition receptors that influence the type and intensity of immune responses [80]. As 
studies in patients demonstrated, the gut microbiome influenced the efficacy of immune 
checkpoint inhibitors against epithelial tumors: superior efficacy is observed with the 
presence of specific gut microbes, however, it can be diminished with administration of 
antibiotics [81,82]. Considering these examples, a better understanding of the functionality 
of the microbiome will be useful for risk assessment, novel diagnostics and therapeutic 
approaches, e.g. with pre-, pro-, syn- or probiotics, and for the establishment of future 
strategies of personalized or precision medicine.  
 
IV) Effects of xenobiotics on the gut microbiome  
There is evidence that exposure to xenobiotics, both chemicals and drugs, can affect the gut 
microbial composition and that this is associated with neurobehavioral, immunological, 
metabolic, gastrointestinal, cardiovascular diseases and even cancer, although not for all 
causality has been established. Endocrine disrupting chemicals, heavy metals, air pollution, 
and nanoparticles can affect the host-microbial interaction by inducing a shift of the gut 
microbial community or altering its functionality [4]. Further, pesticides may play a role for 
living organisms in our ecosystem [83]. Also the consumption of drugs, such as the anti-
diabetic metformin [84], nonsteroidal anti-inflammatory drugs [85], or antibiotics as shown 
in this thesis, has been associated with changes in the gut microbial composition. In a recent 
study, more than 1,000 marketed drugs from different therapeutic classes were screened 
against 40 representative gut bacterial strains, and found that 24% of the drugs inhibited the 
growth of at least one strain in vitro [86]. It would thus seem that nearly everything has an 
effect on the gut microbiome. However, it is often not clear if such changes of the gut 
microbiome are associated with any form of adverseness and increased efforts to establish 
causality are needed which also applies to research communication. The potential risk of 
xenobiotics and drugs needs further exploration, and suitable methods have to be developed 
to analyze gut microbiome changes which might subsequently induce pathophysiological 
responses in the host. As microbiome-derived or -associated metabolites seem to play a 
central role in these pathogenic mechanisms, the use of metabolomics could help to develop 
prevention and remediation strategies.  
 
V) Effects of the gut microbiome on xenobiotics including effects on their metabolism and 
systemic bioavailability  
The intestinal microbes possess a metabolic capacity to biotransform xenobiotics. This is of 
direct relevance for pharmacology and toxicology since this can directly and indirectly 
affect the xenobiotic metabolism of the host. The processes the microbes mediate are 
poorly understood and experimental systems to address this complex process of gut 
microbial metabolic capacity are lacking. Microbial transformation mechanisms include 
processes like reduction, hydrolysis, removal of succinate groups, dehydroxylation, de-
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/acetylation, cleavage of N-oxide bonds, proteolysis, or denitration [87], which can lead to 
the formation of metabolites with increased or decreased toxicity [88]. Indirect interactions 
have also been described, including microbial effects on the host gene expression, and 
activity of components of host xenobiotic metabolism, which finally leads to an altered host 
(drug) metabolism [89]. The consequence of the microbial metabolism was demonstrated in 
many cases, e.g. in Japan in the late 1990s, 18 patients died caused by interactions of 
sorivudine, an antiviral drug, with the cancer drug 5-fluorouracil, when the metabolite 
bromovinyluracil produced by the gut microbiota inhibited an enzyme dihydropyrimidine 
dehydrogenase (DPD) in the host responsible for detoxification of the cancer drug [88]. In 
general, there is a lack of knowledge in understanding the potential microbial contribution 
to substance toxification and exposure. In this context, it is of interest to note that the gut 
microbiome is not (yet) included in the ADME – absorption, distribution, metabolism, 
excretion - concept used in the pharmacological and toxicological field, e.g. acting as first 
pass metabolism thereby influencing the nature and amount of the actual absorbed dose 
[90]. However, this knowledge and data might be essential for paving the way for a new era 
of toxicology where in vivo experiments shall be more and more replaced by alternative 
methods and modeling in which the effects of the gut microbiota are no longer implicitly 
included in the safety testing. 
 
VI) Availability and suitability of in vitro models  
In mechanistic and experimental studies, rodents have frequently been used as animal 
models exploring the correlations between gastrointestinal microorganisms and diseases 
and have significantly contributed to the understanding of the microbiome. However, as 
mentioned before there are significant interindividual and interspecies differences in the 
composition of the microbiome. As described in Chapter 1, analyses of the rat intestinal 
microbiota revealed a bacterial diversity exceeding that of the human gut by a factor of two 
to three [91]. The phylogenetic classification suggested that the rodent (rats and mice) and 
human microbiome are similar at the phylum level, but different at the genus level [14]. 
There is a lack of knowledge in understanding the potential microbial contribution to 
substance (de)toxification and to which extent these results are transferable between 
rodents, in vitro models and humans. Interestingly, contrary to differences in the human and 
murine intestinal genera, almost 80% of the functional genes of the murine microbiome 
were identical to the human microbiome, indicating a functional overlap [92]. Similarly, in 
the human microbiome, the interindividual variation in expression of bacterial metabolic 
enzymes is less diverse than the taxonomic profiles [93]. That means that determining the 
functional endpoints rather than the composition can contribute to a greater understanding 
of how microbial communities function, their complex interactions and metabolic 
capacities, also in close interaction with the host. Thus, to develop appropriate in vitro 
models an essential first step is to measure the metabolite profile in different matrices, e.g. 
feces, from rodents and humans, in order to identify species-specific effects and to possibly 
reveal individual susceptibility to chemical toxicity or pharmacological effects. 
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Metagenomic tools could be applied to mine the genome for metabolic enzymes and 
interspecies differences. Analyzing different endpoints, as the metabolome in different 
matrices as plasma and feces, compositional changes in the microbiome after treatment 
with a substance, and the modified xenobiotics itself to capture inter- and intraspecies 
differences could be the first stage of a series of investigations that have the ultimate goal 
of assessing the pharmacological benefit or toxicological risk of new compounds regarding 
the gut microbiome.  
 
VII) Including the gut microbiota in ADME and PBK models 
Even though humans and rodents have many similarities in their intestine regarding 
physiological, anatomical and histological features, there are not only differences in size, 
metabolic rate and dietary habits but also profound differences in their microbial 
composition [6]. This raises the question to which extent the results of animal models are 
transferable between rodents and humans. However, so far there is no better alternative to 
the animal model to study the mechanistic and metabolic capacity of the gut microbiome 
and its role in health and disease. Regarding the (xenobiotic) metabolic capacity of the gut 
microbiome and the large intra- and interindividual variability, as a first step it is essential 
to understand how xenobiotic compounds are biotransformed by resident microbiota and 
how this influences the composition and functionality of the microbiome. Therefore, novel 
tools and new methods have to be developed to give detailed mechanistic understanding of 
the gut microbiome. In consideration of the Three Rs – replacement, refinement, reduction 
– concept there is a need of appropriate in vitro models which could gain insight into 
interspecies and interindividual differences with the final goal to extrapolate from in vitro 
to in vivo data. In vivo models in rodents should be compared to anaerobic in vitro models 
using rat and human feces, and a representative standard community. With these models 
interspecies and interindividual differences in the intestinal microbial metabolism of the 
same xenobiotic, e.g. (foodborne) chemicals or pharmaceuticals, of pharmacological or 
toxicological relevance could be elucidated. The transformation of in vitro to in vivo data 
requires profound knowledge about the differences between the functionality and metabolic 
capacity of the gut microbiome. Therefore, an approach to integrate intestinal microbioal 
metabolic capacity in an in vitro to in vivo extrapolation (IVIVE) has to be developed. In 
vitro data have to be extrapolated to in vivo effects, as well as animal to human responses. 
These results can be correlated with in vitro models to pave the way for future human-
relevant in vitro based risk assessment strategies, that include interspecies and 
interindividual differences in the IVIVE and physiologically-based kinetic (PBK) modeling 
used. Here, metabolic rates can be defined and incorporated into the models. Concentration-
response curves for chemical-induced changes in key metabolites can be used to define 
relevant parameters for PBK modeling based reverse dosimetry [94]. In general, 
mathematical modeling-based methods have the potential to generate new insights of the 
gut microbiome in health and disease [95,96]. For example, a systems biology approach 
utilizing the metabolome and taxonomic profiling data can be used to correlate these results 
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to identify species of the rodent and human microbiome that contribute to its metabolic 
output and share functions. In a study of Stein et al., they developed and demonstrated in a 
first-of-a-kind experimental validation the usefulness of a mathematical microbiome–
immune system model which the authors called a stepping-stone to the accelerated 
prototyping and rational design of microbiome therapies [97].  
 
VIII) Conclusion 
Regarding the complexity of the microbiome itself and the tight host-microbe interactions, 
there are still many challenges to overcome. Since in both pharmacological and 
toxicological research the examined and evaluated endpoints are in the majority of cases 
systemic effects, one may query the role of the gut microbiome for these endpoints. 
Nevertheless, the fundamental role of the intestinal microbiome for the health of a host 
organism is nowadays generally accepted. It is known since decades that the intestinal 
microbiome has an influence on the metabolism of food-born constituents and xenobiotics. 
Hence, it is of utmost importance for future research directions in pharmacology and 
(eco)toxicology not just to understand the gut microbiome’s role in the absorption of 
xenobiotics, but also to understand whether gut microbial changes have an impact on the 
metabolic functionality of the microbiome and in how far this can affect the intestinal 
metabolism as well as the systemic bioavailability of model compounds including both 
drugs and other xenobiotics, as well as endogenous metabolites. As emerges from the gut 
microbial research directions described above as well as in this thesis, a key aspect is – 
despite this wide variety of research fields – the gut microbial functionality. With this 
thesis, the first stage of investigations assessing the functionality of the microbiome using 
metabolomics in the field of microbiome and toxicology were performed. The results 
suggest that plasma based metabolic profiling is a suitable tool to investigate the 
functionality of the gut microbiome, and laid the basis for the development of a promising 
method to elucidate the underlying mechanisms leading to adverse effects in the host 
system.  
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SUMMARY 
The gut microbiome has become a burgeoning field of research and is proven to play a role 
in in many host physiological aspects, also contributing to the blood metabolome that is 
otherwise produced by tissues of the host organism. In order to increase the mechanistic 
understanding of how the microbiome influences its host health, there is a need to integrate 
knowledge of the composition of the gut microbiome with its functionality in terms of 
microbiota-mediated metabolic processes. The aim of this project was to obtain detailed 
insight in the mammalian-microbiome co-metabolism of endogenous metabolites and the 
extent to which the microbiome influences the plasma metabolome observed. This was 
achieved with the help of the MetaMap®Tox database.  
 
The crosstalk between microbiome and host is often based on signal molecules or 
metabolites (in this context natural constituents of cells or biofluids) which can affect the 
host, for example via nuclear receptors leading to changes in signaling pathways, e.g. in 
energy metabolism or regulation of the immune system. The first stage of the investigations 
was the identification of microbiota-derived metabolites in plasma of male Wistar rats via 
treatment with antibiotics from different classes known to induce a shift of the intestinal 
microbiota (Chapter 2). Three specific plasma metabolome patterns for respectively the 
class of aminoglycosides, fluoroquinolones and tetracyclines could be established in the 
metabolome database called MetaMap®Tox, and plasma metabolites related to changes of 
the gut microbiome’s functionality due to antibiotic treatment were identified. Besides 
metabolites such as amino acids and amino acid related metabolites, hippuric acid, indole-
3-acetic acid and glycerol appeared to be microbiome-derived or -associated plasma 
metabolites. Indole-3-propionic acid was found to be a unique biomarker plasma metabolite 
for the aminoglycosides and 3-indoxylsulfate for the tetracyclines. Other plasma 
metabolites such as coenzyme Q, glutamine, glutamate, putrescine and spermidine were 
found to be mammalian-microbiome co-metabolites.  
 
The subsequent approach entailed the metabolite profiling of different matrices of the gut of 
rats after treatment with antibiotics from different classes (vancomycin, streptomycin and 
roxithromycin) in order to evaluate metabolite changes observed at different dose levels 
and in male and female rats, and to identify the best tissue matrix for further investigations 
(Chapter 3). The same set of plasma metabolites measured in Chapter 2, with the 
exception of steroids and catecholamines, was also measured in the different gut matrices. 
The effects of the three antibiotics, each possessing a different activity spectrum, could be 
separated from each other in feces and cecum content, and in line with its broad spectrum 
of activity, vancomycin showed the most profound effect on the metabolite profile, 
followed by roxithromycin and then by streptomycin. Largest changes were observed for 
the classes of lipids, bile acids and amino acids. There were only minimal, if any, 
differences between males and females regarding the main metabolites driving the 
separation in a principal component analysis. After vancomycin treatment, a dose-
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dependent change in metabolites could be observed in feces and cecum content. Whereas in 
gut tissue no obvious treatment-related effect could be observed, the metabolic profiling in 
feces and cecum content demonstrated clear effects, allowing for an assessment to what 
extent the gut microbiota is affected by antibiotica. It could also be shown that metabolome 
changes can be detected equally well in feces as in the cecum content, thus allowing to use 
a non invasive method for measurements of studies on metabolism by the gut microbiota. 
 
To gain a more comprehensive understanding of the effects and dynamics of microbiome 
alterations, we performed a metabolite profiling in both plasma and feces of rats after 
lincosamides treatment, another class of antibiotics, as well as a community analysis to 
characterize changes in the gut microbiome following treatment (Chapter 4). Additionally, 
the potential impact of the vehicle control carboxymethylcellulose (CMC) was investigated. 
A specific metabolite pattern could be established in the MetaMap®Tox database and 
further key metabolites indicating gut microbial changes could be identified or existing key 
metabolites could be consolidated. Most changes were observed in metabolites belonging to 
the class of bile acids, complex lipids, fatty acids and related metabolites, as well as amino 
acids and related metabolites. The diversity of the community showed no sex-specific 
differences and was drastically narrowed down after lincosamides treatment. Also, the 
vehicle control CMC showed negligible effects on both the metabolome and microbial 
communities.  
 
Since the three primary bile acids which were analyzed in the metabolite profiling turned 
out to be consistent key metabolites indicating gut microbial changes, 20 primary and 
secondary bile acids were analyzed in plasma and feces of Wistar rats treated with six 
different antibiotics from five different classes (Chapter 5). The antibiotics had a profound 
impact on the bile acid metabolism via harming the intestinal microbiota - in particular 
shown by the poorly or non-bioavailable antibiotics streptomycin and vancomycin - and via 
potential feedback mechanisms regarding the bile acid production in the liver. In general, 
the effect of the antibiotic treatment was stronger in the feces than in plasma. Although 
different classes of antibiotics with different activity spectra against gut microbes were 
applied, they all induced an increase of taurine-conjugated primary bile acids in both 
plasma and feces. Contrary, cholic acid and most of the secondary bile acids were 
significantly downregulated in plasma whereas it accumulated in the feces. This 
accumulation was not seen for roxithromycin indicating a different mode of action for the 
macrolide antibiotic. This evaluation of changes in the plasma and feces bile acid pool 
helped to gain a more comprehensive understanding of how microbial changes can 
influence the bile acid metabolism and availability. Thus, antibiotic treatment is likely to 
have an influence on bioavailability of compounds and food constituents depending on bile 
acids for their uptake. In addition, bile acids play a role as signaling molecules. Thus, the 
consequences of bile acid changes for the host merit further investigations.  
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The aim of this thesis was to assess functional microbial changes of the gut microbiome and 
to elucidate interactions between gut microbes and the host by applying metabolomics and 
taxonomic profiling. The results of this thesis suggest that plasma and feces based 
metabolic profiling via a targeted analysis turned out to be a suitable tool to investigate the 
microbial functionality of the gut microbiome. However, limitations emerged such as the 
potential systemic toxicity of the bioavailable antibiotics tested or confounders of the 
qualitative 16S rRNA analysis, which were discussed and future research directions were 
suggested in Chapter 6. In the future, alternative methods to animal studies are needed to 
be developed to assess, compare and to finally extrapolate the metabolic capacity of the gut 
microbiome from in vitro to in vivo data which is of direct relevance for pharmacology and 
toxicology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
179 
 
 
 
 
 
 
 
 
 
 


Acknowledgements 
183 
ACKNOWLEDGEMENTS  
First of all, I want to thank my promoter Ben. You already supervised my master thesis 
years ago and since then I have been continuously learning from you. With you I could 
vigorously discuss scientific and non-scientific topics and opinions, philosophize about life, 
laugh about the same jokes others couldn’t understand, fool around, and celebrate 
successes. You always supported me and I don’t want to miss you in the future. I gratefully 
want to thank my promoter Ivonne, for your guidance, reliability and thriving suggestions 
throughout the project. I am proud for having been your PhD student. Karsten, with you as 
my co-promotor, it couldn’t have been better for me. Thanks for all the fruitful meetings, 
constructive discussions, and your sincere cordiality. 
I want to thank all my co-authors and the metabolome team (special thanks to Saskia, 
Volker S., Eric, Barbara, Werner, Hennicke, Tilmann, Micha S., Hunter, and Volker H.). It 
was an outstanding chance to work with you, and in the three years of my PhD project I 
have learned incredibly much, both scientifically and humanly. This experience has 
influenced and shaped my personality, and has proved invaluable for me and the next steps 
of life. A special thank goes to Nicole D., who had an important role in the successful 
outcome of the project: you introduced me to your microbiology lab and techniques, 
discussed with me reasonable methods for my project, and always provided me with good 
advice. 
Big thanks to the committee members for evaluating my thesis! 
A big part of the work was also performed by my colleagues from the mechanistic 
toxicology (special thanks to Martina, Claudia and Burkhard) and pathology (special thanks 
to Frauke, Marco and Peter). Marco and Peter, I also want to thank you for all the cheerful 
moments and delighting coffee breaks, and of course for giving me the majestic name 
“Kackequeen” and the appropriate crown, which I both carry with biggest honor. Many 
thanks also go to the team of the clinical chemistry, first and foremost, to Irmgard: you 
were always there for me, thanks for your never-ending patience. Thanks Caro, for your 
unswerving optimism, and Gareth, thanks for your fine humor, your kind-hearted nature, 
and of course for the self-made scones (for which I had been waiting impatiently for years); 
Mrs Blum, thanks for being the good fairy of the department, for having always an open 
ear, the right words and free space on your couch. A big thank to all my BASF colleagues 
for the nice time, enjoyable talks, and your help: Gaby, Dieter D., Uwe, Frank, Markus, 
Thomas, Berta, Ante, Martina D., Diana&Peter, Naveed, Mr Landsiedel, Björn, Dieter B., 
Kathi M., Mrs Bächle, Volker S., Lukas, Susanne, Basak, Anna T., Dani and Felix K.. 
An everlasting source of joy was my cozy office, namely Café UT, and this was due to all 
my colleagues and our awesome “neighbors” who accompanied me over the three years: 
first of all Xiaoqi and Johanna; Flora, Christian&Lisa, Daniel, Juliane, Sabina, Elodie, 
Dunja, Eleonora, Veronique, Svenja and Jessica; Stephan, Martina and Beate. We shared 
uncountable special and funny moments, mountains of sweets, and developed crazy ideas 
Appendix 
184 
(e.g. THE Taxi company). I found support and comprehension, and we had smart solutions 
for almost any problem. I also want to thank the guests of Café UT from WUR: Maria, 
Annelies, Mengying and Katja, who delighted me with joy and laughter - also at every visit 
in Wageningen, as well as my colleagues from WUR, especially Mark, Laura, Lidy and 
Nacho. 
My deep gratitude goes to my paranymphs Laura and Johanna who both played key roles 
before and during my PhD time. Laura, I met you when I started my master thesis at the 
WUR tox department, and from then on, I profited from your good mood and advice, care, 
cordiality and creative madness. Johanna, you were my PhD student buddy and it felt we 
complemented each other in a mutual way. Thanks for your sensitive handling with my 
fears (“Midpoint”!) and your encouraging words.  
Personally and outside of work, the last years have been very tough and I had to cope and 
struggle with many difficulties. I would not stand at the very good point where I am now 
without my noble friends and family. Chris, Max and my third sister Serpil, you are the 
persons who make me feel at home here, always being on my side in all walks of life. 
Meike, Ina, Xiaoqi, Georg, Yaschar, Nico, Lük, Dirk and Christoph, I want to thank you for 
your help, advice, humor and, above all, creating the wonderful moments of the lightness of 
being. Konstantin, I want to thank you for the last years. Without you, my crucial and so 
essential change of mind-set would not have started. Lastly, I want to thank my parents and 
my beloved siblings Antje, Nico and Caro for your never-ending and wholehearted support 
in every sense, and simply for being my family.  
 
Curriculum Vitae 
185 
CURRICULUM VITAE  
Christina Behr was born on 14 July 1985 in Heidelberg, Germany. During her Bachelor 
studies at HS Mannheim, Germany, she conducted the practical semester at the Fraunhofer 
Institute for Interfacial Engineering and Biotechnology, Stuttgart, Germany, and graduated 
with the Bachelor’s thesis performed at the Helmholtz-Zentrum Geesthacht, Germany, in 
2012. Subsequently, she started the Master program in Toxicology at University of 
Kaiserslautern, Germany, and spent six months at the Division of Toxicology, Wageningen 
University, in cooperation with BASF SE, Germany, for MSc graduation. In 2015, 
Christina started her PhD study as an external PhD student at the Department of 
Experimental Toxicology and Ecology, BASF SE, in Ludwigshafen and the Division of 
Toxicology, Wageningen University, under the supervision of Prof. Bennard van 
Ravenzwaay and Prof. Ivonne Rietjens, as well as Dr. Karsten Beekmann. During her PhD, 
she followed a postgraduate education program in Toxicology, which enables to register as 
“Fachtoxikologin DGPT” and European Toxicologist.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
186 
LIST OF PUBLICATIONS 
 
Behr, C., Kamp, H., Fabian, E., Krennrich, G., Mellert, W., Peter, E., Strauss, V., Walk, T., 
Rietjens, I.M.C.M., van Ravenzwaay, B., 2017. Gut microbiome-related metabolic changes 
in plasma of antibiotic-treated rats. Arch. Toxicol. 91, 3439–3454. 
https://doi.org/10.1007/s00204-017-1949-2 
 
Behr, C., Sperber, S., Jiang, X., Strauss, V., Kamp, H., Walk, T., Herold, M., Beekmann, 
K., Rietjens, I.M.C.M., van Ravenzwaay, B., 2018b. Microbiome-related metabolite 
changes in gut tissue, cecum content and feces of rats treated with antibiotics. Toxicol. 
Appl. Pharmacol. 355, 198–210. https://doi.org/10.1016/j.taap.2018.06.028 
 
Behr, C., Ramírez-Hincapié, S., Cameron, H.J., Strauss, V., Walk, T., Herold, M., 
Beekmann, K., Rietjens, I.M.C.M., van Ravenzwaay, B., 2018a. Impact of lincosamides 
antibiotics on the composition of the rat gut microbiota and the metabolite profile of plasma 
and feces. Toxicol. Lett. 296, 139–151. https://doi.org/10.1016/j.toxlet.2018.08.002 
 
Behr, C., Slopianka, M., Haake, V., Strauss, V., Sperber, S., Kamp, H., Walk, T., 
Beekmann, K., Rietjens, I.M.C.M., van Ravenzwaay, B., 2019. Analysis of metabolome 
changes in the bile acid pool in feces and plasma of antibiotic-treated rats. Toxicol. Appl. 
Pharmacol. 363, 79–87. https://doi.org/10.1016/j.taap.2018.11.012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overview of training activities 
187 
OVERVIEW OF TRAINING ACTIVITIES 
 
Discipline specific courses (DGPT courses) 
Molecular Toxicology Munich, Germany 2016 
Metabolism of xenobiotics and toxicokinetics Zurich, Switzerland 2016 
Risk assessment Berlin, Germany 2017 
Organ Toxicology Erfurt, Germany 2017 
Ecotoxicology Schmallenberg, Germany 2018 
 
 
Meetings and conferences 
German Pharm-Tox Summit, 
   Poster presentation 
Berlin, Germany 2016 
German Pharm-Tox Summit, 
   Poster presentation 
Heidelberg, Germany 2017 
Eurotox meeting, 
   Oral presentation 
Bratislava, Slovakia 2017 
Heidelberg Forum for Young Life Scientists Heidelberg, Germany 2017 
German Pharm-Tox Summit, 
   Oral and poster presentation 
Göttingen, Germany 2018 
Annual Meeting of the Society of Toxicology, 
   Oral and poster presentation 
San Antonio, USA 2018 
 
General courses and optional activities 
Preparation of PhD research proposal BASF Tox, Germany 2015 
Introduction course to R University of Mannheim, 
Germany 
2017 
Preparation of LRI research proposal BASF Tox, Germany 2018 
Attending scientific presentations BASF Tox, Germany 2015-2018 
General Toxicology BASF Tox, Germany 2015-2018 
 
 
 
 
 
 

  
The research described in this thesis was financed by BASF SE, Ludwigshafen, Germany. 
 
Financial support from Wageningen University for printing this thesis is gratefully 
acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover & Layout design by Carolin Behr and Antje Behr 
Printed by Digiforce || Proefschriftmaken.nl, Vianen, the Netherlands 
